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Tendon is a band of connective tissue that transmits muscular forces to the bone, and as a result, 
is constantly subjected to large mechanical loads. Over 10 million people suffer from tendon 
injury and/or chronic tendinopathy in the United States with the cost of treatment exceeding 30 
billion dollars each year. While mechanical overloading is considered to be a major risk factor, 
the molecular mechanism for the development of tendinopathy is largely unknown. The highly 
conserved nuclear protein, high mobility group box1 (HMGB1), is identified as a potent 
inflammatory mediator when released to the extracellular matrix from inflammatory or stromal 
cells in response to stimulation with inflammatory agents or mechanical stress.  
Therefore, in this study we hypothesized that HMGB1is responsible for tendinopathy 
development due to mechanical overloading placed on the tendon. To test the hypothesis, we 
performed in vitro and in vivo studies. We found that HMGB1 in tendon cells translocates from 
nucleus to extracellular matrix when challenged with mechanical overloading in vitro and in 
vivo. When implanted in rat patellar tendons in vivo, HMGB1 causes cellular and structural 
changes that mimic the features of tendinopathy. Treatment with glycyrrhizin (GL), a specific 
inhibitor of HMGB1, blocks HMGB1-induced inflammatory reaction in vitro and mechanical 
overloading-induced tendon inflammation in vivo. GL treatment also largely reduces 
degenerative changes in Achilles tendons of mice subjected to chronic mechanical overloading 
through treadmill running.  
HMGB1 INDUCES TENDINOPATHY DEVELOPMENT DUE TO MECHANICAL 
OVERLOADING 
 
Guangyi Zhao, PhD 
University of Pittsburgh, 2017
 
 v 
Thus, our study shows that extracellular HMGB1 is a key molecule that plays a vital role 
in the onset of tendon inflammation, and eventual tendon degeneration in response to mechanical 
overloading. The findings of this study also indicate that GL may be used to prevent 
tendinopathy development by blocking HMGB1 signaling in the tendon, particularly in the 
athletic setting.  
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 1 
1.0  INTRODUCTION 
1.1 TENDON BIOLOGY 
1.1.1 Tendon structure and composition 
Tendon is a band of connective tissue responsible for the function of transmitting forces from 
muscle to bone and is constantly subjected to large mechanical loads. Tendon has greater 
mechanical strength per unit area than muscle [1]. The anatomy of tendons reflects this as it 
mainly consists of well-organized parallel bundles of collagen with rod- or spindle-shaped 
fibroblast-like cells called tenocytes [2]. The dry mass of human tendon is about 30% of the total 
tendon mass, water account for the rest 70%. The major component of the extracellular matrix is 
predominately collagen type I (65%-80% dry mass) [3], whereas collagen type III, V and XII [4], 
and elastin [5] are also found in tendon tissue. The extracellular matrix also contains 
proteoglycans, glycosaminoglycan, glycoprotein, and several other small molecules including 
tenascin-C, fibronectin, and thrombospondin[6, 7], which are crucial in the healing and repair 
process of the tendon. Collagen in the tendon is organized hierarchically fashion. It begins with 
the triple helix polypeptide chain, tropocollagen that forms fibrils. Fibrils form fibers and 
subfascicles that aggregate into fascicles, which then form fiber bundles and finally the entire 
tendon tissue [8] (Fig. 1). The connective tissues in between the fibers are called endotenon and  
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Figure 1. Tendon structure and composition. The figure shows hierarchical structure of tendon tissue. All 
structure are longitudinally arranged. Tropocollagen secreted by tenocytes united into collagen fibril then form a 
fiber; fibers are packed up into subfascicle, fascicle and tertiary fiber bundle, Tenocytes are packed in between the 
dense collagen fibers. Endotenon and epitenon are loose connective tissue hold fibers together; the tendon is 
surrounded by another layer of connective tissue called paratenon. Those connective tissues are thought to provide 
microvasculature for the tendon. Some tendon like Flexor tendon are housed within a synovial sheath, but some 
others like Achilles and patellar tendons are not. Figure source: [9], slightly modified. 
 
 
 
epitenon, which hold the fibers together. Tendon is also wrapped in a thin layer of loose 
connective tissue called paratenon which contains blood vessels and nerves [10]. Some tendons 
in hands and feet also possess synovial tendon sheath, which ensures efficient lubrication as 
these areas are subjected to more friction and act like a pulley system [1, 8]. The well-organized 
and hierarchical structure enables the tendon to withstand significant tensile loads, but not 
compression forces [11]. 
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1.1.2 Cellular component 
Tenogenic cells constitute about 90%-95% of the cell component in the tendon, the other 5%-
10% percent of tendon cells are chondrocytes, synovial cells, vascular cells[12]. Recently, a new 
cell type, tendon stem/progenitor cells (TSCs), was isolated and characterized in human, 
mouse[13] rat[14] and rabbit[15]tendon tissues. This new type of cells have multi-differentiation 
potential capable of differentiating into tenocytes (or tendon fibroblasts), chondrocytes, 
osteocytes and adipocytes as shown by in vitro and in vivo under different conditions [16-
18].TSCs cannot be visualized in the tendon in situ because of lack of specific markers[19]; the 
niche where TSCs reside and developmental origin of TSCs are yet to be discovered[20]. Tendon 
has a low metabolic rate; the oxygen consumption of tendon is 7.5 times lower than that of 
skeletal muscles [21]. Tenocytes generate energy through aerobic Krebs cycle, anaerobic 
glycolysis, and pentose phosphate shunt [3]. This anaerobic metabolic feature allows tendon 
tissue to sustain long-term mechanical loading with low risk of ischemic damage, but the low 
metabolic rate, on the other hand, will slow the healing rate after injury[5]. 
1.1.3 Blood supply 
The healthy tendon is relatively avascular. Tendon receives blood supply mainly from three 
sources, muscle-tendon junction, bone-tendon junction, and extrinsic system through paratenon 
or tendon sheath [22, 23]. However, the blood vessels originating from junction sites are unlikely 
to extend to the mid- one-third of the tendon in Achilles tendon. There is a hypovascularity zone 
that is 2 to 7 cm proximal to the Achilles tendon insertion site [24, 25]. Tendon blood flow is 
reported to decrease along with aging and mechanical loading [26]. The avascular nature of 
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tendon is considered to be responsible for the slow and incomplete healing after tendon injury 
[27].  
1.1.4 Mechanobiology of tendon  
Tendon tissue possesses high mechanical strength and unique viscoelasticity property to transmit 
large tensile force while absorbing excessive energy [28]. Tendons respond in different ways 
when subjected to various magnitudes of mechanical loading. When at rest, the collagen fibers 
are in a crimped configuration [29], and as the strain reaches 2%, the crimped tendon fibrils are 
“stretched out”. As the strain increases to 4%, which is the physiological upper limit of the 
tendon, the tendon behaves in an elastic fashion. When strain exceeds 4%, microscopic level 
tearing of collagen fibers takes place, and when the strain increases to 8%-10%, macroscopic 
tearing occurs and finally leads to tendon rupture [12, 28, 30](Fig. 2). Besides responding 
mechanically variabilty, physiologically and pathologically also tendon responds differently to 
different strain levels. Previous studies have shown that proper mechanical loading is beneficial 
to the tendon regarding inducing the synthesis of matrix collagens and enhancing the tendon 
strength [31]. It has been reported that four weeks of exercise improved the tensile strength of 
peroneus breivis tendon in rabbit [32]. But excessive loading could be detrimental resulting in 
cell shape change and matrix degeneration [33, 34]. 
In consideration of the uniaxial loading condition of patellar and Achilles tendons, our 
laboratory has developed an in vitro system to mimic the cell alignment and repetitive uniaxial 
stretching condition in vivo [35]. Using this system, we found that with moderate stretching, 
tendon fibroblasts would increase proliferation and produce more type I collagen[36], but with 
excessive stretch, there was a significant increase in the inflammatory mediator, PGE2. This  
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Figure 2. Tendon stress-strain curve. Tendon fibers are crimped when at rest, straightened at 2% strain and 
physiologically can be stretched to about 4%. If the strain is greater than 4%, microscopic failure of collagen fibers 
occurs. Finally, if the stain is greater than 8%, macroscopic failure and rupture will take place. Figure source: [30] 
 
 
 
increase may lead to degenerative changes of tendon tissue which may be attributed to the 
decreased collagen production [37] and non-tenogenic differentiation of TSCs [16]. With a 
mouse treadmill running model, myofibroblasts are found in the tendons of intensive treadmill 
running mice, which actively participate in tendon repair and remodeling. This finding indicates 
that treadmill running might result in tendon micro-injury [38, 39]. 
Insufficient mechanical loading is also detrimental to tendons. Immobilization or disuse 
of limb leads to significant change in tendon's cellular number and shape; matrix integrity is also 
adversely affected. These changes would finally result in loss of tendon weight, stiffness and 
strength that eventually lead to tendon degeneration [40-42]. Mechano-responses of the tendon 
are mainly due to the mechanical stress (tensile stress, compressive stress, and shear stress) 
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acting on tendon cells, and the cellular and molecular responses to mechanical loading that may 
explain the development of tendon disorders such as chronic tendon injury. 
1.2 TENDON INJURY AND TENDINOPATHY  
Over 10 million people suffer from acute tendon injury or chronic tendinopathy each year in the 
United States[43] with the cost of treatment that goes over 30 billion dollars [44]. Additionally, 
the clinical outcome from slow or incomplete healing of tendon injuries has become a growing 
problem in sports/orthopaedic medicine [45].  
Tendon injury can be divided into two categories, acute and chronic. Acute injury like 
tendon rupture may be spontaneous or caused by direct trauma and/or sudden excessive 
mechanical loading. On the other hand, chronic tendon injury, or tendinopathy, is manifested 
with compromised tendon tissue due to the change of tendon cellular and matrix components 
(tendon degeneration), which will increase the risk of acute injury like rupture or tear[2, 46].  
1.2.1 Acute tendon injury  
In acute trauma of tendon, the sudden acceleration-deceleration mechanism has been seen in 
90% Achilles rupture in sports related field [47]. Histological degenerative changes are very 
often found in spontaneous tendon ruptures[48], suggesting that acute injury is often not a stand-
alone event; rather it is the final result of gradual weakening and degenerating tendon under 
long-term excessive mechanical loading. 
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1.2.2 Natural healing of tendon  
 Most tendon healing studies are performed on acute tendon rupture in human or animal model 
with transected tendons [12]. The healing of ruptured or transected tendon can be divided into 
three overlapping stages [49], which is similar to wound healing of skin, i.e., 1) inflammatory 
stage; 2) proliferative or repair stage, and 3) remodeling stage.  
Inflammatory stage typically lasts for a few days to 1 week. The blood clot forms right 
after the rupture, and the platelets release growth factors and chemoattractants. The fibrin-based 
clot serves as a temporary scaffold for invading cells such as neutrophils, monocytes and 
lymphocytes, and tenocytes in tendon and circulating progenitor cells are recruited to the wound 
site [2]. Approximately two days after the initial injury, the proliferative/repair stage begins. It is 
characterized by massive proliferation and synthetic activity. The two main cell types that are 
crucial in this stage are macrophages and tenogenic fibroblasts. Some researchers also have 
suggested that tendon stem/progenitor cells (TSCs) differentiated into tenocytes are the sources 
of the fibroblastic cells participating in repair [50]. In this stage, macrophages’ role shift from 
phagocytic to reparative, and begin to secrete growth factors, cytokines, and direct cell 
recruitment. The intrinsic tenocytes also migrate to the wound site. But a recent research 
suggested that those “local tenocyte” did not massively participate in the wound repair. Instead, 
α-SMA -positive progenitor cells from paratenon dominated the wound area in the first few 
weeks [51]. The level of neutrophils gradually declines in this stage. The tenogenic fibroblasts in 
this stage deposit a temporary matrix mainly composed of collagen III, as well as GAGs [52]. 
The remodeling stage begins 1-2 month after the initial injury and can last up to 1 or 2 years. In 
this stage, the matrix gradually becomes aligned with the direction of tension, collagen I replace 
collagen III in the wound site, and also the cellularity decreases. The repaired, not regenerative 
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fibrous tissue becomes scar-like [53] and can reach up to 70% of the mechanical properties 
compared to intact tendon tissue [54]. In other words, after injury tendon never heals completely 
such that normal structural and mechanical properties are restored to injured tendons. 
1.2.3 Tendinopathy/Chronic tendon injury 
Unlike acute tendon injury, tendinopathy is not manifested with macroscopic tearing or rupture 
of the tendon. Clinically, it is related to pain, focal tenderness, decreased strength and limitation 
of movement of the affected tendon [55]. Histologically, tendinopathy often has the following 
features: disorganization of collagen fibrils, increased proteoglycan and GAGs in the 
extracellular matrix (ECM), hypercellularity, and neo-vascularization [12, 55, 56] (Fig. 3). 
Different types of tendon degeneration changes can be found in tendinopathy, including lipid 
accumulation typically found in Achilles tendon[57], and fibrocartilaginous metaplasia and 
calcium deposition in rotator cuff tendinopathy[58]. 
Tendinopathy is caused by intrinsic and extrinsic factors; excessive repetitive mechanical 
loading is considered as the main extrinsic factor for Achilles tendinopathy. It is reported that 
tendon subjected to repetitive overloading above the physiological limit results in inflammation 
of the sheath, and degeneration in tendon body [59]. Excessive mechanical loading may result in 
increased and imbalanced cytokine levels, including the release of VEGF, and MMPs [60, 61], 
which may lead to the degeneration and structural changes in the tendon. These changes could 
result in further modulation of cell activity, and the cumulative long term effect will finally end 
up with macro-scale tendon pathological changes that are manifested by clinical symptoms like 
pain and impaired movement [62]. 
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Figure 3. Histological structure in normal and tendinopathic tendon in the human patient. (A) Normal tendon 
has parallel and well-organized collagen fiber structure (pink) and elongated tenocytes (dark blue, arrows). Note that 
the cell density is relatively low. (B) Early tendinopathy with increased cellularity (arrow) and cell morphological 
change from elongated to round shape. Additionally, tendon matrix becomes slightly disorganized (arrowhead). (C) 
In the late stages of tendinopathy, the tendon is highly degenerated, its matrix organization is totally disrupted, and 
cell density is greatly decreased. 
 
 
 
Tendinopathy displays some common features of the healing process, but more in a 
disorderly manner. Tendinopathy could be the result of long-term imbalanced cellular activity 
and matrix integrity from repetitive, excessive mechanical loading. Tendinopathic tendons are 
susceptible to rupture because of their weakened mechanical strength. The role of inflammation 
in the development of tendinopathy is not clear, and it has been controversial. Inflammation is 
not typically reported in tendinopathy in early studies, but recent studies have found evidence of 
inflammation in human tendinopathic tendons using flow cytometry and immunochemical 
histology [63]. For example, in a human study in spontaneous ruptured Achilles tendon, 
immunohistochemical staining confirmed the presence of macrophages (CD68), T cells (CD3) 
and B cells (CD20) in all 60 ruptured tendon samples [64]. Another study later demonstrated B 
cells T cells and macrophages are increased in Achilles tendinopathy samples [65]. And many 
pro-inflammatory agents like prostaglandins and cytokines (i.e.IL-6, IL-1β) have been identified 
during the tendinopathic process [63, 66]. It is possible that the biopsies from the patients are 
more likely to represent chronic and cumulative effect rather than early phase phenomenon in the 
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development of tendinopathy [53]. It has been reported that cyclic mechanical loading increases 
inflammatory mediator PGE2 in vitro and in vivo, and it might be the cause of tendon 
degeneration due to the non-tenogenic differentiation of TSCs in response to mechanical 
overloading [16, 37, 45]. Finally, even when inflammation may not usually be present in patients 
with tendinopathy, it may still play a predominant role in the onset of the disease.  
1.2.4 Achilles tendon and Achilles Insertional tendinopathy  
The Achilles tendon (also known as the calcaneal tendon) is the strongest and largest tendon in 
the human body; it attaches the posterior gastrocnemius, and soleus muscles to the calcaneus 
(heel bone)[67](Fig. 4A), the length of Achilles tendon is around 220 - 230mm in adults [68]. Its 
action is to plantarflex the ankle actively and to resist dorsiflexion. It can withhold a load of 
about four times a person's body weight during walking. Achilles tendon is vulnerable to injury, 
especially because of the considerable tension placed on it. 
Achilles tendinopathy is one of the most frequently reported overuse injury in sports 
medicine [69] (Fig. 4B). It affects about 9% of recreational runners and causes up to 5% of 
athletes to end their sports careers [70].One research with 291 elite runners also showed that 
Achilles tendinopathy is the most common running-associated tendon problem, and 10 years+ 
runners have a higher risk of development of the disease [71]. 
Achilles tendinopathy can be divided into insertional and non-insertional tendinopathy 
(Figs. 4C, D). The insertional site of Achilles tendon is located at the tendon-bone junction, and 
it is divided into four continuous zones, 1) tendon, 2) fibrocartilage,3) mineralized fibrocartilage; 
and 4) bone[72]. Insertional Achilles tendinopathy often occurs in the tendon matrix proximal to 
the insertion into the heel bone; it is a degeneration of the tendon fibers and may be associated  
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Figure 4. Achilles tendon Anatomy and Insertional Achilles Tendinopathy. Achilles tendon attaches 
gastrocnemius and soleus muscle to calcaneus bone (A). Achilles tendinopathy is usually associated with tendon 
degeneration. (B) Achilles tendinopathy can be divided into insertional (C), and non-insertional (D). The insertional 
tendinopathy occurs 2-6cm proximal to the insertion site. Non-insertional tendinopathy occurs in mid-portion of 
Achilles tendon. Insertional tendinopathy has a higher incidence rate in relatively young and active population such 
as athletes. Figure Source: Images from Medical Multimedia Group 
 
 
 
with an inflammation of the bursa. Histological studies on insertional Achilles tendinopathy 
show the typical degenerative appearance of tissues, increased number of cells and more GAGs 
in the matrix as well as disorganized collagen fibers [73]. Insertional tendinopathy accounts for 
about 20% of all Achilles tendon disorder [74]. The insertional tendinopathy is considered to 
occur more in young (the average patient age is in the 40s) and in the active population, whereas 
non-insertional tendinopathy is found more in older, less active and overweight population [75]. 
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Insertional tendinopathy often causes pain, and impaired movement of the ankle and about 10 -
30% patients need surgical intervention [76].  
1.2.5 Treatment of Tendon injury and tendinopathy 
1.2.5.1  Surgical intervention  
Reconstructive surgery is often required for ruptured tendon [77]. The surgery often includes 
suture and anchor techniques. Severe and reluctant tendinopathy may also need surgical 
intervention [78], but it comes with the risk of infection. 
1.2.5.2 Physical therapy 
Active movements and proper mechanical loading are considered beneficial to tendon healing 
[78]. The eccentric exercise involves lengthening of the (affected) muscle-tendon unit slowly, 
which strength the muscle. It is reported that eccentric exercise decreases pain in Achilles 
tendinopathy [79]. Therefore, eccentric exercise is considered to be the most efficient therapy for 
chronic tendinopathy now and is recommended as first-line treatment [80].  
Additionally, many other physical modalities have been used in tendon disorder 
treatment. For example, extracorporeal shock wave [81], pulsed magnetic fields[82], therapeutic 
ultrasound[83], laser phototherapy[84], and massage are considered as second-line therapy; 
however, the efficacy of these treatments is inconsistent [85]. 
Autologous platelet-rich plasma (PRP) has been considered readily available and safe 
method for the treatment of tendinopathy. PRP promotes tendon cell proliferation and collagen 
deposition [43, 86], but the efficacy of PRP treatment in clinical studies has been very 
controversial. Some researchers claim that the inconsistencies of the treatment outcome of PRP 
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arise from different preparation conditions of PRP and various pathological conditions of 
tendinopathic patients [86, 87]. Therefore, the patient conditions should be carefully evaluated 
before proper PRP preparation is used for treatment. 
1.2.5.3  NSAIDs and Steroids 
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are broadly used for management of pain and 
inflammation in tendinopathy [88], but there is little evidence showing that they are effective in 
treating the chronic tendon injury [89]. Long-term use of NSAIDs to treat tendinopathy may 
carry a high risk of adverse effects [90]. While steroids like corticosteroids are used in non-
inflammatory degenerative tendinopathy, they only provide short-term pain relief [91, 92]. Some 
studies suggested that steroids might, in fact, weaken tendon tissue, and lead to tendon rupture 
particularly in weight-bearing tendons like patellar and Achilles tendons [93]. A recent study 
found that the popular dexamethasone treatment may result in non-tenogenic differentiation of 
TSCs, which may lead to tendon degeneration [94]. 
1.2.5.4 Tendon tissue engineering  
Tissue engineering approach is also employed for tendon healing. Mesenchymal stem cells 
(MSCs) [95], adipose-derived stem cells (ADSCs)[96] and tendon stem/progenitor cells (TSCs) 
[20] have been proposed for augmentation of tendon healing. Among these cells, the TSCs seem 
to be the most promising, since it will spontaneously differentiate into tenogenic cells while 
other cells might differentiate into another type of cells i.e. adipocyte, chondrocyte or osteocyte 
which might lead to tendon degeneration. However, harvesting autologous TSCs for tendon 
treatment is not possible in the clinical setting at present, so alternative strategies with the use of 
MSCs and ADSCs are also actively being studied. 
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The scaffold is another critical element for tendon tissue engineering. These temporary 
and degradable synthetic/native biomaterials will provide biomechanical support, and physical 
niche for the cells to move in, reside, proliferate and deposit new matrix. Scaffolds can also be 
modified or combined with growth factors or stem cells to improve repair/regeneration potential 
[97].  
Various growth factors are reported to participate in tendon development and healing 
process, and they have been studied widely for their potential to improve tendon healing. They 
include IGF[98], VEGF[99], TGF-β family[100, 101], PDGF[102], and bFGF[103]. These 
growth factors promote the proliferation and migration of tendon cells, and cellular production of 
collagen as well as the deposition of tendon matrix.  
1.2.6 Experimental models for tendinopathy  
Animal models have been extensively utilized for tendinopathy studies, especially using rodents 
such as rats and rabbits. Two types of experimental models, chemically-induced and mechanical 
loading -induced, are popular to induce tendinopathy in animals.  
1.2.6.1  Chemically- induced tendinopathy model 
Collagenase was first introduced to produce experimental injury to the tendon in animals [104]. 
It is the most widely used chemical-based tendinopathy model, and it can induce a repeatable 
lesion with tendon inflammation and degeneration. It has been applied in rat [105], rabbit [106] 
and horse [107], and experiments were conducted on flexor, Achilles, patellar and supraspinatus 
tendons [108]. It has been used as a standard model to investigate the effects of all types of 
treatment intervention.  
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Carrageenan, a type of vegetable polysaccharide, was reported to induce leukocyte 
invasion resulting in tendon damage when injected into rat Achilles tendon. This approach also 
found increased MMP activity and decreased TIMP concentration [109]. This chemical also 
attracts more macrophages than neutrophils. 
Injection of corticosteroid into rat Achilles tendon has been shown to increase cellularity 
and vascularity, but only 20% of the animals show significant symptoms of tendinopathy [110]. 
Although corticosteroid injection is not considered to generate a valid experimental model, this 
study did highlight the potential detrimental effects of corticosteroid injection in athletes. 
Prostaglandins were also used to induce tendinopathy since they were seen to be 
increased in overloading animal models in vivo [66] and in vitro [35, 66, 111]. The injection of 
PGE2 resulted in decreased collagen fibril diameter, and moreover, PGE2 is also suggested to 
induce the differentiation of TSCs into non-tenogenic lineage resulting in tendon degeneration 
[16].  
Recently, a strong chondrogenic reagent kartogenin (KGN) was reported to induce 
tendinopathic changes like the presence of chondrocytes and proteoglycan accumulation in rat 
Achilles tendon after 5-weeks of implantation [112]. This study also suggested that TSCs are 
involved in chondrogenic differentiation. Peritendinous elastase was recently utilized to create 
tendinopathy model by inducing degeneration in rat Achilles tendon [113]. 
1.2.6.2  Mechanical-loading induced tendinopathy model 
The most popular model to induce tendinopathy through mechanical loading is treadmill running 
of rodents, especially for rat supraspinatus tendinopathy. The model requires rats to run on a 
17m/min treadmill track with a 10-degree decline for 1hr/day, 5 days/week [114]. After the 
treadmill running regimen, the cross-sectional area of supraspinatus tendon increased but with 
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poor mechanical properties. Histologically, the tendon after treadmill running showed 
hypercellularity, round chondrocyte-like cells, enhanced vascularity, GAGs deposition and 
disorganized collagen fibers, the damages in the tendon increased with longer duration of 
treadmill running [115]. The cartilage marker expression was also found in this treadmill running 
model [33], indicating a possible fibrocartilaginous change in the tendon that resulted from 
tendon overuse [34]. 
Mouse treadmill running protocol (TRP) is similar to that of rat, but current mouse TRP 
is utilized mainly to explore the pathological change of hinder leg weight bearing tendons like 
Achilles and patellar tendon, and the speed is lower (12-15m/min) with longer duration each day 
(3-5hrs), without decline running. It was found that intensive running causes an increase in the 
production of inflammatory mediator PGE2, while moderate running does not cannot [66]. It was 
also reported that treadmill running results in myofibroblast accumulation in mouse patellar 
tendon [39]. Some other studies also found short-term treadmill running may help to expand the 
stem cell pool[116] and improve tendon quality on a chemically- induced tendinopathy model 
[117]. 
Another category of mechanically- induced model is passive loading. In this model, 
usually the animal is under anesthesia, and the tendon is passively stretched. One rabbit model 
has used a kicking machine by inducing active muscle contraction with electrical stimulation and 
found that the exercised tendon exhibited altered cell nuclei shape and increased fibroblast and 
vascularity in paratenon with infiltrated inflammatory cells [118]. A passive rat patellar tendon 
fatigue loading model secured tibia and patella toe to a customized machine to allow loading to 
patellar tendon [119]. Gene expression levels of collagen I, III were found to be increased with 
decreased cellularity and disorganized matrix. Additionally, CITED2 and MMP-3 expression 
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greatly increased with the moderate level of fatigue loading compared to non-loaded tendon 
tissue [119, 120]. 
1.3 HMGB1 
1.3.1  PAMPs, DAMPs, alarmins and HMGB1  
When the mammalian body needs to detect and monitor microorganisms that invade and cause 
tissue/cell damage, it activates the defense and repair mechanisms with innate and adaptive 
immune responses. The activation processes often start with recognition of certain molecules or 
molecular patterns [121]. Pathogen-associated molecular patterns (PAMPs) are a set of microbe 
–derived molecules such as lipopolysaccharide (LPS), viral RNA and bacterial peptidoglycans. 
These molecules can be recognized by cells of the innate and acquired immune system, usually 
through Toll-like receptors(TLRs), and they can activate several signaling pathways including 
the most distinctive one, NF-κB [122]. Besides PAMPs, there is another set of endogenous 
molecules that mainly signal tissue and cell damage, called alarmins. Alarmins are equivalent of 
PAMPs, but they will be released only due to nonprogrammed cell death (necrosis) or cellular 
injury/stress. The word alarmin was first created in 2006, and at that time, both alarmins and 
PAMPs were proposed as a subgroup of Damage-associated molecular patterns (DAMPs). 
However, nowadays, researchers use both alarmins and DAMPs interchangeably, and both refer 
to the endogenous danger signal molecules that trigger inflammation and tissue repair. The 
striking features of alarmin/DAMPs molecules are: 1) rapid release from nonprogrammed cell 
death (necrosis); 2) could be produced and secreted by the immune system; 3) recruit and active 
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innate immune cells; and 4) help restore homeostasis in damaged tissue [123]. Proposed 
alarmins/DAMPs include HMGB1, S100 proteins, heat shock proteins (HSPs), IL-1α and more 
[123]. Among them, HMGB1 is the only molecule that meets all the four criteria, and thus 
become the most studied alarmin/DAMP.  
1.3.2 Discovery of HMG family of proteins 
HMG proteins were first discovered in 1973 from calf thymus chromatin and were named “high-
mobility group” protein because they migrate rapidly in polyacrylamide gel without aggregation 
[124]. The two proteins HMG-1 and HMG-2 were identified with at least 10^5 molecules in the 
nucleus of each cell [125]. Along with other HMG family proteins, HMG-1 and HMG-2 were 
renamed as HMGB1 and HMGB2, respectively, in 2001 because of its HMG-box functional 
domain. Other superfamily members were renamed HMGA (formerly HMG-14/17) and HMGN 
(formerly HMG-1/Y) because of their unique functional motif [126]. HMGB family has totally 
four members with ~80% amino acid sequence identity.  
HMGB1 is the most expressed HMG family member with about 10^6 molecules per 
mammalian cell. HMGB1 is an extremely evolutionally conserved protein from 525 million 
years ago [127]. A homolog of mammalian HMGB1 was discovered in yeast, Drosophila, 
Chironomidae, echinoderms, bacteria, plants, fish, and C. Elegans [128-130]. The protein 
sequence of HMGB1 is 100% identical between mouse and rat, and 99% identical between 
rodent and human, only two amino acids on C-terminal are different [131, 132]. HMGB1 
knockout mice die shortly after birth due to hypoglycemia [133] suggesting the critical role of 
HMGB1 as a structural chromosomal protein. 
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1.3.3 HMGB1 structure and function 
HMGB1 consists of 215 amino acid residues and is about 30KDa in molecular weight. It has two 
DNA binding domains (Box A [9-79aa], Box B [95-163aa]), which are not sequence-specific, 
and an acidic C-terminal tail (186-215aa), which is the transcription stimulatory domain[134]. 
There are two nuclear localization signal (NLS) regions, NLS1 (28-44aa), and NLS2c (179-
185aa). The “default” location for HMGB1 is in the nucleus, and the change of NLS or nuclear-
emigration signals (NES) will result in HMGB1’s translocation [135](Fig. 5A). Due to its high 
mobility, HMGB1 can move into the cytosol from the nucleus or other organelles within 1-2s 
[136, 137]. HMGB1 also has a binding site for RAGE (150-183aa), which is related to cell 
migration[138], and TLR4 binding site (89-108), which is cytokine activity domain, and p53 
transactivation binding domain (7-74aa), which is responsible for regulation of inflammation and 
downstream gene expression[60]. The C-terminal consists of acidic amino acid residues, and this 
region was thought to protect Box A and Box B. But, later it was found to be related to DNA 
binding process of HMGB1 [139]. The secondary structure of two HMG boxes of HMGB1 is 
very similar with 3 alpha-helices and two loops that form an “L” shape with an 80-degree angle 
between two arms [140] (Fig. 5B, C). The tertiary structure of HMGB1 features 3 cysteines at 
position 23, 45 and 106, the forming of cys23-cys45 disulfide bond can alter the HMGB1 
interaction with receptors [141]. For quaternary structure, HMGB1 is usually in the homodimer 
and oligomer forms but may vary due to different extraction methods which potentially inactive 
HMGB1 [142, 143].  
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Figure 5. The structure and functional domains of HMGB1. (A) Beginning with N-terminal, HMGB1 protein 
consists of Box A domain  (red, 1-79aa), Box B domain (red,89-163aa), and c-terminal acidic tail (blue, 185-215aa), 
and connecting segments between them (80-88aa,164-184aa). Box A and Box B are sequence-independent DNA 
binding domains made up of basic amino acids. Box A (1-89aa), when isolated from the rest of the molecule, acts as 
a specific antagonist of HMGB1. Box B (90-176aa), when stand-alone, acts as cytokine-inducing molecular. The 
minimal peptide with HMGB1 cytokine activity is 20 amino acid segment of Box B (89-109aa). The region required 
for the activation of RAGE is located between residues 150 and 183. (B) Ribbon representation of A box, B box, 
and the c-terminal acidic tail. (C) Space-filling representation of A box and B box, the two box regions can rotate 
freely, blue regions show the basic residues that can interact with the acidic tail. Figure source: A: [144], B&C: 
[145]. 
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1.3.3.1 Nuclear and cytoplasmic HMGB1 
HMGB1 has distinct functions depending on its location (Fig. 6). Nuclear HMGB1 is a DNA-
chaperone and plays a major role in DNA activities like replication, repair, transcription and 
genomic stability with DNA binding and bending abilities [130]. HMGB1 in the cytoplasm was 
reported in living fibroblast with a normal ratio (nuclear to cytoplasm) 30:1 [146]. It is known by 
now that HMGB1 can translocate from nucleus to cytosol when the cells are stimulated with 
several stressors (cytokines, heat, hypoxia, hydroperoxide, etc.) [147]. A group of researchers 
has shown that cytoplasmic HMGB1 plays a positive regulatory role of autophagy [148, 149], 
which is a protective mechanism when the cell is under stress.  
 
 
 
Figure 6. HMGB1 function in nucleus, cytoplasm and extracellular milieu. HMGB1 acts as a DNA chaperone 
in the nucleus and regulates gene expression and DNA functions. HMGB1 in the cytoplasm is related to cell 
autophagy. Extracellular HMGB1 is a damage signal, exerting its function through DAMPs receptors like RAGE 
and TLRs and regulates inflammation and immune responses. HMGB1 also participates in the development of auto-
immune disease and tissue regeneration. Figure source: [150]. 
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1.3.3.2 Extracellular HMGB1- release and function 
The extracellular role of HMGB1 was uncovered in sepsis in 1999 [151]. Extracellular HMGB1 
is either passively released from necrotic, injured, stressed stromal cells, or actively released by 
immune cells like monocytes and macrophages (Figs.7A, B). Once released, extracellular 
HMGB1 has cytokine and chemokine activities. HMGB1 induces proliferation, cell migration, 
and survival, as well as development and maintenance of inflammatory response through the 
induction of its own release from inflammatory cells  [152-154].  
 
 
 
Figure 7. The current theory of HMGB1 extracellular release. (A) HMGB1 is released from cells via different 
pathways. HMGB1 can be actively released when immune cells like macrophages are stimulated by pathogenic 
agents like LPS. After initial stimulation, modification of HMGB1 occurs to facilitate HMGB1 release later. It takes 
a few hours for HMGB1 to be released. (B) HMGB1 can be passively released from somatic cells subjected to 
injury or under severe stress. The cells under primary necrosis will release HMGB1 passively and rapidly. 
Previously found HMGB1 are retained in the nucleus during apoptosis. Recent findings indicate that when those 
apoptotic cells undergo secondary necrosis, HMGB1 can be released from the apoptotic cells. Figure Source: [155]. 
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HMGB1, through binding to TLR or RAGE, actives macrophages, monocytes, 
neutrophils, fibroblasts, endothelial cells, and T-cells to produce all kinds of known cytokines 
like TNF, IL-1β, and IL-6. Also, HMGB1 exerts its pro-inflammatory activity through activation 
of NF-κb, ERK, and JNK pathways. HMGB1 can also bind to other DAMP or PAMP like LPS, 
DNA to amplify its pro-inflammatory potential [156, 157]. Inhibition of HMGB1 can 
significantly decrease the inflammatory response and tissue damage. HMGB1 is no doubt a 
critical pro-inflammatory cytokine. A key feature of HMGB1 is that it is abundant in cells and 
can be readily released upon any tissue damage. So HMGB1 was categorized as damage 
associated molecular pattern (DAMPs) member [158, 159]. It has the potential to “translate” 
other stress signal, i.e. mechanical stress into the biochemical signal, thus initiating inflammatory 
cascade. 
HMGB1 also promotes cell migration in several cell types including smooth muscle cells, 
stem cells, endothelial cells, monocytes, dendritic cells, and neutrophils [160-162]. These 
findings suggested that migration initiated by HMGB1 may contribute to the recruitment of 
immune cells and stem cells to tissue damage repair or wound healing site [163]. 
Only a few studies reported that HMGB1 promotes angiogenesis by showing that 
HMGB1 could induce endothelial cell migration in vitro [164]. Some studies revealed that 
HMGB1could induce proliferation of a particular type of mesoangioblasts and cardiac stem cells 
[161, 165]. In addition to the direct effect of HMGB1 on a certain type of cells on proliferation 
and angiogenesis, it is highly possible that HMGB1, through the recruitment of immune cells, 
indirectly promotes cell proliferation and new vessel formation in the injured site. 
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1.3.4 Redox Status and HMGB1 function  
It is suggested that the HMGB1’s function largely depends on its redox status [149]. HMGB1 
contains three cysteine residues C23, C45, and C106, of which C23 and C45 could form an 
intramolecular disulfide bond. HMGB1 has three redox status; the first one is fully reduced 
HMGB1, with all three cysteine residues in reduced status. A few research findings indicate that 
the fully reduced HMGB1 acts as chemokine and can form heterocomplex with CXCL12 and 
bind to CXCR4 [153]. The second is disulfide HMGB1 that refers to the HMGB1 with disulfide 
bond connecting C23 and C45. It was reported to act as a pro-inflammatory cytokine with 
minimal chemoattractant activity [166]. The third status is fully oxidized HMGB1 that is 
featured by all cysteine residues oxidized completely. This type of HMGB1 has no activity in 
cell migration, and cytokine induction [167, 168]. However, some other studies indicate that 
oxidized HMGB1 can still activate neutrophils, vascular inflammation, and age-associated 
inflammation [169, 170]. The redox form of HMGB1 can only be detected with mass 
spectrometry (MS) [171] or nuclear magnetic resonance (NMR) spectroscopy [172].There is no 
other convenient method available currently.  
1.3.5 HMGB1 in diseases 
HMGB1 has been extensively studied in several major diseases including cancer, stroke, 
endotoxemia, and joint disorders [173]. HMGB1 also has a key pathogenic role in diseases of 
kidney and lung, and arthritis, sepsis because of its pro-inflammatory effect [130, 174-177]. 
Recently, it was reported that a mechanism for the pathogenic role of HMGB1 in arthritis could 
be through enhancement of inflammatory and destructive mechanisms induced by other pro-
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inflammatory mediators present in the arthritic joint [178]. Injection of HMGB1 into normal 
joint caused the development of arthritis in 80% of animals in the study (other 20% without 
obvious arthritis development), whereas development of arthritis could be prevented if HMGB1 
was inhibited in this disease model [179]. Another study successfully treated the collagen- 
induced arthritis by targeting HMGB1 further implicating the crucial role of HMGB1 in the 
development of this disease [180].  
1.3.6 HMGB1 and mechanical loading  
There are only a few studies that applied mechanical loading to understand the alterations of 
HMGB1 expression, translocation, and its regulatory role in vitro and in vivo. For example, a 
group of researchers recently demonstrated a basal HMGB1 expression in periodontal ligament 
(PDL) cell cultures [181], and a significant increase of the mediator when challenged 
by mechanical loading similar to force levels being applied in orthodontic treatment in vivo 
[182]. They transferred these findings to an in vivo microenvironment in an animal model of 
tooth movement in rats [181]. Their data indicated the potential role of this protein in the 
regulation of the periodontal remodeling process in the course of orthodontic tooth movement. 
Later, another study also showed the expression of HMGB1 in the periodontal tissue subjected to 
orthodontic force application in mice [183]. 
1.3.7 HMGB1 and tendon injury 
Repetitive mechanical loading is considered as a major risk factor for tendinopathy, but to date, 
no direct mediator has been identified between the mechanical loading and the biochemical 
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response in tendon tissue. How the "mechanical signal" translate to injury related "molecular 
signals" to initiate the pathological development of tendinopathy has been unknown. Moreover, 
the presence of basal level expression of HMGB1 in tendons, its pathogenic role as an 
inflammatory mediator, and its potential as a therapeutic target in tendinopathy have not been 
investigated.  
In this study, we hypothesized that tendon cells and tissues under mechanical overloading 
release high levels of HMGB1 extracellularly to initiate an inflammatory cascade. Indeed we 
observed in this study that mechanical overloading of tendon cells and tissues translocated 
HMGB1 from nucleus to extracellular matrix. The addition of HMGB1 initiated an inflammatory 
cascade via enhancement of COX-2 and PGE2, inflammatory cell migration in vitro, and 
implantation of HMGB1initiated hypercellularity, angiogenesis, and inflammatory cell 
infiltration in vivo. Also, HMGB1 specific inhibitor, GL reversed these inflammatory reactions 
both in vitro and in mechanically overloaded in vivo models. 
1.4 CURRENT KNOWLEDGE AND GAP IN TENDINOPATHY 
1.4.1 Mechanical overloading/overuse is a major risk factor for tendinopathy 
For chronic tendon injury, tendinopathy is the term used to describe a complex pathology of the 
tendon with pain, the decline in function, and reduced exercise tolerance [184]. Histologically, it 
is often characterized by drastic degenerative changes in tendon such as cell shape change, 
deposition of GAGs, and disorganized collagen matrix [185].  
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It is intuitively reasonable that tendinopathy is the result of tendon overuse. Clinical and 
animal studies also provide some evidence for the intuition. For example, the incidence of 
tendinopathy is rising in developed countries because of increased participation in sports and 
physical activities [186]. It was reported that about 30% runners exhibit Achilles tendinopathy, 
with a 7-9% annual incidence [70]. Compared with age-matched control, long-distance runners 
have increased the incidence of Achilles tendinopathy [187]. Patellar tendinopathy is common in 
volleyball, handball, basketball, track and field as well as in soccer [188]. The fact that athletes 
are more prone to tendinopathy compared to general population suggests that the disease could 
be a cumulative result of long-term overuse. 
 In animals, tendinopathy in rat supraspinatus tendon has been successfully created with 
overuse through treadmill running [33]. The tendon with tendinopathy showed degenerative 
changes such as increased cellularity and loss of normal collagen fiber organization similar to 
those in human patients. Another study revealed that uphill treadmill running of rats could also 
induce the cellular and structural changes typical of tendinopathy degeneration in Achilles 
tendon [34].  
1.4.2  Whether inflammation is involved in tendinopathy has been controversial 
Early sports-related tendinopathy studies in human patients have shown that there is neither 
clinical evidence (redness, tenderness, skin changes or elevated inflammatory markers in blood) 
nor microscopic evidence (inflammatory cell infiltration) of inflammation in degenerative tendon 
tissue specimens [189, 190]. Also, anti-inflammatory agents were largely unsuccessful in treating 
the condition[191]. The opinion that tendinopathy is devoid of inflammatory process was widely 
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accepted among the clinicians and basic science researchers in early times. So the involvement 
of inflammation has long been underestimated in the development of tendinopathy. 
1.4.3 A continuum pathology model for the development of tendinopathy 
One popular theory to explain the pathology of tendinopathy without inflammation was proposed 
by Dr. Jill Cook in 2009, based on clinical, histological and imaging evidence. She suggested 
that a progression of tendinopathy consists of three related stages, so-called three-stage 
continuum model. The excessive mechanical load is considered as a risk factor to move towards 
the irreversible degenerative tendinopathy. The three stages involved in tendinopathy 
development are as follows.  
1. Reactive tendinopathy, characterized by a non-inflammatory proliferative response in 
cell and matrix, thickness of tendon, which is considered to result from acute overload or 
unloaded tendon. 
2. The second stage is tendon disrepair. This stage is manifested by increased cell 
number, mainly as chondrocyte-like cells and myofibroblasts, with increased presence of 
proteoglycans in the tendon, which results in disorganization of the matrix and may associate 
with vascular and neuron ingrowth. Moreover, the first two stages, if mechanical loading is 
properly modified, could be reversed; in other words, the tendinopathic tendons at the two stage 
could be back to normal tendon.  
3. The third and final stage is degenerative tendinopathy with cell death, a vast area of the 
disordered matrix and a large amount of vessel ingrowth, and the affected tendon has little 
capacity of reversing its pathological changes[192]. 
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This model was mainly established based on findings from human tendinopathic patients; 
the model is also used to develop the treatment plan for tendinopathy patients. In this theory, 
neither is inflammation included nor is it considered as a causative factor in the eventual 
degenerative development of tendinopathy. 
1.4.4 Tendinopathy is related to inflammatory response in recent studies 
It has been observed that the incidence of tendinopathy is higher in patients with obesity and 
decreased insulin sensitivity, as seen in type 1 and type 2 diabetes mellitus (T1/T2DM) patients 
[193-195]. One common shared risk of these two patient populations is the development of 
chronic low-grade, systemic inflammation [194, 196]. Inspired by this finding, researchers began 
to investigate the possible role of inflammation in tendinopathy.  
Recent discoveries in tendinopathy that have recognized the lack of acute inflammatory 
infiltrate in the late stage tendinopathy patients do not exclude the role of inflammation in the 
pathogenesis of tendinopathy in its early onset. Increasing evidence suggests that inflammatory 
mechanisms are activated during the early stage of tendinopathy development that probably 
contributes to dysregulated homeostasis [197]. One study has found the infiltration of 
macrophages, mast cells, B and T cells in early supraspinatus tendinopathy in human patients 
[198]. Also, the presence of CD68 and CD206 markers representing the macrophages has been 
found in both equine [199] and human [200] tendinopathy in the early and late stage of the 
tendon disease. A systematic review also revealed increased number of macrophages in four 
studies, mast cell in three studies, T-cells in one study in tendinopathic tissues compared to 
healthy control tendons [201].  
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 Previous studies conducted in our lab found that inflammation could be connected with 
tendinopathy through the non-tenogenic differentiation of TSCs, and high levels of PGE2 can 
induce TSCs to differentiate into adipocytes, chondrocytes, and osteocytes, which could be 
responsible for lipid deposition, proteoglycan accumulation, and calcification in tendinopathic 
tendons [16, 66, 202]. 
1.4.5 A proposed inflammation oriented tendinopathy theory  
The model Dr. Cook developed was widely approved but did not give consideration to the 
immune system; the model is not in complete agreement with recent findings suggesting a 
possible role of inflammation in tendinopathy. Another theory was recently proposed by Dr. 
Neal Miller based on recent findings related to inflammation in tendinopathy. He suggested that 
at least three compartments are involved in the development of tendinopathy. 
The stromal compartment, mostly tenocytes, may respond to DAMPs or PAMPs and shift 
into proinflammatory phenotype and interact with leukocytes as a similar behavior has been 
reported in rheumatoid arthritis synovial fibroblasts (RASFs). The previous study showed that 
activation of the RASFs resulted in accumulation, survival, and retention of leukocytes at the site 
of disease [203]. The immune-sensing compartment is composed of resident immune cells since 
mast cells have been found in both normal tendon and tendinopathic tendon [200]. Mast cells 
have been found to stimulate tenocytes to produce increased level of COX-2 and PGE2, as well 
as elevated MMP1 and MMP7 transcription in 3D collagen lattice, reflecting their potential role 
in homeostatic and tendinopathy development [204].The infiltrating compartment is comprised 
of influx immune cells, as increased number of macrophage, mast cells, NK cells, and T cells 
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have been found in tendinopathy biopsy [201, 205], indicating the important role of infiltrating 
immune cells in the development of tendinopathy.  
1.4.6  Tendon overuse induces inflammatory reactions  
Animal models have been widely explored to study the relationship between overuse and 
inflammation in tendon tissue, and much evidence indicates that overuse of tendon may result in 
an inflammatory phenotype of the tendon in terms of inflammatory cell infiltration and increased 
expression of inflammatory markers. For example, a repetitive upper extremity overuse rat 
model study suggested an accumulation of macrophages and mast cells in rat flexor tendon due 
to long-term (12 weeks) mechanical loading [206]. Another rat overuse model suggested 
increased mast cell infiltration in the calcaneal tendon with 7-week treadmill running [207]. 
IL-1β as an important inflammatory regulator of innate and adaptive immunity was found 
to be increased due to mechanical stretching of tendon cells, and it down-regulated the 
expression of collagen type I mRNA which may result in imbalanced ECM turnover in vivo 
[208]. Another study has shown that overuse with treadmill running led to the production of the 
potent inflammatory mediator PGE2 in mouse patellar and Achilles tendons at 3-week time point 
[66]. Also, repeated high dosage intratendinous injection of PGE2 caused degenerative changes 
in mouse tendon [45]. Moreover, peritenodinous injection of PGE1 resulted in the pathologically 
thickened tendon at both 1-week (1.34 times thicker) and 4-week (1.25 times thicker) time 
points. Therefore, it is likely that the development of tendinopathy could involve prolonged 
unresolved chronic inflammation. 
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1.4.7 Current knowledge gap: what is the contributing mechanism of abnormal 
mechanical loading in the onset and maintenance of inflammation in overused tendon? 
With the knowledge from several studies, a possible relationship among tendinopathy, tendon 
mechanical overloading(overuse) and inflammation could be deduced. The repetitive tendon 
overuse results in inflammation that contribute to the early development of tendinopathy 
potentially by the prolonged deregulated inflammatory response with subsequent degenerative 
changes (Fig. 8). 
 
 
 
Figure 8. The knowledge gap for the development of tendinopathy. Mechanical overloading of the tendon, or 
tendon overuse, has long been considered as a risk factor for the development of tendinopathy. It is known that 
mechanical overloading can result in tendon inflammation. Growing evidence indicates that tendon inflammation is 
involved in the development of tendinopathy possibly through the non-tenogenic differentiation and breakdown of 
the matrix with MMPs from inflammation. But how the mechanical overloading as a physical signal triggers the 
cellular response that invokes tendon inflammation is largely unknown.  
 
However, the mechanism by which the mechanical stress from overuse is converted into 
the initial inflammatory response is not clear [209]. Literature supported that stromal cells may 
play a crucial role in the onset and persistence of chronic inflammation [210]. Considering the 
 33 
lack of such studies in the tendon, another musculoskeletal disease such as rheumatoid arthritis 
(RA) might be informative in inflammatory responses. RA synovial fibroblasts (RASFs) as a 
pathological phenotype of synovial fibroblast, could alter ECM synthesis and produce 
inflammatory cytokines and chemokines such as MCP-4, CCL18, CXCL9, SDF-1, MCP-1 that 
recruit and maintain leukocytes in the synovial compartment and thus promote chronic 
inflammation [211].The resident tenocytes in tendon tissue may function similarly, as they are 
directly subjected to mechanical stress in the overuse scenario, a similar mechanism by which 
cytokines or inflammatory mediators are released to attract immune cells might operate by 
tenocytes, thus causing the onset and development of the chronic inflammation in overuse 
tendon. 
Some studies have been performed to fill the knowledge gap. One of them involves heat 
shock proteins, a member of the DAMPs. HSP72 protein was found to increase in tendon 
fibroblasts subjected to mechanical stress [212]. HSP 27 and HSP70 were also expressed in the 
matrix of torn supraspinatus (established pathological model) and matched subscapularis (early 
tendinopathy model) [213]. However, further studies are needed to determine the role of HSP as 
an inflammatory mediator in the development of tendinopathy. 
Hypoxia is considered as a risk factor of inflammation and apoptosis in early 
tendinopathy. A recent study found that the expression of hypoxia-inducible factor 1α (HIF-1α) 
in intact subscapularis tendon (representing early pathology) was elevated compared to matched 
torn supraspinatus tendon (established pathology) in human patients. Tenocytes under hypoxia 
showed increased production of proinflammatory cytokines like IL-6, IL-8, MCP-1[214], and 
another study also suggested that hypoxia contributes to apoptosis of tenocyte that may 
contribute to the development of tendinopathy [215]. Studies performed in our lab showed that 
 34 
TSCs might participate in the development of degenerative tendinopathy when exposed to 
inflammation conditions; specifically, TSCs exposed to high levels of PGE2, an inflammatory 
mediator, undergo non-tenocyte differentiation in vitro[16, 66]. 
1.4.8 HMGB1 causes the onset of tendon inflammation due to mechanical overloading  
In tendinopathy, external pathogens do not contribute to the development of the disease, because 
such a tendon injury is usually not associated with an open wound, but it is related to mechanical 
loading. If the development of tendinopathy is related to inflammation, the signal that invokes 
inflammation should be internally generated within the tendon.  
Damage-associated molecular patterns (DAMPs) are normal intracellular molecules that 
are released from cells upon cell death or cellular damage [121]. They recruit and activate 
inflammatory cells in the innate immune system including neutrophils, macrophages, and 
dendritic cells. Major DAMPs include HMGB1, S100, and heat shock proteins (HSPs) [123], 
among which HMGB1 is the most widely studied molecule. 
 HMGB1 is a highly conserved non-histone nuclear protein that binds to DNA and 
participates in stabilizing nucleosomes and regulates gene expression [130, 170]. It is considered 
to be present in all types of mammalian cells [130]. HMGB1 possesses unique characteristics; 
firstly it can be passively released in damaged/necrotic cells (or cell under severe stress) while 
retained in apoptotic cells. However, S100 and HSPs are released in both cases. The apoptotic 
cells can modify their chromatin so that HMGB1 binds irreversibly, and therefore it is not 
released [158]. Secondly, once released from the cytoplasm, HMGB1 participates in triggering 
inflammatory response through chemotactic activities on immune cells like monocytes, 
macrophages, neutrophils and dendritic cells [123], as well as on other type of cells that 
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participate in the wound healing process, including smooth muscle cells [163], and endothelial 
cells [216], and even certain kind of stem cells [161]. HMGB1 can also be released through 
active non-classic secretion by immune cells like macrophages. Additionally, HMGB1 is 
released upon mechanical stress in periodontal ligament tissue and synovial fibroblasts [181, 
183]. This particular feature is of great importance as they demonstrated that HMGB1 could be 
released upon mechanical stress very similar to what tenocytes are subjected to in overused 
tendon. Extracellular HMGB1 has been studied in kidney, lung, arthritis, sepsis and other 
diseases for its pro-inflammatory effect [130, 174-177, 217]. HMGB1 has been targeted in 
multiple preclinical models of sterile diseases, including arthritis, by inhibition of its pro-
inflammatory effect [218, 219]. All the features of HMGB1 indicate that it could be an excellent 
candidate to fill the knowledge gap of how damage signal is generated in response to abnormal 
mechanical stress and subsequent inflammatory reaction. However, its presence and function 
have rarely been studied in tendon biology or tendinopathy. To date, there is only a single 
published report that found higher expression of HMGB1 in tenocyte of the rotator cuff in 
arthritis patients [220]. However, studies are lacking in terms of the role of HMGB1 as an 
inflammatory agent in overuse models or clinical tendinopathy. 
1.5 GOAL OF THE STUDY AND CENTRAL HYPOTHESIS 
The goal of this research is to investigate the origin and inflammatory function of HMGB1 in 
tendon biology, and its role in overuse tendinopathy model, as well as to explore a therapeutic 
method to treat or even prevent the development of tendinopathy at the early stage by blocking 
the effects of HMGB1. The central hypothesis is that extracellular HMGB1 induced by excessive 
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mechanical loading in overuse tendon model is responsible for the onset of tendon inflammation 
and early development of degenerative tendinopathy, and inhibition of HMGB1 activity may be 
beneficial in treatment or prevention of tendinopathy. 
 
To test this central hypothesis, we propose the following three aims:  
Aim 1: To demonstrate the presence of HMGB1 in both tendon cells and tissues as well as 
their ability to release HMGB1 from tendon cells to the extracellular space/matrix after 
mechanical overloading 
Immunofluorescence (IF) staining and Western blotting (WB) were performed to demonstrate 
the presence of HMGB1 in the tendon. In vitro cyclic stretching on tendon cells was conducted 
to determine HMGB1 release upon mechanical stimuli. An in vivo mouse treadmill running 
model with different intensities was conducted, and HMGB1 released to the tendon extracellular 
matrix was measured.  
 
Aim 2: To investigate the function of extracellular HMGB1 in triggering the inflammatory 
reaction in tendon cells in vitro and tendon tissue in vivo.  
The pro-inflammatory in vitro effect of HMGB1 on tendon cells was determined by 
administration of HMGB1 protein to cultured tendon cells. The effects of HMGB1 on cell 
proliferation and migration were evaluated. Inflammatory factors such as PGE2, COX-2, and 
MMP-3 were measured by Western blotting/ELISA.  
The in vivo inflammatory effect of HMGB1 was tested by administration of recombinant 
HMGB1 into tendon tissue at various time points. H&E and IHC staining were utilized to 
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evaluate overall tendon structure and cell density, vessel formation, and inflammatory cell 
infiltration, as well as COX-2 and MMP-3 presence.  
Aim 3: To explore the effect of glycyrrhizin (GL), a direct HMGB1 inhibitor, on preventing 
of the development of degenerative tendinopathy due to mechanical overloading 
In vitro inhibitory effects of GL on HMGB1 were performed with tenocytes and measured for 
COX-2 and MMP-3 with ELISA and IHC staining.  
Mice were subjected to intensive treadmill running for 3-24 weeks with/without 
treatment with HMGB1 inhibitor glycyrrhizin. ELISA and immunostaining were used to 
evaluate the short-term (3 weeks) effect of GL in blocking overloading induced the inflammatory 
effect. The tendon structure and cellular composition were examined by H&E, IHC staining to 
verify the development of the degenerative model and prevention effect from GL. 
In Chapter 2, major finding on the HMGB1 presence in tendon and how HMGB1 release 
is related to mechanical loading will be presented, as well as studies on the release mechanism of 
HMGB1 from tendon cells induced by mechanical loading. In chapter 3, the results from Aim 2 
will be covered, by analyzing/determining the potential effect of HMGB1 in tendon tissue and 
cells. In chapter 4, findings from Aim 3 will be presented, and also how GL, a known HMGB1 
inhibitor, could reverse the inflammatory and degenerative change of overloaded tendon in short 
and long term overloading model in mice will be presented. In Chapter 5, extensive discussion of 
the significance of the findings from this study will be presented with an emphasis on how they 
fit in with current knowledge in terms of the development of tendinopathy, and how these 
finding can advance our understanding of tendon biology, pathology, and etiology of 
degenerative tendinopathy. 
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2.0  HMGB1 IS PRESENT IN TENDONS AND IS RELEASED UPON 
OVERLOADING 
This chapter will introduce the evidence for the presence of HMGB1 in the tendon, and its 
release due to mechanical loading. We found that HMGB1 is present in both cells in tendon 
tissue and cultured tendon cells, while the HMGB1 is not present in the matrix of tendon tissue. 
HMGB1 is released to extracellular milieu when the tendon cells are being excessively stretched 
in vitro and HMGB1 is released in vivo in tendon tissue due to intensive treadmill running in 
mice. Mechanism of HMGB1 release from tendon cell was studied, and we have shown that 
mechanical loading -induced HMGB1 acetylation is likely responsible for the translocation of 
HMGB1 to the cytoplasm and temporary membrane damage may provide the pathway of 
HMGB1 release into extracellular space from tendon cells. 
2.1 HMGB1 IS PRESENT IN NORMAL TENDON TISSUE AND CELLS 
2.1.1 Rationale 
HMGB1 is a conserved nuclear protein with an important function on genome stability and gene 
expression, as well as DNA folding. HMGB1 has been reported to be present in most 
mammalian cell types [130]. It is reported that there are 10^6 HMGB1 molecules in one cell, 
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which is only an order of magnitude less than the core histone protein[221], which indicates the 
constructive role of HMGB1 in the cell nucleus. A Previous study reported that HMGB1 is 
present in the cytoplasm in rat fibroblasts [146]. The normal content of cytoplasm HMGB1 is 
about 1/30 of that in the nucleus[222], and there is a signaling system that controls the nuclear 
localization of HMGB1 which involves the modification of two nuclear localization signals on 
HMGB1 protein[135]. In the normal state, HMGB1 is stored in the nucleus but can translocate to 
the cytoplasm, or it can be even released from cells when cells are under stress or damaged. 
However, neither its presence nor its role has been studied carefully in tendon cells or 
tissue. Considering HMGB1’s fundamental role in maintaining normal cell function, it is highly 
expected to be present in the tendon cells as well as within tenocytes in tendon tissue.  
We first explored the presence of HMGB1 in tendon tissue and cells with Western 
blotting and immunostaining. Fig. 9B shows HMGB1 is present in the total lysate of the patellar 
tendon (PT) and Achilles tendon (AT), and in both types of tendon cells isolated from the 
corresponding tendon tissue (Fig. 9A). The Western blot bands are generated by an infrared tag 
with Odyssey Clx infrared imaging system (LI-COR Biosciences, Lincoln, NE). Fig. 9C shows 
that HMGB1 is not present in the normal tendon matrix. The tendon tissue was not processed 
with detergent to penetrate the cells. So intracellular HMGB1 is not shown in this figure. Fig. 9D 
shows the tendon tissue penetrated with 0.2% Triton X-100 for 30min and stained for HMGB1, 
which demonstrates that HMGB1 is present in both nucleus and cytoplasm in tenocyte in vivo. 
As we see that no HMGB1 signal was detected in tendon matrix with immunostaining (Fig. 9C) 
but can be found within the tendon cells in the tendon (Fig. 9D). This means HMGB1 detected 
using western blot (Fig. 9A) in the tendon tissue lysate come from the tendon cells. At the same 
time, we found not all tenocytes are positive for HMGB1 in vivo (Fig. 9D). But in Figs. 9E, F, 
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and G show that in normal cultured tendon cells, HMGB1 is almost positive in 100% of the cells 
and concentrated in the nucleus with minimal staining in the cytoplasm (passage 3, rat Achilles 
tenocytes). The differential distribution of HMGB1 in vivo and in vitro will be discussed in detail 
in chapter 5. 
 
 
 
Figure 9. HMGB1 is present in tendon cells in vitro and tendon tissue in vivo. (A) Tendon cells isolated from 
the patellar (PT) and Achilles (AT) tendons show HMGB1 presence in vitro. Western blot analysis was performed, 
and β-actin was used as an internal reference. (B) The presence of HMGB1 in both patellar tendon (PT) and Achilles 
tendon (AT) tissues in vivo. (C) Tendon tissue stained with HMGB1 without penetration with detergent show that 
HMGB1 is minimal in tendon matrix. (D) HMGB1 staining in the tendon with Triton X-100 penetration shows that 
HMGB1 is expressed in tendon cell nucleus and cytoplasm. Note that some cells in tendon are negative for HMGB1 
staining. (E) HMGB1 staining in Achilles tendon cells cultured in vitro (red), which overlaps with the Hoechst 
H33342 stained nuclei (F, blue). (G) Overlay of both stainings showed the presence of HMGB1 in the nuclei of 
tendon cells (pink). Bar - 50 µm. 
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2.2 RELEASE OF HMGB1 FROM TENDON CELLS IN VITRO 
2.2.1 Rationale 
It is regarded that extracellular HMGB1 is not naturally present in normal physiological 
conditions, but only released from inflammatory or stromal cells through active secretion or 
passive release under certain stimulation or damage. Active release is mainly found in 
macrophages and other inflammatory cells upon the stimulation of PAMPs or DAMPs. HMGB1 
has known to be passively released from necrotic cells and triggers inflammatory reactions [158]. 
It can also be released when stromal cells are subjected to severe stress, including hypoxia [223], 
irradiation, hyperthermia, and hyper pressure [224]. Recently, it has been reported that 
mechanical loading can induce HMGB1 release in periodontal ligament tissue [181]. Since 
tendon cells are exposed to highly repetitive mechanical loading conditions in vivo, HMGB1 can 
be stimulated to be released from tendon cells by mechanical loading. 
2.2.2 The translocation and release of HMGB1 from nucleus of tendon cells to cytoplasm 
and extracellular space in vitro in response to excessive mechanical loading 
 The previous study showed an increased inflammatory mediator PGE2 release from 8% cyclic 
stretched tenocytes but not from 4%, compared to non-stretched control [66]. This model was 
selected for this experimental setting as 8% stretch is considered as excessive loading condition 
and 4% stretch as moderate loading. To mimic the human activity in the in vitro experiment, the 
stretching frequency was set at 0.5Hz. Fig. 10A shows the customized stretching machine used 
for the in vitro stretching, and Fig. 10B shows the microgroove surface of the stretching dish 
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which carries the cells. It was designed to mimic in vivo arrangement of the tendon cells that is 
displayed in Fig. 10C. Detailed description and discussion of this model and the customized 
stretching machine can be found in chapter 5. 
 
 
 
Figure 10. Custom designed apparatus for cyclical cell stretching in vitro.  (A) Tendon cells are seeded into 
microgrooved silicone dishes (green rectangles, A) attached to the cyclical stretching machine, with which uniaxial 
stretching is applied to cultured cells to mimic physiological mechanical loading conditions on tendon tissue. (B) 
Cells are plated and stretched in the center of each silicone dish where the surface strains are uniform. Black arrow 
points to a tendon cell on the microgrooved culture surface; green arrows show the stretching direction. Tendon cells 
align along the ridge of the microgrooved surface with the same axis where stretching is applied. (C) It is very 
similar to the physiological condition of the tendon cells in vivo shown by black arrows in (C) that point to the 
tendon cells in normal tendon tissue that align along the collagen fibers. Bars - 50 µm 
 
 
 
Rat Achilles tendon cells at passage 4 were seeded in the microgrooved dishes. After 
72hrs stretching, immunostaining with monoclonal HMGB1 antibody showed that HMGB1 was 
predominantly expressed in the nuclei of tendon cells in the unstretched control group (Fig. 11A, 
D), as well as in the group subjected to moderate stretching at 4% stretch level for 72hrs (Fig. 11 
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B, E). In contrast, HMGB1 staining was negative in the nuclei of about 65% tendon cells 
stretched excessively at 8% strain level for the same duration (Fig. 11C, F). This suggests that 
excessive mechanical stretching triggers the translocation of HMGB1 from the nuclei of tendon 
cells to the cytoplasm. Semi-quantification of the immunostaining also revealed an ~ 65% 
decrease in HMGB1 staining in the cell nucleus stretched excessively at 8% strain level (Fig. 
11G). Of the 65% cells without nuclear HMGB1, about 40% cells showed cytoplasmic staining 
of HMGB1, and about 25% cells completely lost HMGB1 staining (Fig. 11H), which indicated 
that HMGB1 might have been released to the medium. To test whether HMGB1 is released into 
the medium from tendon cells, HMGB1 from the supernatants of culture medium in each group 
was quantified by ELISA. Compared to the control level, HMGB1 level in the 4% stretching 
group showed no significant change. However, the HMGB1 protein level in the medium of the 
8% stretched cells was significantly higher than the control group (2.4 fold higher, P < 0.05) 
(Fig11. I). This result confirmed that HMGB1 translocated to the cytoplasm and subsequently 
released to extracellular space in response to excessive mechanical loading in tendon cells in 
vitro.  
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Figure 11. Mechanical overload induces translocation of nuclear HMGB1 to the cytoplasm and extracellular 
milieu in tendon cells. (A, D)  Unstretched control cell nuclei stained positive for HMGB1. (B, E) 4% stretched cell 
nuclei also stained positive for HMGB1. (C, F) 8% stretched cell shows sparse positive stain for HMGB1 in the 
nuclei indicating that it has translocated from the nuclei under excess mechanical load (8%). The majority of cells at 
8% stretch show HMGB1 in the cytoplasm, which is not seen in unstretched control or 4% stretch group. (F) Cells 
were immunostained for HMGB1 and counterstained with Hoechst 33342. Data shown are representative of at least 
two replicate experiments. (G) Unstretched control and 4% stretched cells are enriched with HMGB1 positive nuclei 
(~95%), but in 8% stretched cells, there is ~60% reduction in HMGB1 positive nuclei. (H) Distribution of HMGB1 
in 8% stretching group. About 17% cells retain HMGB1 in nucleus without HMGB1 in the cytoplasm, and 
approximately similar percentage of cells are with both nuclear HMGB1 and cytoplasm HMGB1; these cells are 
considered only slightly affected by the stretching. About 25% cells completely lost HMGB1 in nucleus and 
cytoplasm, which could have been released to extracellular space. About 40% cells are with cytoplasm staining but 
not nucleus staining of HMGB1; these cells might be in the process of releasing HMGB1. (I) The levels of HMGB1 
in unstretched control, 4%, and 8% stretched cells after 3 days of stretching at 0.5Hz. 8% stretch significantly 
increases HMGB1 levels in culture medium compared to control and 4% stretch when quantified by ELISA. All 
data are means ± SD. n=6 *P< 0.05. Bars - 50 µm. 
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2.3 MECHANISM FOR HMGB1 TRANSLOCATION DURING CYCLIC 
MECHANICAL LOADING ON TENDON CELLS 
2.3.1 Rationale 
The mechanism of HMGB1 translocation during excessive mechanical loading was investigated 
subsequently. Acetylation is a process that when an acetyl functional group is transferred from 
one molecule to another. In the proteins, it happens to the epsilon-amino group of a lysine 
residue. Deacetylation is the reverse reaction when the acetyl group is removed from, this two 
processes are typically enzyme catalyzed in cells, acetylation can be mediated by histone 
acetyltransferase (HAT), and deacetylation is induced by histone deacetylase(HDAC), even 
namely histone related, the acetylation targets are not restricted to histones, but also found in 
transcription factors, other nuclear proteins(i.e. HMGB1), and cytoskeleton, metabolic enzymes 
and signaling regulators in cytoplasm [154]. Acetylation is considered as a major post-
translational modification nowadays, and this process affects protein functions and localizations 
in cells. [225] 
It is reported that acetylation is critical for HMGB1 localization, and hyperacetylation of 
HMGB1 in monocytes will direct its translocation from nucleus to the cytoplasm [135]. In this 
study, researchers found that upon external stimulation (i.e. LPS), HMGB1 could be acetylated 
and will lose the nuclear-localization signal then traffic, and accumulate in the cytoplasm instead 
of staying in the nucleus in macrophages[135]. When monocytes are stimulated by LPS, 
HMGB1 is known to translocate to the cytoplasm, then secreted, and deacetylation could block 
this translocation process through inhibition of HATs [226]. These two studies together suggest 
that acetylation is involved in HMGB1 translocation in inflammatory cells. We tested this 
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mechanism in tendon cells and found that HMGB1 translocation is at least partially due to the 
acetylation induced by the excessive mechanical loading. 
During the in vitro tendon cell stretching experiment (Fig. 11), it is shown that tendon 
cells that lost HMGB1 in nucleus due to mechanical loading are still firmly attached to the dish 
surface, unlike necrotic cells which would detach and float in the medium. Based on these 
results, it is possible that HMGB1 translocated in tendon cells from nucleus to cytoplasm due to 
the acetylation of HMGB1 that is mediated by excessive mechanical loading and then released to 
the extracellular milieu.  
2.3.2 HMGB1 translocates from nucleus to cytoplasm upon hyper-acetylation 
Trichostatin A (TSA), a deacetylase inhibitor, is widely used to inhibit the deacetylation process. 
As in cells, both the acetylase and deacetylase co-exist and delicately balanced, if one type of 
enzyme was inhibited, the balance would drastically skew to the other direction, in our 
experimental setting, the inhibition of deacetylase with TSA will result in hyperacetylation of 
nuclear and cytoplasm proteins.  
The treatment of TSA resulted in HMGB1 translocation in macrophage due to 
hyperacetylation of HMGB1 in a previous study [135]. We expect that treatment of TSA on 
tendon cells may lead HMGB1 to translocate to the cytoplasm in normal culture condition. 
Rat Achilles tendon cells at passage 4 were treated with 0, 10, and 100 ng/ml TSA for 
2hrs, and then immunostained with HMGB1. The results showed a significant increase of 
HMGB1 staining in the cytoplasm in both 10 and 100 mg/ml TSA treated groups (Fig. 12B, C), 
while HMGB1 was constrained in the nucleus of the non-treated cells (Fig. 12A).  
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Figure 12. Inhibition of deacetylation by Trichostatin A (TSA) treatment results in HMGB1 translocation 
from nucleus to cytoplasm in cultured tendon cells. Tendon cells (rat AT P4) were treated with 0, 10,100ng/ml 
TSA for 2hrs and stained for HMGB1. The cells without TSA treatment show HMGB1 signal restricted to the 
nucleus (A) but with 10 ng/ml (B) or 100 mg/ml (C) TSA treatment show HMGB1 translocation to the cytoplasm in 
the majority of the cells. When the TSA (10 ng/ml) was removed after 2 hrs treatment and fresh medium was 
supplied to the cells for 4hrs recovery (10ng/ml+REC), the HMGB1 returns to the nucleus from cytoplasm after 
4hrs. This shows that HMGB1 translocation is reversible (D). A small percentage of cells (4-5%) with TSA 
treatment may have completely lost HMGB in the nucleus (arrow in B, C). Semi-quantification of cytoplasm 
HMGB1 positive percentage is from at least 3 replicate wells (E). *P<0.05 compare to control Bars - 50 µm 
 
 
 
Interestingly, this effect was reversible when the TSA treated cells were supplied with 
fresh medium for 4hrs, most HMGB1 translocated back to the nucleus (Fig. 12C). However, the 
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observation that not all HMGB1 translocated from nucleus to cytoplasm indicated that other 
mechanisms or post-translational modification might be possibly involved.  
2.3.3 Mechanical loading-induced HMGB1 translocation is blocked by inhibition of 
acetylation process 
It was reported that LPS mediated HMGB1 translocation in macrophage could be blocked by 
anacardic acid (AA), which is a histone acetyltransferase activity (HAT) inhibitor [226]. It could 
block the acetylation process of HMGB1 and result in HMGB1 deacetylation in nucleus and 
cytoplasm. Now that we found HMGB1 is translocated during the hyperacetylation in tendon 
cells in section 2.3.2, and excessive mechanical loading can also translocate and release 
HMGB1, it is reasonable to propose that the translocation of HMGB1 may be mediated by 
acetylation of HMGB1 in the nucleus. If that is true, blocking the acetylation process during 
stretching should help to keep HMGB1 in the nucleus of tendon cells. 
Similar to the previous stretching experiment settings with the customized stretching 
machine, the tendon cells were stretched under 8% strain with 0, 5, and 25 µM AA for 72hrs 
with changes of fresh medium (with the corresponding different concentration of AA) every 
24hrs. 100 µM AA caused major cell death. Therefore it was not included in the assay. At the 
end of the stretching, cells were stained with HMGB1. Immunostaining results show that 
HMGB1 is expressed in the nucleus in non-stretched cells (Fig. 13A, E). , About 55% of tendon 
cells lost HMGB1 in the nucleus in the stretch only group (Fig. 13B, F). HMGB1 was partially 
retained in the nucleus after stretching with 5 µM and 25 µM AA treatment groups (Fig. 13 C, 
D, G, H). Semi-quantification showed that 70% and 85% cells are with HMGB1 staining in the 
nucleus with 5 µM or 25 µM AA treatment respectively (Fig. 13I).  
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Figure 13. Blocking the acetylation process induced by mechanical loading with Anacardic Acid (AA) 
prevents the HMGB1 translocation.  AA was found to prevent the HMGB1 translocation from macrophage due to 
LPS treatment. Tendon cells (rat AT P4) were seeded in microgrooved dishes and subjected to 8% stretch for 3 days, 
and 0, 5, and 25 µm AA were added to culture medium with a change of medium every day. Cells were stained with 
HMGB1 by the end of day 3. (A) In cells without stretching, HMGB1 is located in most nuclei. (B) There is a 
drastic loss of HMGB1 in nuclei after 8% stretching for 3 days. (C) AA treatment (5 µm) helps to retain HMGB1 in 
nuclei in part of the cells after stretching. (D) The addition of 25 µm AA prevents more cells from the translocation 
of HMGB1 induced by stretching than 5 µm. (E),(F),(G), and (H) are merged images of (A),(B),(C), and(D) with 
nucleus counter-stained with H33342(sigma). (I) Semi-quantification shows HMGB1 positive percentage in cell 
nucleus in each group (*P<0.05 compared to all other groups). Bars - 100 µm 
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AA prevents HMGB1 translocation with excessive mechanical loading likely in a 
dosage-dependent manner. However, some cells are still negative for HMGB1 staining after AA 
treatment. The result indicated that mechanical loading-induced HMGB1 translocation is 
mediated by the acetylation of HMGB1 in tendon cells. Blocking the acetylation process may 
help to retain HMGB1 in the nucleus, and may prevent the release of HMGB1 from the 
cytoplasm to extracellular space, but the mechanism by which HMGB1 in the cytoplasm is 
released is not known previously. 
2.4 HMGB1 RELEASE MECHANISM FROM TENDON CELLS DURING 
STRETCHING 
2.4.1 Rationale 
HMGB1 can be released from cells through active or passive ways; it is widely accepted that 
active release is restricted to inflammatory cells [227]. HMGB1 is known to be passively 
released from stromal cells when the cells are damaged or under stress. Tendon cells under 
mechanical stress translocate and release HMGB1 to extracellular space. In section 2.3, we have 
discussed the translocation mechanism but how HMGB1 is released after translocated to 
cytoplasm from the nucleus is still not clear. The two possibilities are that excessive mechanical 
loading is severe physical stress that might induce temporary damage to the plasma membrane 
[228], or it could be related to mechanical loading mediated DNA damage-induced apoptosis and 
secondary necrosis [152, 229]. Or maybe both processes are involved. 
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Figure 14. DNA damage is not necessary for HMGB1 translocation from the nucleus.  Rat AT tendon cells 
were stretched for 3 days at 8%, then stained with (A) γ-H2AX as a DNA damage marker and (B) HMGB1 (C) 
staining images merged with counter-staining of the nucleus with H33342. (D) Cells can be divided into 4 different 
types depending on whether they are positive for γ-H2AX and/or HMGB1 in the nucleus. a) γ-H2AX-
/HMGB1+(49.3%), which represents the cells in normal status with no DNA damage or HMGB1 translocation, 
which are not many in this analysis. b) γ-H2AX-/HMGB1-(32.3% arrowhead), cells with HMGB1 translocation 
without DNA damage. A large number of this type of cells indicates HMGB1 translocation without DNA damage. 
c) γ-H2AX+/HMGB1+(18.2%, arrows) cells are with DNA damage but without HMGB1 translocation, which also 
suggests that DNA damage is not associated with HMGB1 translocation. d) γ-H2AX+/HMGB1-(1.5%) type with 
DNA damage and HMGB1 translocation but is very rare in our experiment. So from the distribution of various cell 
types, we can conclude that DNA damage is not likely associated with HMGB1 translocation induced by mechanical 
stretching. Note that cell numbers were counted in 3 different regions of each well, and a total of separate wells were 
included.  
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2.4.2 DNA damage is not related to mechanical loading-induced HMGB1 release 
To explore the possible DNA damage-related HMGB1 release by mechanical loading, γ-H2AX 
was utilized as a DNA damage marker. H2AX is a variant of the H2A protein family, which is 
part of the histone octomer structure, and when DNA damages histones are phosphorylated 
subsequently, and the newly phosphorylated protein γ-H2AX, is responsible for recruiting and 
localizing proteins for DNA repair[230]. γ-H2AX was used to visualize DNA damage caused by 
chemical agents, environmental and physical damage[230]. In this experiment, we employed γ-
H2AX as DNA damage marker and tested the possible DNA damage induced by excessive 
mechanical loading and the relationship between DNA damage and HMGB1 release.  
With a similar setting as previously mentioned stretching experiments, tendon cells were 
stretched 8% for 72hrs, and γ-H2AX and HMGB1 double staining was performed to study the 
correlation of DNA damage and HMGB1 release. Cells can be divided into four types according 
to the positive staining of γ-H2AX and HMGB1. The first type of cells that are about 45-50% is 
the γ-H2AX negative/HMGB1 positive cells. These cells are without HMGB1 release or DNA 
damage, and this type of cells is considered normal cells. The second type of cells which are 
about 30-35% is the γ-H2AX negative/HMGB1 negative cells (Fig. 14 A, B, C arrowheads). 
These cells show that HMGB1 could be released without DNA damage. The third type of cells 
that represented about 15-20% of all cells are γ-H2AX positive / HMGB1 positive (Fig. 14A, B, 
C arrows), which means those cells are with DNA damage, but without HMGB1 release. The 
fourth type of cells is rare (<3%) with γ-H2AX positive/HMGB1 negative; that should be 
abundant if DNA damage is associated with HMGB1 release due to mechanical loading. 
Considering that the cells can release HMGB1 without DNA damage and cells with DNA 
 53 
damage do not necessarily release HMGB1, we can conclude that DNA damage is not directly 
related 
2.4.3 Temporary plasma membrane damage may contribute to HMGB1 release 
It is suggested mechanical loading could introduce temporary disruption of the plasma 
membrane [228], and this might be the mechanism how the translocated nuclear HMGB1 in 
tendon cells will be released from cytoplasm to extracellular milieu. To study this possibility, the 
live/dead cell assay with Propidium Iodide (PI) and Fluorescein Diacetate (FDA) was performed. 
While FDA is an esterase substrate that can mark the live cells with green fluorescence when 
hydrolyzed by intracellular esterase, PI is a membrane- impermeable DNA binding agent that 
generally will not stain live cells. It specifically stains the necrotic cells by binding to its DNA 
through the compromised membrane. Hence, the special feature of PI is very helpful in our 
experimental settings as it could go through the plasma membrane if the membrane is 
temporarily disrupted. So, by using PI and FDA double staining, we can identify live cells that 
had temporary membrane disruption, which may help explain the HMGB1 release mechanism. It 
is reasonable to propose that during excessive mechanical stretching, the tendon cell membrane 
will be temporarily disrupted and will allow diffusion of PI into tendon cells. 
Tendon cells are stretched with 8% strain following the previous stretching protocol for 
6hrs. 20 µg/ml PI were added at the beginning of the experiment and 10 µg/ml FDA were added 
at the end of the stretching to make sure cells survived the stretching was measured. After 
addition of FDA, cells were then kept still for 1hr before counter-staining with H33342 and then 
pictures were taken.  
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Figure 15. Mechanical loading-induced plasma membrane damage but not cell death may explain HMGB1 
release.  Tendon cells were seeded in microgrooved silicone dish with or without 8% stretching for 6h, and 
Fluorescein Diacetate (FDA, 10 µg/ml) and Propodium Iodide (PI, 20 µg/ml) were added to the culture medium at 
the beginning of the stretching. Cells without stretching (A) or with stretching (E) are positive for FDA derived 
green fluorescence signal indicating live cells. Control cells are negative for PI (B), but most cells in the stretch 
group (F) is positive for PI indicating that they may be subjected to temporary plasma membrane damage. (C, G) 
show merged images of FDA derived signal, PI and nuclear counter-staining with H33342. (D, H) enlarged figures 
to show positive staining of PI in stretching group (H, arrows) but not in control group (D). (I) Semi-quantification 
shows ~50% cells after stretching are positive for both FDA derived signal and PI. PI detects dead cells with plasma 
membrane leak and binds to DNA, and the reason for the live cells with PI signal is that the temporary and 
reversible damage of plasma membrane allow PI to enter through the membrane. HMGB1 may diffuse to 
extracellular space through the temporary cellular plasma membrane damage.  Bars - 50 µm 
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We found that in the control group without stretching, the green signal (which come from 
the processed FDA in live cells) was very strong, and almost all cells were positive for green 
fluorescence signal (Fig. 15A), and this also holds true for the stretched cells (Fig. 15B). As 
expected, the red signal of PI in the control cells is minimal (Fig. 15C), but is strong in stretched 
group (Fig. 15D), and Fig. 15H clearly shows that the PI staining inside the nucleus of green 
signal positive cells. 
Semi-quantification indicates that after stretching, about ~50% cells are positive for both 
PI and green signal (Fig. 15I), which means those were live cells subjected to temporary plasma 
membrane damage during the stretching. This implied that HMGB1 could be released during the 
temporary disruption of plasma membrane induced by excessive mechanical loading. 
In summary (sections 2.3 and 2.4), in vitro HMGB1 was translocated from nucleus to 
cytoplasm and released from tendon cells due to excessive mechanical loading. This process is 
regulated by acetylation of HMGB1 and temporary disruption of plasma membrane when tendon 
cells are subjected to mechanical stress.  
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2.5 IN VIVO HMGB1 RELEASE INDUCED BY MECHANICAL OVERLOADING IN 
TENDON TISSUE 
2.5.1 Rationale 
Having established the translocation and release of HMGB1 in vitro by mechanical overload and 
explored the related mechanism, next question would be whether mechanical overloading 
induces the release of HMGB1 in the tendon in vivo. Mouse treadmill running was utilized as an 
in vivo model, since the previous study in our laboratory has found that intensive treadmill 
running resulted in an inflammatory reaction, indicating that tendon tissue damage might be 
induced in this model[66].  
2.5.2 HMGB1 is released to extracellular matrix after long-term or one-time intensive 
treadmill running 
8-week old C57BL/6 mice were divided into 4 groups, 1) a cage control group without any 
treadmill running (cage control), 2) a moderate treadmill running group (MTR), 3) an intensive 
treadmill running group (ITR), and 4) a one-time fatigue treadmill running group (OTR). The 
running regimens are presented in Table 1. All the running mice received 1-week 
acclimatization training with 15 min running for 5 days before the individual treadmill running 
regimen started. 
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Table 1 Treadmill Running Protocol 
 
 
 
Achilles tendon sections of the cage control group showed the presence of tendon cells 
that stained blue with Hoechst 33342, but the tendon matrix was not stained red indicating the 
absence of HMGB1 in tendon matrix both in the mid-portion and near insertion site of the tendon 
(Fig. 16 A, B, C, D). The tissue sample was not penetrated with detergent to show the HMGB1 
signal only in the matrix. The 2x magnification of Fig. 16A, that is Fig. 16B, clearly shows the 
blue staining of cells, but the absence of red staining in the matrix; this also applies to the tendon 
matrix near the insertion site (Fig. 16C, D). Some peripheral areas that appear red are not tendon 
tissues, but are paratenons (Fig. 16. A, C, E, arrows). In the tendon sections from mice on the 
moderate treadmill running (MTR) regimen, HMGB1 staining was absent in the tendon matrix of 
the mid-portion and near insertion site(Fig. 16 E, F, G, H). However, a marked increase in 
HMGB1 staining was observed in the tendon matrix of mice on the intensive treadmill running 
(ITR) regimen (Fig. 16 J, K, L, M). A 2x magnification of Fig. 16J shows clear red staining that 
is positive for HMGB1 (Fig. 16K).The HMGB1 staining is present outside the tendon cells and 
in the tendon matrix (Fig. 16J, arrowheads). 
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Figure 16. Mechanical overloading increases HMGB1 levels in Achilles tendon ECM in both mid-portion and 
near the insertional site. Cell nuclei in all figures show negative stain for HMGB1 because sections were not 
permeabilized with detergent. (A) Mid-portion of control Achilles tendon (AT) shows minimal HMGB1 staining in 
tendon matrix. (B) 2x magnification of A clearly shows the absence of HMGB1 staining in the matrix. (C) Tendon 
tissue in control AT near insertional site is negative for HMGB1. (D) 2x magnification of C. (E) A representative 
tendon section from moderate treadmill running (MTR) group showing no positive stain in the matrix. (F) 2x 
magnification of E showing negative for HMGB1. (G) HMGB1 near the insertional site of MTR AT (H) 2x of G. 
Both G and H are negative for HMGB1 near the insertional site of MTR AT. (I) Tendon matrix shows strong 
positive stain in the intense treadmill running (ITR) group indicating that HMGB1 has released to the matrix. (J) 2x 
magnification of I clearly shows positive stain in the matrix. Arrows point to positive staining. (K) HMGB1 is 
positive near the insertional site. (L) 2x of K shows HMGB1 positive staining more clearly. (M) Similar HMGB1 
positive staining in the matrix of tendon mid-portion section from one-time treadmill running (OTR). (N) 2x of M. 
(O) HMGB1 positive staining near the insertional site. (P) 2x of O. Arrowhead points at the Positive HMGB1 site. 
Control mice were allowed cage activity without running, MTR running regimen was 50min/day and ITR 3h/day, 5 
days/week for 3 weeks, and OTR was more than 5h until fatigued at a running speed of 15 m/min. The sections were 
not permeabilized with detergent to avoid the release of HMGB1 from the nuclei. Also, the pink stains observed in 
the periphery of A, C, and E (arrows) are not tendon tissues but may be paratenon or adjacent connective tissue. 
Data are the representatives from two independent experiments (n=6 each group) of AT sections. Bars - 50 µm. 
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HMGB1 is also expressed in the matrix of the tendon tissue near the insertion site(Fig. 16L, 
M).The same increasing trend for HMGB1 staining was observed in the tendon matrix of mice 
on the OTR regimen in the mid-portion and near insertion site(Fig. 16 M, N, O, P, arrowheads). 
 
Figure 17. HMGB1 content is increased in tendon matrix in mechanically overloaded tendons.  (A) Intense and 
one-time treadmill running (ITR and OTR) significantly increases HMGB1 levels in Achilles tendons (AT) 
compared to control. There is no significant change in moderate treadmill running (MTR) group. (B) ITR 
significantly increases HMGB1 levels, and OTR and MTR do not significantly alter HMGB1 levels in patellar 
tendons (PT) compared to control. HMGB1 content is normalized to tissue weight. Data represent mean ± SD. n = 6. 
*P < 0.05. (C) DNA content is same in control and treadmill running groups in the homogenized tendon sample 
indicating that the high levels of HMGB1 in ITR and OTR group are not from the damage of cells since live cells 
contain HMGB1 in the nuclei.  
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This finding was also confirmed by ELISA measurement of HMGB1 levels in mice 
Achilles and patellar tendon matrices (AT & PT respectively) subjected to mechanical loading 
protocols (Fig. 17 A, B). Those tendon samples were mildly processed to avoid destruction of 
cells which might create a high background for HMGB1 measurement in matrix only. 
Compared to the control level, both AT and PT in MTR groups did not show a significant 
difference in HMGB1 when quantified using ELISA (Fig17. A, B) However, in mice that were 
on ITR regimen, the maximum amounts of HMGB1 were observed in both tendon tissues. 
Specifically, HMGB1 levels were 6.6 fold higher in Achilles tendon, and 6.8 times higher in 
patellar tendon of ITR group when compared to the control mice (Fig. 17 A, B). HMGB1 levels 
were also significantly higher in the Achilles tendon tissues of OTR mice (3.2-fold higher; p< 
0.05) when compared to the control, while patellar tendon tissues showed a 2.32-fold change 
compared to control without statistical significance (Fig. 17A, B). These results indicated that 
only excessive mechanical loading conditions, ITR and OTR triggered the release of HMGB1 
from the tendon cell nuclei into the tendon matrix. 
2.5.3 Measurement of tendon lysate DNA content shows minimal damage of cells in 
processing TR tendon samples 
The tendon samples for the measurement of HMGB1 concentration using ELISA were prepared 
in a gentle manner by only mincing and soaking them in PBS. It is still possible that the 
intracellular HMGB1 in tendon cells may be released during the preparation process and 
“contaminate” the extracellular HMGB1 that we were measuring. It is known that HMGB1 in 
the damaged cells releases together with the DNA. To confirm that the higher HMGB1 
concentration in ITR and OTR groups is not greatly affected by the “contamination” from 
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intracellular HMGB1, the total DNA content was measured in all samples as indicators of cell 
destruction and “contamination” gauge.  
It is found that all the samples are with equivalent and significantly lower DNA content 
than total lysis tendon sample with T-PER lysis buffer and vigorous homogenization using 
BioMasher(Takara, Japan)(Fig. 17C). This result helped to explain the baseline concentration of 
HMGB1 found in the control and MTR group, and also validate that the increased HMGB1 
measurement in ITR and OTR are due to the effect of repetitive mechanical loading-released 
HMGB1 in the tendon matrix.  
2.5.4 Intensive treadmill running results in inflammatory cell infiltration in Achilles 
tendon 
 Since extracellular HMGB1 is the cause of sterile inflammation in many organs[231], and it is 
known to function as a chemoattractant for inflammatory cells, and the tendon proper is largely 
avascular, long-term repetitive loading may still result in the establishment of HMGB1 level 
gradient and induce inflammatory cell infiltration in the tendon. Clinically, inflammation is not 
apparent in degenerative tendinopathy [55, 232]. However, since most patients seek medical 
intervention usually at their late stage of tendinopathy, inflammation could still be there and play 
a crucial role during the early development of the disease and could be easily overlooked, and 
inflammation could take place long before the symptoms appear. Therefore, signs of 
inflammatory cells in the intensive treadmill running tendons could be helpful to explain the 
development of tendinopathy in the long run. 
 The result showed that immunohistochemical staining for the inflammatory cell marker, 
CD68, was absent in the cage control group (Fig. 18A, E) and in both mid-portion and near 
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insertion site of MTR group (Fig. 18B, F). However CD68 signal was clearly visible in the 
Achilles tendon sections of mice on the ITR regimen, and positive in both mid-portion and near 
the insertion site (Fig. 18C, G). The induction of inflammatory cell infiltration by ITR implies 
that HMGB1 may invoke the inflammatory reaction in the tendon (arrowheads, Fig. 18C, G). 
CD68 was found negative in OTR regimen (Fig. 18D, H). Collectively, these data show that 
excess mechanical loading induces significant HMGB1 release into the Achilles tendon matrix 
resulting in inflammatory cell infiltration in the long run. 
 
 
 
Figure 18. Inflammatory cells infiltrate in long-term mechanical overloaded tendons (ITR) but not in one-
bout excessive loading (OTR).  Treadmill running mouse ATs were stained with CD68 for inflammatory cells like 
macrophages and monocytes. In Mouse AT without running, neither the mid-portion of the tendon (A) nor the 
insertional site towards heel bone (E) is stained positively with CD68. (B) MTR group mice’s AT is similar with 
cage control group showing no CD68 staining within the tendon mid-portion tissue and (F) near the insertional site. 
(C) AT from ITR group with several positive spots for CD68 in both the mid-portion and (G) near the insertional 
site. (D, H) CD68 is not positive in OTR group in both mid-portion and near the insertion site. Note that the brown 
at the edge of the tendon in adjacent soft tissue is staining artifacts, possibly because of trapped antibody there.  
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2.6 MATERIALS AND METHODS  
2.6.1 Tendon cell isolation and culture 
Tendon cells were isolated from patellar and Achilles tendons of 3-4 months old female Sprague 
Dowley (SD) rats weighing 200-250 g. Briefly, tendons dissected from rats were minced into 
small pieces and digested by incubating in phosphate-buffered saline (PBS) containing 3 mg/ml 
collagenase type I (Worthington Biochemical Corporation, Lakewood, NJ) and 4 mg dispase 
(StemCell Technologies Inc., Vancouver, BC, Canada) at 37°C for 2-6 hrs. The digest was then 
filtered through a 70 µm filter to remove tissue residue and centrifuged at 700 g for 10 min. The 
cell pellet was resuspended in 20% Fetal Bovine Serum (FBS, Atlanta Biologicals, Flowery 
Branch, GA) in Dulbecco’s modified Eagle’s medium (DMEM, Lonza Group, Basel, 
Switzerland) with 100 U/ml penicillin and 100 U/ml streptomycin. Finally, the cells were plated 
in T-25 or T-75 flasks and cultured at 37°C in the presence of 5% CO2. Cultured tendon cells 
were split when 80% confluence was reached. For all experiments, cells in passages 3-5 were 
used. 
2.6.2 Immunostaining of tendon cells  
Tendon cells (1x105 cells/well) were seeded in 12-well plates and allowed to grow to 70-80% 
confluence at 37°C in the presence of 5% CO2. Then, the culture medium was removed, and the 
cells were fixed in 4% paraformaldehyde for 10 min and treated with 0.1% Triton-X in PBS to 
allow antibodies to penetrate the nuclear membrane for an effective immunostaining. The cells 
were then incubated with rabbit anti-HMGB1 antibody (1 µg/ml,ab18256, Abcam, Cambridge, 
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UK) at 4°C overnight, followed by a 2hrs incubation at room temperature with goat anti-rabbit 
secondary antibody conjugated with Cy3 (1 µg/ml, EMD Millipore, Billerica, MA, AP132C). 
Cell nuclei were counterstained with Hoechst 33342 (10 µg/ml Sigma, St. Louis, MO, B2261) 
and were visualized with an inverted fluorescence microscope (NIKON, Tokyo, Japan) equipped 
with a CCD camera. The percentage of cells that stained positive by immunostaining was 
calculated by semi-quantification. Briefly, five random images were first obtained per well using 
the SPOT™ imaging software (Diagnostic Instruments, Inc., Sterling Heights, MI). Then, the 
percentage of positive staining was calculated by dividing the total area viewed through the 
microscope by the positively stained area. These values were averaged to represent the 
proportion of cells that stained positive for HMGB1. 
Immunostaining for cells in stretching silicone dish is similar as described above, and the 
staining of γ-H2AX together with HMGB1, monoclonal mouse anti- γ-H2AX antibody was used 
(1 µg/ml, ab26350, Abcam, Cambridge, UK). 2nd antibody reaction was conducted with goat 
anti-mouse secondary antibody conjugated with FITC(1 µg/ml, EMD Millipore, Billerica, MA, 
AP124F) was utilized. 
2.6.3 Western blot analysis of HMGB1 in tendon tissue and cells 
Total protein was extracted from rat Achilles and patellar tendons using the protein extraction 
reagent (ThermoFisher, Pittsburgh, PA). After quantification, 20 µg of total protein from each 
tendon sample was separated on a 10% SDS-PAGE, transferred onto a nylon membrane and 
incubated with rabbit anti-HMGB1 primary antibody followed by goat anti-rabbit infrared tag 
conjugated secondary antibody (LI-COR Biosciences, Lincoln, NE) following the 
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manufacturer’s instructions. Positive signals were detected via the Odyssey CLx infrared 
imaging system (LI-COR Biosciences, Lincoln, NE).  
2.6.4 In vitro mechanical stretching experiment 
Mechanical loading was applied to tendon cells in vitro using our customized mechanical 
loading device (Fig. 10), which can apply repetitive uni-axial loading on cells in silicon dishes. 
The micro-grooved silicon dishes in the loading device were sterilized and coated with 100 
µg/ml collagen solution (Stem Cell, Vancouver, Canada, 04902) for 2hrs at room temperature to 
facilitate cell attachment to the dish surface. The dishes were washed with PBS 3 times; cells 
were then plated in the silicon dishes at a density of 0.5X105 per dish accounting to about 50% 
confluence in 20% FBS DMEM medium. Cells were allowed to attach to the dish surface 
overnight followed by 4% or 8% stretching at 0.5Hz for 3 days according to our previous 
published protocol. Moreover, these stretching magnitudes represent moderate (4%) and 
excessive (8%) mechanical stretching on cells [66, 233]. Un-stretched cells served as controls. 
2.6.5 Translocation of HMGB1 with TSA treatment in tendon cells 
Rat tendon cells were seeded as described above, and after leaving them overnight for attaching, 
the medium was removed, and 10% FBS DMEM was added. Then 0, 10, 100ng/ml TSA was 
added to the culture medium for 2hrs. Half of the cells were fixed immediately, and for the other 
half, the medium with TSA was removed, and fresh medium with 10% FBS was supplied, after 
4hrs in fresh medium. All the rest of the cells were fixed with 4% PFA for 10min and proceeded 
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to perform HMGB1 immunostaining in the same way as mentioned above. Each condition was 
done in triplicate. 
2.6.6  Blocking HMGB1 translocation induced by mechanical loading with anacardic acid 
in tendon cells 
A total of 5X104 rat tendon cells were seeded in 12 microgrooved silicone dishes, and 0, 5 µM, 
25 µM, and 100 µM AA were added to the 10% FBS DMEM culture medium of 4 dishes. The 
groups with AA addition received a change to fresh medium with the corresponding 
concentration of AA every 24hrs to keep the AA concentration at a stable level, and the 
stretching was done 8% at 1Hz for 72hrs. Immediately at the end of the stretching, cells were 
fixed with 4% PFA, and HMGB1 staining was conducted as described above. 
2.6.7 In vivo mouse treadmill running model 
In total, 48 mice were used for the in vivo treadmill running experiments and were divided into 
four groups with 12 mice in each group. The control mice remained in cages and were allowed 
cage activities. The remaining three groups ran on the treadmill but at different intensities; i) 
moderate treadmill running (MTR), ii) intensive treadmill running (ITR), and iii) onetime 
treadmill running (OTR). The running speed for all regimens was 15 meters/min. In the 1st week, 
mice were trained for 15 min to acclimatize them to the treadmill running protocol and 
environment. In the following 3 weeks, mice in the MTR group ran for 50 min, and those in the 
ITR group ran for 3hrs a day, 5 days a week. Mice in the OTR ran for more than 5h until fatigue. 
The performance of the mice (i.e. running time) was recorded to recommend inclusive/exclusive 
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criteria. The treadmill running experiment was done twice independently to record variability. 
Immediately after running, the Achilles and patellar tendon tissues were harvested from the 4 
mice groups. Half of the samples were used for ELISA tests, and the remaining half was used for 
immunostaining.  
2.6.8 ELISA assay of HMGB1 in cell culture medium 
In this study, cell culture medium was collected after the stretching experiment and centrifuged 
at 3000g for 10min; the supernatant was collected for HMGB1 level measurement (Shino-Test 
Corporation, Tokyo, Japan, ST51011) according to manufacturer's instructions. All samples were 
analyzed in duplicates. The kit used “sandwich” ELISA method. 
2.6.9 ELISA assay and immunostaining of HMGB1 in tendon tissue  
For tendon tissue ELISA, mice Achilles, and patellar tendon tissues were weighed, minced and 
soaked in PBS (about 200 µl) for 2hrs in room temperature allow HMGB1 diffuse from the 
minced tissue to the solution. This is considered gentle homogenization in order to keep the 
tendon cells intact. This was done to prevent intracellular HMGB1 leaking during the preparation 
process which may interfere with the detection of extracellular HMGB1. This process allowed 
precise quantification of HMGB1 that was released to the extracellular space. The samples were 
then centrifuged at 2,000 g for 30 min at 4°C, and the supernatants were collected to measure 
HMGB1 concentrations using ELISA kit (Shino-Test Corporation, Tokyo, Japan, ST 51011) 
according to the manufacturer's instructions. All samples were analyzed in duplicates.  
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For all HMGB1 immunostaining, Achilles and patellar tendons dissected from the mice 
were immediately immersed in O.C.T compound (SAKURA FINETEK USA INC, Torrance, 
CA) in disposable molds and frozen at -80°C. Then, cryostat sectioning was performed at -25˚C 
to obtain about 8 µm thick tissue sections, which were fixed in 4% paraformaldehyde for 1 min 
and blocked with universal blocking solution (ThermoFisher Scientific, Pittsburgh, PA, 37515). 
The sections were then incubated with rabbit anti-mouse HMGB1 antibody (1 µg/ml, Abcam, 
ab18256) at 4˚C overnight followed by goat anti-rabbit secondary antibody conjugated with Cy3 
for 1hr at room temperature (0.5 µg/ml, Millipore, Billerica, MA, AP132C), then counterstained 
for the nucleus with Hoechst 33342(10 µg/ml.ThermoFisher, Pittsburgh, PA, H3570). Since the 
purpose of this staining was to evaluate the presence of HMGB1 in the extracellular milieu, the 
tissue sections were not treated with the penetration reagent-Triton X-100 that permeates the 
nuclear membrane. HMGB1 levels in each tendon sample were normalized to the corresponding 
tissue weight. 
2.6.10 Measurement of DNA concentration in tendon lysate 
Tendon lysate samples from treadmill running mice were collected as described above. The 
samples were gently processed as mentioned in section 2.6.9 to avoid destruction of the cell 
membrane. Total lysates from Achilles and patellar tendons were prepared with T-PER tissue 
protein extraction reagent (ThermoFisher, Pittsburgh, PA, 78510) instead of PBS. The samples 
were weighed and vigorously homogenized with BioMasher Standard (Takara, Shiga, Japan, 
9790A). The DNA content was measured using DNA quantitation kit with bisBenzimide (Sigma, 
St. Louis, MO, DNAQF) according to the manufacturer’s instruction, and the final result was 
normalized by the corresponding tissue weight.  
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2.6.11 FDA and PI staining for stretched cells 
Cells (5X105, rat AT P4) were seeded in the microgrooved dish as described previously and 
stretched at 8% strain level for 6hrs with 20 µg/ml PI in 10% FBS DMEM medium, and 10 
µg/ml FDA were added to the culture medium at the end of the stretching and left for 1hr. A 
non-stretched group of dishes was utilized as the control. The cells were washed with PBS and 
immediately counter-stained with H33342 10 µg/ml for 5 min without fixation and pictures were 
taken similar to the procedure for immunostaining. 
2.6.12 Statistical Analysis 
Student’s t-test and One-way ANOVA was used, followed by Fisher's least significant difference 
(LSD) test for multiple comparisons. When P-values were less than 0.05, the two groups 
compared were considered to be significantly different.  
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3.0  INFLAMMATORY EFFECT OF HMGB1 ON TENDON IN VITRO AND IN VIVO 
In the previous chapter, a series of evidence were drawn to show the presence of HMGB1 in 
tendon cells, as well as its release upon excessive repetitive mechanical loading in vitro and in 
vivo. The next step is to explore the physiological and pathological function of HMGB1 in terms 
of its effects on tendon cells and tendon tissue. HMGB1 is known to be a pro-inflammatory 
cytokine with chemoattractant properties for inflammatory cells [153, 158], endothelial cells 
[216, 234, 235] and stromal cells [236, 237]. Previous studies reported that HMGB1 could attract 
blood-derived stem cells [238] and promote wound healing by activating fibroblasts in vitro 
[236]. Therefore, it is reasonable to propose that HMGB1 can invoke inflammatory reaction by 
attracting inflammatory cells, induce angiogenesis, and may activate resident tendon cells in 
tendon tissue. However, tendon proper is highly avascular in nature [27] and constantly 
subjected to large mechanical loads. Its cellular response to HMGB1 might be different from 
other types of tissues. The effect of HMGB1 on tendon cells has not been studied yet. This 
chapter presents the mechano-biological responses of tendon cells in vitro by examining 
proliferation, migration, and the effects of HMGB1 in tendon tissue with in vivo HMGB1 
implantation method, e.g. angiogenesis, infiltration of inflammatory cells, etc. We found that 
HMGB1 did not stimulate the proliferation of tendon cells alone in vitro and had minimal 
angiogenesis potential, but promoted tendon cell migration. However, in vivo experiments, we 
found that HMGB1 implantation induced inflammatory cell infiltration, angiogenesis, and cell 
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proliferation in tendon tissue. The reason behind the differential response in vivo compared to the 
in vitro situation could be due to the presence of multiple types of cells like macrophages, and 
endothelial cells that may be simultaneously acting in vivo. Detail discussion about the different 
effects can be found in chapter 5. 
3.1 HMGB1’S EFFECT ON TENDON CELLS AND ENDOTHELIAL CELLS IN 
VITRO  
3.1.1 HMGB1 Alone does not promote proliferation of tenocyte in vitro 
First, we evaluated the proliferative effect of HMGB1 on tendon cells. In clinical settings, some 
tendinopathic patients show signs of hypercellularity in the affected area which are represented 
by the abnormally high density of cells [239]. It is possible that the HMGB1 released from 
mechanical overloading can induce proliferation of tendon cells through cytokines secreted by 
the recruited of macrophages. The direct effect was tested with in vitro tendon cell model.  
Briefly, cultured rat tendon cells were exposed to concentrations ranging from 0.1 to 10 
µg/ml of HMGB1 in DMEM medium without FBS. Tendon cells exposed to 0% FBS without 
HMGB1 in the medium was set as the negative control, tendon cells with 2% or 20% FBS 
supplied medium were used as positive control. After 48hrs, total cell numbers were measured 
by CCK-8 kit (Sigma), which is based on a similar mechanism as MTT assay as a colorimetric 
assay for the determination of the number of viable cells. The results showed that HMGB1 did 
not increase tendon cell number at any of the concentrations tested (0.1, 1, 10 µg/ml) compared to 
the negative control (Fig. 19A).  
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Figure 19. HMGB1 does not promote proliferation but exerts chemoattractant effect and induces COX-2 
expression and PGE2 production in rat Achilles tendon cells in vitro. (A) HMGB1 does not induce cell 
proliferation at all the concentrations tested at 48h, while 20% FBS control induces significant cell proliferation. (B) 
HMGB1 (1 and 10 µg/ml) induces significant cell migration after 24h. Growth medium with neither FBS nor 
HMGB1 served as negative control (first column). (C) Representative 40x images of the control transwell 
membranes stained with H33342 show a small number of cells migrated. (D-F) Images of samples treated with 0.1 
µg/ml, 1 µg/ml, and 10 g/ml HMGB1 show that tendon cell migration increased with the HMGB1 concentration. 
Three microscopic fields were counted per transwell membrane, and 4 replicates were used per group. (G) HMGB1 
(10 µg/ml) induces 3.2-fold COX-2 protein expression compared to control. The band is a representative one from 
three different experiments. GAPDH shows an equal amount of protein loading. (H) PGE2 significantly increases in 
response to 10 µg/ml HMGB1 at 0.5 and 1hr. Lower concentrations of HMGB1 do not bring about a significant 
increase in PGE2 production. 
 
 
 
In contrast, tendon cells cultured in the presence of various concentrations of FBS 
significantly increased tendon cell proliferation (Fig. 19A).  
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The results showed that HMGB1 alone does not affect tendon cell proliferation, in other 
words, HMGB1 does not induce tendon cell proliferation directly. 
3.1.2 HMGB1 promotes tendon cell migration in vitro 
Next, we evaluated the effects of various concentrations of exogenously added HMGB1 on 
tendon cell migration. It is known that HMGB1 functions as a chemoattractant for many types of 
cells, including macrophages, neutrophils, endothelial cells and fibroblasts through the receptor 
for the advanced glycation end-products (RAGE). It also has a paramount role in skin wound 
healing by recruiting various types of cells to the wound site [240]. It is possible HMGB1 
produced during mechanical overloading in tendon may also play a similar role.  
To determine whether HMGB1 has chemoattractant properties on tendon cells, we then 
performed an experiment in a transwell system. Briefly, tendon cells suspended in DMEM 
medium without FBS were planted on a polycarbonate microporous membrane with 8 µm pores 
mounted on an upper chamber, and the DMEM medium (without FBS) with/without various 
concentrations of HMGB1 (0.1,1,10 µg/ml) were added to the lower chamber. The cells attracted 
by HMGB1 in lower chamber would migrate across the pores and attach to the other side of the 
membrane. The non-migrated cells (cells remained on the upper side of the membrane) were 
removed, and only cells migrated to the lower chamber were stained with H33342 and counted to 
reflect the corresponding chemoattractant potential of HMGB1 in the growth medium. The 
results revealed that in the control group, the lower chamber that contained the culture medium 
with no HMGB1 showed a minimal number of cells migrated through the microporous 
membrane, 24hrs after plating the cells in the upper chamber (Fig. 19C). Similarly, only a 
minimal number of cells were present in the group treated with 0.1 µg/ml of HMGB1 (Fig. 19D). 
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However, significantly higher numbers of tendon cells had migrated to lower chamber wells 
containing 1 and 10 µg/ml HMGB1 (Fig. 19E, F). Semi-quantification of the data specifically 
showed that tendon cell numbers in the group treated with 1 and 10 µg/ml HMGB1 were about 
11- and 14-fold higher than the control respectively(Fig. 19B). These results indicated that 
HMGB1 is a chemoattractant for tendon cells in vitro at relatively high concentrations and in a 
dosage-dependent manner. 
3.1.3 HMGB1 exerts inflammatory effect on tendon cells in vitro 
As an inflammatory mediator and Damage Associate Molecular Pattern (DAMPs), HMGB1 has 
been well studied for its inflammatory effect on macrophages. It is considered as a trigger of 
sterile inflammation in several diseases, like ischemic damage in the heart, kidney, and lung 
[241-243], as well as in arthritis [244]. Previously, our group reported that tendon cells release 
PGE2 when subjected to intensive mechanical loading [66]. This inflammatory response might be 
mediated by HMGB1. In order to assess whether HMGB1 mediates PGE2 production in 
tenocytes, cultured tendon cells were exposed to different concentrations of HMGB1 (0.1-10 
µg/ml) for 0.5 and 1hr. First, using Western blot analysis, we showed that COX-2, an upstream 
regulator of PGE2 synthesis, was produced at significantly higher levels in tendon cells treated 
with 10 µg/ml of HMGB1 for as short as 0.5hr (Fig. 19E). There was 3.9- fold increase in COX-
2 when compared to control. Next, we determined the effect of various concentrations of 
HMGB1 on PGE2 production. PGE2 levels in the tendon cells treated with 0.1 and 1.0 µg/ml of 
HMGB1 for 0.5 and 1hr showed no significant increase (Fig. 19F). However, PGE2 levels were 
significantly increased at the highest concentration of HMGB1 (10 µg/ml) for both treatment and 
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at 1h, it was 3.82-fold higher than the control. durations (Fig. 19F). Specifically, at 0.5hr, PGE2 
levels were 5.28-fold higher than the control,  
 
 
 
Figure 20. HMGB1 induces MMP-3 expression and release in tendon cells in vitro. (A) Tendon cells without 
HMGB1 treatment show some extent of HMGB1 staining in the cytoplasm (B) High concentration of HMGB1(10 
µg/ml) treatment for 24h significantly increases MMP-3 expression compared to control in tendon cells. (C) Semi-
quantification shows a significant increase in the proportion of MMP-3 positive cells with 10 µg/ml HMGB1 
treatment. (D) HMGB1 at 10 µg/ml significantly increases MMP-3 release to culture medium from tendon cells at 
24hrs. Data represent mean ± SD from six experiments. *P<0.05 Bars - 50 µm. 
 
 
 
HMGB1 has been shown to increase the production of MMPs [178]. In our study, we 
found that matrix metalloproteinase-3 (MMP-3) is also increased upon HMGB1 stimulation. 
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Cultured tendon cells were stimulated for 24hrs by a high dosage of HMGB1 10 µg/ml). In the 
control group without HMGB1 treatment, about 50% cells are positive for MMP-3 in the 
cytoplasm (Fig. 20A, C). The proportion of HMGB1 positive cell increased to about 80% after 
24hrs HMGB1 treatment (Fig. 20B, C). The MMP-3 expression level assayed using ELISA in 
the culture medium of the HMGB1 treated cells is much higher than that in the control group 
(Fig. 20D). MMP-3 released to culture medium is 2.1-fold in the HMGB1 stimulated cells 
compared to that in control group. Collectively, these data show that HMGB1 can induce the 
release of an inflammatory mediator such as PGE2 and matrix-degrading enzyme, MMP-3 in 
tendon cells. 
3.1.4 HMGB1 does not induce angiogenesis in vitro  
HMGB1 was found to promote endothelial cell function and participate in angiogenesis process 
[245, 246]. It was also suggested that 1 µg/ml HMGB1 could induce angiogenesis in vitro in the 
hypoxic condition in Human dermal microvascular endothelial cells [234]. Therefore, we tested 
the effect of HMGB1 on angiogenesis process in vitro. For that purpose, an endothelial cell tube 
formation assay was utilized. Briefly, Human Umbilical Vein Endothelial Cells (HUVECs) was 
seeded on solidified Matrigel with 1 µg/ml or 10 µg/ml HMGB1 for 24hrs. A basal medium 
without FBS was served as negative control, and 2% FBS was added to the culture medium as a 
positive control. While there is no tube formation in the negative control (Fig. 21A), the 
endothelial tubes formed successfully in the 2% FBS group (Fig. 21B). However, like the 
negative control group (there is no tube formation in either concentration of HMGB1 in DMEM 
only medium (Fig. 21C, D). These results suggested that HMGB1 alone may not induce 
angiogenesis in vitro.  
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Figure 21. HMGB1 alone does not induce angiogenesis in vitro.  HUVEC cells (10^5 ) were seeded on Matrigel 
in a 24 well plate and then added with 0% FBS, 2% FBS, 1 µg/ml or 10 µg/ml HMGB1 in the basic HUVEC 
medium, and the cells were allowed to grown in respective conditions for 24h. (A) The group without FBS shows no 
tube formation by the endothelial cells. (B) The group with 2% FBS exhibits visible tube formation. (C, D) Neither 
1 µg/ml nor 10 µg/ml HMGB1 induces tube formation by endothelial cells.  
 
 
 
3.2 HMGB1 IMPLANTATION RESULTS IN CELL INFILTRATION AND 
INFLAMMATORY REACTIONS IN TENDON TISSUE IN VIVO 
After presenting some evidence about the in vitro effect of HMGB1 on tendon cells as a 
chemoattractant and inflammatory mediator, we proceeded to explore in vivo function of 
HMGB1 in tendon tissue by administration of HMGB1 with alginate beads into rat tendon tissue. 
We found that HMGB1 implantation results in inflammatory cell infiltration, angiogenesis, 
hypercellularity, and inflammatory marker COX-2 and matrix degenerative enzyme MMP-3 
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expression after 2 weeks. Those effects vanish at the 4-week time point, indicating that HMGB1 
induces a reversible inflammatory reaction in vivo. 
3.2.1 Using alginate beads for HMGB1 implantation  
We found in our treadmill running experiment that HMGB1 may accumulate in tendon tissue 
after long-term mechanical loading. We suspected that continuous exposure of HMGB1 in 
tendon tissue might be the necessary to evoke the inflammatory effect of HMGB1. So, we 
decided to establish a local and relatively long-term HMGB1delivery system.  
 
 
 
Figure 22. Illustration of the procedures for fabricating alginate gel beads in containing cells and the 
appearance of prepared beads. (A) Alginate solution (2%) with/without HMGB1 was added to 2% CaCl2 solution 
with a 10 µl pipette; each gel spheres volume is 5ul. Once contacted with the CaCl2 solution, the alginate drop 
immediately crosslinks and forms a gelled bead. The gel spheres were retrieved from CaCl2 solution with two wash 
of PBS. (B) Prepared alginate beads, the diameter of the alginate beads with 5ul volume is about 0.3~0.5mm 
 
 
 
We chose alginate beads to encapsulate HMGB1 and implant into the tendon. Our laboratory has 
previous experience using this drug delivery method to successfully create tendinopathy model 
 79 
[112]. Besides, alginate is a non-toxic natural polysaccharide with excellent biocompatibility and 
biodegradability [247] with minimal pro-inflammatory effect. It has been widely used in wound 
healing, cartilage repair, bone regeneration, and drug delivery [248, 249]. Although many other 
synthetic biomaterials could serve as delivery systems, the denaturing and loss of bioactivity of 
the carried drug is a big concern as preparation of these materials often involves the use of using 
organic solvents [250]. Alginate could be easily cross-linked and shaped with metal ions (usually 
Ca2+) under room temperature and does not require other harsh chemical processing, which 
makes it an excellent carrier for HMGB1 protein. 
3.2.2 HMGB1 beads implanted subcutaneously induced cell infiltration and angiogenesis 
in skin tissue 
Before implanting the HMGB1 beads into the tendon, we first validated its effect by 
implanting the beads subcutaneously. After 1-week implantation, the skin tissue was dissected, 
and we observed that HMGB1 beads were able to attract a large number of cells to infiltrate into 
the beads area and also induce angiogenesis around the beads implantation site (Fig. 23A, C), 
while the blank control beads are almost empty with few cell infiltration (Fig. 23B, D). The 
result indicated that HMGB1 in vivo could induce strong “wound healing” effect in skin tissue, 
and HMGB1 was active and functional through the preparation process of alginate beads.  
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Figure 23. Implantation of HMGB1 beads in subcutaneous tissue. induces tissue formation, angiogenesis, and 
cell infiltration. Alginate beads with/without HMGB1 were implanted subcutaneously for 1 week. (A) HMGB1 
beads induce tissue ingrowth and vessel formation in the implanted site (arrow heads). Dash lines show the rough 
edge of the bead. (C) Enlarged area of the HMGB1 bead implanted group shows massive cell infiltration and tissue 
formation. (B) The tissue section with an empty bead implanted. The dash line indicates the actual bead boundary. 
Cell infiltration can be seen in the bead area but is much less than the HMGB1 group with no obvious vessel 
formation in or near the implantation site. (D) The enlarged area of the implanted empty bead. Cell accumulation is 
seen near the edge of the implanted beads but with minimal cell infiltration or tissue ingrowth. 
 
 
 
3.2.3 HMGB1 beads implanted in rat patellar tendon induced hypercellularity, 
angiogenesis, and inflammatory cell infiltration  
We conducted the in vivo evaluation of the effect of HMGB1 on tendon tissue by implanting 
HMGB1 protein encapsulated in 2% alginate beads into rat patellar tendons. The reason for 
using rat patellar tendon is that, rat is relatively larger than mice and easy to operate on, and 
patellar tendon is generally flat (compared to other most researched tendon Achilles, shape of 
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which is cylindrical) and easier to implant the alginate beads at same location every time to 
prevent the migration of the beads. 
Each bead was 5 µl in volume and contained 2.5 µg HMGB1. We chose the 2 weeks and 
4 week time points instead of 1-week time point to avoid possible confusion with the 
spontaneous healing reaction of the tendon, since at week 1, the inflammation may result from 
the surgical injury itself. By week 2, the inflammation may have subsided, and we may be 
measuring the relatively more actual effect of HMGB1 itself. 
We chose a high concentration of HMGB1 (0.5 µg/µl) in the implantation in a measure to 
compensate the relatively short experimental time to develop the model. Since we know that 
chronic tendinopathy with tendon structural changes, which might be the result of the HMGB1 
effect may take years or decades to develop in human patients, it is nearly impossible to 
recapitulate the development of the disease in an animal model. So, we assume that the short 
term high dosage effect, at least to some degree, may reflect the cumulative effect and 
cellular/structural changes in the development of tendinopathy in patients. 
After sterilization and opening the rat knee skin, the soft tissue above tendon was 
carefully dissected, and the patellar tendon was split along the long axis with microsurgical 
tweezers to create a spot for bead implantation (Fig. 24). This procedure ensures minimal trauma 
injury to the tendon tissue that may provoke wound healing which may mask the HMGB1 effect. 
At 2 and 4 weeks after bead implantation, the overall structure and inflammation signs 
were evaluated by H&E and immunohistochemical staining Generally, we found that very 
drastic cellular and structural changes occurred in 2 weeks but not in 4 weeks group with 
HMGB1 implantation. . At 4 weeks, the major changes might have resolved as HMGB1 may 
have been depleted by that time as the tendon tissue was subsequently repaired.  
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Figure 24. Surgical photograph shows the implantation of the beads into rat patellar tendon. Arrow points to 
the alginate bead, and the green box indicates the patellar tendon, and the bead was implanted near the mid-portion 
of the patellar tendon. The spot for implantation was created by splitting the tendon along the long axis of the 
patellar tendon. 
 
 
 
Unlike the control (Fig. 25A), the HMGB1-bead implanted tendon region shows 
hypercellularity after 2 weeks (highlighted in the white box, Fig. 25B). Moreover, the 4-week 
group shows slightly higher cellularity in some area (arrow in Fig. 25C) than control but is 
significantly lower than that in 2 weeks group (Fig. 25C). Moreover, significant inflammatory 
cell infiltration was also observed in the HMGB1 bead implanted tendon in 2 weeks’ time point. 
The HMGB1 bead implanted tendon section is stained positive for CD68 (arrowhead, Fig. 25E), 
which is a marker for inflammatory cells such as macrophages/monocytes. These cells are not 
present in the control tendons implanted with only alginate bead (Fig. 25D) or the 4 weeks 
HMGB1 implanted group (Fig. 25F). It is also observed that there are a lot of CD68 negative 
cells surrounding the CD68 positive cells (Fig. 25E). These cells might be the migrated tendon 
cells in response to both by the chemoattractant HMGB1 as well as by the growth factors and 
cytokines secreted by the recruited CD68 positive inflammatory cells. 
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Figure 25. HMGB1 induces hypercellularity and inflammatory cell infiltration in rat tendons at 2-week but 
not at the 4-week time point.  (A) H&E staining of control tendon implanted with 5 µl empty beads shows no cell 
proliferation. (B) Tendon section with implanted HMGB1 beads (2.5 µg in 5 µl) shows extensive cell proliferation 
(highlighted in the white square) at 2 weeks post-implantation. (C) The implantation site at 4 weeks; higher number 
of cells (arrow) compared to control can be seen but is much less compared to the 2 weeks group. (D) Control with 
no positive CD68 staining. (E) Positive CD68 staining in HMGB1 implanted sample for 2 weeks (arrows). (F) 
HMGB1 bead implantation group at 4 weeks shows minimal positive staining for CD68. Each image shows 
representative results from at least 3 samples. Bars - 100 µm.  
 
 
 
Moreover, the presence of blood vessel formation is found in 2-week implantation group 
(arrowheads, Fig. 26A), which also stained positive for the endothelial cell marker, CD31, by 
immunohistochemical staining (arrowhead, Fig. 26B). The similar structure was not found in 
control or the 4-week implantation group.  
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Figure 26. HMGB1 induces angiogenesis in rat tendons at 2 weeks. (A) HMGB1 bead group at 2 weeks post-
implantation shows vessel-like structures; arrows point to vessels formed in the region. (B) Positive staining for 
CD31 in the tissue sample of the HMGB1 bead group (arrow). No similar staining results were detected in control 
group with empty beads or in 4 weeks implantation group. Bars – 100 µm 
 
 
 
Finally, high expression of COX-2 (Fig. 27B) and MMP-3 (Fig. 27E) could be detected 
near the implantation site in the 2-week implantation group, control tendon with empty beads 
implanted showed negative for both proteins (Fig. 27A, D), 4-weeks group show negative for 
COX-2 staining (Fig. 27C), but show some degree of MMP-3 staining in the cell concentrated 
area (arrow Fig. 27F). It is also noteworthy that the expression of COX-2 and MMP-3 is very 
concentrated in the implanted area and has not spread to adjacent tendon tissue. There was also 
drastic cell density change in the 2 weeks HMGB1 implanted tendon compared to the control.  
Collectively, we demonstrated that HMGB1 exerts inflammatory and chemoattractant 
function in vitro and in vivo, especially in vivo. The administration of HMGB1 showed several 
effects including hypercellularity, inflammatory cell infiltration, and angiogenesis that may link 
to the development of tendinopathy. The release of HMGB1 by mechanical overloading and its 
subsequent chemoattractant and inflammatory functions is a very promising explanation of the 
early onset and subsequent development of tendinopathy. In the human patient settings, the long 
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term overloading of the tendon may result in the continuous production of HMGB1. The 
cumulative effect of HMGB1 by attracting inflammatory cells may lead to chronic low-level 
sterile inflammation in tendon tissue, which may gradually compromise the structure of tendon. 
Given this hypothesis, the next chapter presents the preventive strategies of the chronic effect by 
blocking HMGB1 function. This approach could lead to the development of early prevention 
method for the high-risk tendinopathy population like professional athletes. 
 
 
 
Figure 27. HMGB1 induces COX-2 expression, and PGE2 and MMP-3 production in rat patellar tendons at 2 
weeks.  (A) Control tendon with empty beads shows no sign of COX-2 signal. (B) HMGB1 bead implanted tendon 
at 2 weeks shows intensive COX-2 staining. (C, D) Control tendon shows negative for MMP-3 staining. (E) In the 
HMGB1 bead implanted tendon at 2 weeks, positive staining for MMP-3 of is concentrated in the high cell density 
area. (F) HMGB1 bead implanted tendon at 4 weeks still shows a positive signal for MMP-3 but not as strong as 2 
weeks group (arrow). Note the drastic high cell density is only seen in the 2 weeks group, but neither in control 
group nor in the 4 weeks group. Bars - 100 µm.  
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3.3 MATERIALS AND METHODS  
3.3.1 Quantifying tendon cell proliferation  
Tendon cells isolated from rat patellar tendons at passage 3 (~2000 cells) were seeded in 96 well 
plates and allowed to attach overnight in 10% FBS+DMEM. Next day, the culture medium was 
replaced with serum-free DMEM containing different concentrations of HMGB1 (0.1-10 µg/ml). 
After 48 h, tendon cell proliferation was assessed using the CCK-8 kit (Sigma, St. Louis, MO, 
96992). This experiment was repeated 6 times. 
3.3.2 Tendon cell migration assay  
A transwell system (Corning, Corning, NY, 3422) containing a membrane with 8 µm pore size 
was used to evaluate the chemoattractant effect of HMGB1 on rat patellar tendon cells. P3 cells 
(~1X105 cells) were seeded in the upper chamber, and various concentrations of 
HMGB1(TECAN, Switzerland, REHM114) in DMEM (0, 0.1, 1, 10 µg/ml) were added to the 
lower chamber of the 24 well transwell system. In the positive control well, 20% FBS was added 
to DMEM. After 24 h, cells that migrated into the lower chamber through the membrane were 
counted by visualizing through a microscope (40x) from at least 4 different locations in each 
sample. This experiment was repeated three times.  
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3.3.3 Evaluating inflammation in tendon cells in vitro 
Rat patellar tendon cells at passage 3 were seeded (~2 x105 cells/well) in a 6-well plate 
containing 2% FBS+DMEM with various concentrations of HMGB1 (0, 0.1, 1, and 10 µg/ml). 
After 0.5 and 1 h, the culture medium was collected to quantify PGE2 by ELISA. 
The cells were also collected separately and used for Western blotting. A 20 µg of total 
protein extracted from the cells treated with HMGB1was separated on a 10% SDS-PAGE. The 
proteins were then transferred onto a nylon membrane and incubated with 2 µg/ml rabbit anti-
COX-2 antibody (2 µg/ml, Cell Signaling, Danvers, MA, 12282S) at 4° C overnight followed by 
incubation with 2 µg/ml mouse anti-rabbit secondary antibody conjugated with HRP for 1hr 
(Abcam. Cambridge, UK, ab6721). HRP substrate was added to the membrane and photos were 
taken immediately with Biorad ChemiDoc XRS+ imaging system, with an exposure time of 30 s-
1 min. 
3.3.4 In vitro angiogenesis effect of HMGB1 
HUVEC cells at passage 3 were used for this experiment. Those cells were cultured and 
passaged with the vascular cell basal medium (ATCC, Manassas, VA, PCS-100-030) with the 
addition of endothelial cell growth kit (ATCC, Manassas, VA, PCS-100-040,). 100ul liquid 
Matrigel (Corning lnc., Corning, NY, 354247 ) was added in 24-well dish and allowed to solidify 
at 37°C for 30min. The well was washed with basal medium twice. HUVECs cultured in the 
flask were harvested and resuspended in basal medium, and 1x 10^5 HUVECs were added to 
each well. Then, 2% FBS (final concentration) and 1 or 10 µg/ml HMGB1 were added to 
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corresponding wells; then the plate was incubated at 37°C for 24hrs. The picture was taken with 
SPOT CCD digital camera. 
3.3.5 HMGB1 implantation in vivo 
Since most sports injuries are caused by repetitive or long-term mechanical loading, we 
developed a system to deliver HMGB1 into tendons in vivo to mimic long-term release of 
HMGB1 induced by repetitive mechanical loading. Our delivery system consisted of a 
degradable polymer called alginate that contained HMGB1 to ensure local and continuous 
delivery of HMGB1 to maximize the effect in a relatively short period. 
3.3.6 Preparation of alginate beads  
A 2% alginate solution was first prepared by dissolving alginate powder in double distilled water 
after vigorous vortexing. Then, HMGB1 (TECAN, Switzerland, REHM114) was added to the 
2% alginate solution to reach the final concentration of 0.5 mg/ml. With a pipette, about 5 µl of 
the HMGB1-alginate solution was then added to 2 mM CaCl2 solution in the form of drops, 
which solidified to form alginate beads. Control alginate beads were prepared without adding 
HMGB1. The beads were then removed from the CaCl2 solution and allowed to air dry. The final 
diameter of the beads was around 0.05 mm, which is about 1/6 of the rat patellar tendon width. 
This protocol was developed in our laboratory with the successful delivery of another bioactive 
chemical Kartogenin to develop a rat tendinopathy model [112].  
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3.3.7 HMGB1-alginate bead implantation in rat skin and patellar tendon  
Rats (Female, SD, 6 months) were sedated by inhaling 2-3% isoflurane. The skin over the 
patellar tendon was then shaved, sterilized and a small incision was made on the skin to expose 
the tendon. HMGB1-alginate beads (2.5 µg in 5 µl) or control beads (5 µl) were implanted 
subcutaneously on the back of the rats, and the rats were sacrificed after one week, and the skin 
was used to validate the effect of HMGB1.  
After validation with the skin implantation experiment, HMGB1-alginate beads (2.5 µg 
in 5 µl) or control beads (5 µl) were implanted in the central part of the left and right patellar 
tendons. After 2 and 4 weeks, 3 rats in each group were used for H&E and immunohistochemical 
staining to evaluate structural changes in the tendon tissue. 
3.3.8 Immunohistochemical staining of HMGB1 implanted tendon  
Patellar tendons were harvested from 3 rats that received HMGB1-alginate bead or control bead 
implantation and processed similarly as in the last chapter under ELISA and immunostaining of 
tendon tissue. Anti-rat CD31 antibody (1 µg/ml, Abcam, Cambridge, UK, ab64543) was used to 
detect endothelial cells and vessels. Anti-CD68 antibody (2 µg/ml, Abcam, Cambridge, UK, 
ab125212) was used to detect monocytes/macrophages. Anti MMP-3(1 µg/ml, Abcam 
Cambridge, UK, ab52915) and Anti-COX-2(1 µg/ml, Cell Signaling, Danvers, MA, 12282S) 
were used to evaluate corresponding protein expression in implanted tendon tissue. HE staining 
was used to evaluate overall tendon structure and cell density. 
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3.3.9 Statistical Analysis 
Student’s t-test and One-way ANOVA was used, followed by Fisher's least significant difference 
(LSD) test for multiple comparisons. When P-values were less than 0.05, the two groups 
compared were considered to be significantly different.  
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4.0   INHIBITION OF HMGB1 TO NEGATE THE EFFECTS IN OVERLOADED 
TENDON 
The results from the previous chapter showed that HMGB1 released in response to mechanical 
overloading could invoke inflammatory reactions in vivo and in vitro, and suggested that these 
responses may have an adverse impact on long-term tendon health. Since these results 
demonstrated that HMGB1 could induce inflammatory responses in tendon cells and tissues, the 
next aim was to explore the means to mitigate these effects with inhibition of HMGB1 activity. 
We first tested the in vitro inhibitory effect on HMGB1 with its direct inhibitor 
Glycyrrhizin (GL). We found that in 3-week treadmill running mice, GL could reduce the 
inflammatory response induced by HMGB1. Also, longer time running (12 weeks or 24 weeks) 
induced degenerative changes like increased the presence of chondrocyte-like cells, SOX-9 
expression, GAGs deposition and collagen II deposition in tendon tissue near the insertional site 
of Achilles tendon-bone junction but not in the mid-section of Achilles tendon, or in the patellar 
tendon. Injection of GL to inhibit HMGB1 effect along with the treadmill running for 24 weeks 
could attenuate those degenerative changes.  
In a broad viewpoint, inflammation is a protective response to injuries and infections in 
our body and a complex network of cellular and molecular responses leads to resolving the 
inflammation and/or repair of damaged tissue. However, inflammation is also involved in 
chronic injury and degeneration [218].  
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Chronic sterile inflammation is potentially detrimental in tendon tissue, since it may 
disturb the well-organized tendon structure by introducing inflammatory cells into the tendon 
causing hypercellularity, angiogenesis, and catabolic phenotype of the tendon tissue. Changes in 
the well-organized collagen fibers with cells, vessels or disrupted fibers will substantially impair 
the mechanical properties of the tendon.  
Current treatment for chronic tendon injury with steroids can suppress the overall 
immuno-response, but it is considered harmful for the whole body. Direct anti-inflammatory 
therapy like administration of non-steroid anti-inflammatory drugs (NSAIDs) is widely used in 
clinics, however NSAIDS administration is only inhibiting the downstream mediator, not the 
source itself., for example NSAIDS mainly inhibit COX activity, which is a relatively 
downstream pathway in the inflammatory cascade. Various other cytokines and MMPs can be 
produced upon the stimulation of HMGB1 on inflammatory cells possibly through other 
pathways. Inflammatory cells can induce the catabolic phenotypes of resident tendon cells, 
which result in the production of MMPs and other inflammatory cytokines such as IL-1β and IL-
6. So, it is more important to block the activation and migration of inflammatory cells to the 
tendon tissue in vivo and resolve the inflammation at the very beginning stage. 
In most cases, chronic tendon injury or tendinopathy is not an open wound; there are no 
external inflammatory triggers. HMGB1 is known to be a DAMP molecule that triggers sterile 
inflammation in vivo[231], and it is proposed to play a critical role in the initial recruitment and 
activation of inflammatory cells[153, 231, 251, 252]. Therefore, inhibition of HMGB1 activity 
may suppress the migration of inflammatory cells to tendon tissue, and thus might exert a 
protective effect on tendon tissue.  
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4.1 INHIBITION OF HMGB1 EFFECT IN VITRO WITH GLYCYRRHIZIN 
Glycyrrhizin (GL), a glycoconjugate triterpene produced by the licorice plant, Glycyrrhiza glabra 
(Fig. 28A). It has been shown to inhibit the chemoattractant and mitogenic activity of HMGB1 
in vitro and in vivo by directly binding to the HMGB1 functional domain on Box A(Fig. 28B) 
[253]. 
 
 
 
Figure 28. The structure of glycyrrhizin (GL) and its binding site on Box A of HMGB1.  (A) The chemical 
structure of GL. (B) Model of GL’s binding on the box A of HMGB1. (Sources: Fig. 28A [254], Fig. 28B [255])  
 
 
 
It has been administered to patients with hepatitis B and C, and it is considered safe 
[253]. GL has been widely investigated to inhibit HMGB1 signaling in the treatment of patients 
and research on disease models. GL was found to sequestration HMGB1 effect in patient with 
rhinitis [256], GL was utilized to attenuates HMGB1 induced hepatocyte apoptosis in human cell 
line[257]; GL was also discovered to exert protective effect on focal cerebral 
ischemia/reperfusion-induced inflammation mediated by HMGB1[258], GL inhibit HMGB1 
protect brain injury after diffuse axonal injury model in rat through the anti-inflammatory 
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effects[259], GL administration showed decreased troponin I-induced myocardial inflammation 
in mice mediated by HMGB1 [260]. The detailed discussion on HMGB1 inhibitory agents and 
the logical reason to use GL can be found in chapter 5. 
 
 
 
Figure 29. Toxicity of GL on tendon cells in culture. Tendon cells were exposed to various concentrations of GL 
to test the effect of GL on cell viability using CCK-8 kit. OD450 values represent the live cell numbers in culture. 
The concentrations of GL range from 1 µm to 10 mM. The results showed that GL does not affect cell viability up to 
200 µm. When GL concentration exceeded 1mM, cells viability decreased drastically and in a dosage-dependent 
manner. Blanks are cells untreated with GL and no CCK-8 added, which represent the baseline of OD450 value. 
*p<0.05 compare to the cells not treated with GL. n = 6. 
 
 
 
4.1.1 GL in certain range of concentrations is non-toxic for tendon cells  
GL solution is acidic, which is potentially detrimental to cells. To assess the suitable non-toxic 
working concentration for HMGB1 inhibition, we first tested the effect of GL on cell viability in 
vitro. In previous studies, GL in vitro concentration was used up to 2 mM [257]. Briefly, tendon 
cells were exposed to various concentrations of GL from 1 µM to 10 mM for 72hrs, and cell 
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viability was tested with CCK-8 kit. We found that GL did not affect cell viability up to 200 µM 
(Fig. 29). However, from 1mM to 10mM, the cell viability decreased drastically in a dosage-
dependent manner. To maximize the inhibition potential without adverse effect on cell viability, 
200 µM was selected as the in vitro GL concentration for all following experiments.  
4.1.2 GL negates HMGB1 inflammatory effect and decreases MMP-3 production in 
tendon cells in vitro  
In our previous experiment, we have shown that HMGB1 can induce PGE2 and MMP-3 
production in tendon cells. Cultured tendon cells treated with HMGB1 were used to test the 
inhibitory effect of GL on PGE2 and MMP-3. 
The rat patellar tendon cells were treated with 10 µg/ml HMGB1 for 0.5, 2, and 4hrs and 
measured the PGE2 levels. 10 ng/ml IL-1β was added as a positive control. ELISA results 
showed that there was a significant increase in PGE2 levels at all-time points (p<0.05) (Fig. 
30A). When GL (200 µM) was added together with 10 µg/ml HMGB1, it could effectively 
attenuate the PGE2 production at all-time points. In addition, 200 µM GL has shown the similar 
inhibitory effect on HMGB1-induced MMP-3 release from tendon cells in 24hrs culture with 10 
µg/ml HMGB1 (Fig. 30B).  
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Figure 30. GL treatment blocks HMGB1-induced PGE2 and MMP-3 production in tendon cells in vitro.  (A) 
Rat Achilles tendon cells were treated with 10 µg/ml HMGB1 or 10 µg/ml HMGB1+ 200 µm GL for various 
durations. IL-1β (10ng/ml) was served as a positive control. As seen, PGE2 levels significantly increase in the 
HMGB1 treatment group at 0.5, 2, and 4h post-treatment. However, combined treatment with GL blocks the effects 
of HMGB1. (B) HMGB1 treatment significantly increases MMP-3 production in the tendon cells, and GL treatment 
with HMGB1 blocks the HMGB1 effect and reduces MMP-3 to a similar level as the non-treated control. Data 
represent mean ± SD. n = 4. * P < 0.05. 
 
 
 
4.2 GL REVERSES HMGB1-INDUCED IN VIVO EARLY INFLAMMATION IN 
TENDON SUBJECTED TO INTENSIVE TREADMILL RUNNING  
In the previous chapter, it was shown that long-term intensive treadmill running could induce the 
release of HMGB1 into tendon matrix and it could invoke inflammatory reactions in vivo. The 
next aim of the study was to determine whether inhibition of HMGB1 effect could result in the 
decrease of inflammation in tendon tissue induced by HMGB1 in vivo. The mouse treadmill 
running model was employed in this study. Since GL showed a promising inhibitory effect in in 
vitro study, it was utilized as the HMGB1 inhibitor for in vivo studies. 
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4.2.1 IP injected GL can be transported and maintained in tendon tissue  
Whether GL can be transported and maintained in the tendon region after injections in mice were 
determined first. The dose of GL was selected at 50 mg/kg body weight on the basis of previous 
animal studies using GL. For the GL in vivo administration, the recorded highest dosage was 400 
mg/kg [261], minimal was 10 mg/kg in mice [262] and the average mostly under 100 mg/kg. 
Previous studies showed that 50 mg/kg GL or lower dosage was enough to take effect in vivo to 
treat lung and liver disease models in mice and rats [257, 263, 264]. A dosage of 50 mg/kg was 
selected and verified in tendon study first, because of the concerns about the high concentration 
that might result in unexpected overall health deterioration of the mice, and the low 
concentration that may not be enough to sustain in the rather avascular tendon tissue throughout 
the time frame of the experiment.  
GL (50 mg/kg 400 µl dissolved in PBS) was intraperitoneally (IP) injected into 3 three-
month-old C57B/6 female mice. Three separate mice were injected with the same amount of 
PBS which served as controls. Quantification of GL with thin layer chromatography (TLC) 3hrs 
after injection showed significantly higher amounts of GL in mice patellar and Achilles tendons 
compared to the mice injected with PBS. This result demonstrated that GL could remain in 
tendon tissue in high concentration after IP injection. It can at least last through the treadmill 
running duration (3hrs) to deactivate HMGB1 which may be produced due to the mechanical 
overloading process by intensive treadmill running (Fig. 31). When comparing the quantity of 
HMGB1 and GL that could exist in tendon tissue, HMGB1 could be as high as 10~15 ng/mg 
tissue according to our previous results in Chapter 2 (Fig. 17A, B); GL content was about 30~50 
µg/mg tissue(Fig. 31). The amount of GL is much higher than HMGB1. So, it is possible that 
HMGB1 released from intensive treadmill running can be completely inhibited by injected GL.  
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Figure 31. GL is present in mouse tendons after GL injection. After IP injection of GL (50mg/kg) for 3 h, the 
amount of GL concentration in mouse patellar and Achilles tendons was measured by TLC measurement. Data 
represent mean ± SD. n = 4. * P < 0.05. 
 
 
 
4.2.2 GL reverses the HMGB1-mediated early stage inflammation in vivo that is induced 
by intensive treadmill running 
The next step was to explore the inhibitory effect of GL on HMGB1 in vivo using treadmill 
running model. Totally 24 mice were divided into 4 groups, and 3-week treadmill running 
experiment with or without GL injection was performed.  
1. Cage control group (C): These mice was allowed cage activity, and IP injection of PBS 
(400 µl) was given 5 days a week 
2. Glycyrrhizin only group (GL): This group of mice was also allowed cage activity with 
IP injection of GL (50 mg/kg body weight) 
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3. Intensive treadmill running (TR): In this group, the mice were subjected to treadmill 
running for 3 weeks, 5 days a week, 3hrs a day, 15 m/min with IP injection of PBS (400 
µl) 15min before treadmill running. 
4. Intensive treadmill running with Glycyrrhizin treatment (TR+GL): The mice in this 
group were subjected to intensive treadmill running same as in group 3 with IP injection 
of GL (50 mg/kg body weight) 15min prior to treadmill running.  
The glycyrrhizin only group was set up to monitor the effect of GL injection on the 
overall health of mice. A previous publication has shown that IP injection of GL 50 mg/ml daily 
for 28 days had no side effects in rats [264]. The body weights of all mice were monitored daily. 
Overall activity and appearance were monitored to track any possible side effects of GL 
injection. The body weight changes were tabulated (Table 2). Even though the weights of TR 
and GL+TR mice did not increase as in the controls, these groups of mice showed no significant 
drop in body weights (Table 2). Mice in GL injected group had similar appearance and activity 
levels as the control group.  
 
 
 
Table 2 Mouse Body Weight after 3 weeks Study 
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At the end of week 3, after the last treadmill running, all mice were sacrificed, and the 
patellar and Achilles tendons were harvested and homogenized to measure the inflammatory 
factors (PGE2, MMP-3) in tendon tissues. According to a previous model, treadmill running for 3 
weeks was still in the early inflammatory stage or tendon injury, so that no obvious structural 
changes could be detected at this time point. If structural changes should be visualized, it needed 
at least 12-16 weeks of running according to published papers on similar experiments carried out 
on rats [34, 265]. 
 
 
 
Figure 32. GL injection blocks HMGB1 mediated PGE2 and MMP-3 production due to mechanical 
overloading in vivo.  (A) PGE2 concentrations significantly increase in patellar tendon (PT), and Achilles tendon 
(AT) of intensive treadmill running (ITR) group and GL administration (50 mg/kg body weight, daily IP injection) 
reverses these enhancements. (B) MMP3 levels significantly increase in PT and AT of ITR and GL administration 
reverses these effects. Data represent mean ± SD. n = 6. * P < 0.05. 
 
 
 
ELISA assays of the PGE2 concentration showed that GL injection only mice did not 
alter the PGE2 levels in patellar and Achilles tendon when compared to the control mice (Fig. 
32A). PGE2 levels were significantly higher in TR mice tendons (1.5 and 1.6 fold increase in AT 
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and PT respectively compared to control mice after the TR regimen (Fig. 32A). However, GL 
injection before TR inhibited PGE2 production by reducing it to a similar level as the control 
group (Fig. 32A). Similar effects were observed with MMP-3 levels in mice tendons after GL 
injections. MMP3 levels in both PT and AT were significantly elevated in TR group (1.9 and 1.8 
fold increase compared to control), but GL negated the enhanced release (Fig. 32B). While 
statistically not significant, the MMP-3 levels in GL+TR group appeared to be higher than the 
control group, indicating that there might be other mechanisms regulating MMP-3 production 
(Fig. 32B).  
4.3 LONG-TERM TREADMILL RUNNING INDUCES DEGENERATIVE 
CHANGES IN ACHILLES TENDON NEAR TENDON-BONE INSERTION SITE 
A rat supraspinatus tendon overuse model (treadmill running) showed that there was a significant 
increase in gene expression levels such as Col II and SOX-9 of cartilage lineage in tendon[33] 
indicating the potential degenerative effect of long-term excessive mechanical loading in tendon 
tissue. Before we explored the inhibitory effect of GL on HMGB1, we developed a degenerative 
model in Achilles tendon. Previous studies found that long-term treadmill running can induce 
cellular and structural changes in tendon tissue, including cell rounding and disruption of tendon 
matrix structure [34, 245, 266]. One degenerative change found in tendinopathy is fibro-
cartilaginous[267], which is the degenerative change of tendon tissue with chondrogenesis. 
Chondrocyte markers were expressed in the clinical samples of calcific insertional Achilles 
tendinopathy [268]. The chondrocytes are rare in normal tendon tissue, and they have a very 
unique appearance in histology images, chondrocytes are contained in cavities in the matrix, 
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called cartilage lacunae, which is drastically different from the tendon cells (Fig. 34H). Other 
markers indicate chondrogenesis in tendon includes SOX-9 expression, GAGs deposition and 
collagen II in tendon matrix[112]. 
 
 
 
Figure 33. Minimal cellular or structural changes in the mid-portion of mouse Achilles tendon after 12-week 
ITR. (A) Control tendon with typically organized collagen matrix and spindle shape tenocyte. (B) The enlarged are 
(yellow box, A) shows normal tendon tissue. (C) Representative Achilles tendon shows no overall degenerative 
change. (D) The enlarged area (yellow box, C) shows normal cell shape and intact tendon matrix structure. (E) The 
illustration shows the mid-portion of Achilles tendon. Note that the tendon cells are tightly packed in the collagen 
fibers. Most cells are spindle-shaped and arranged along the long axis of the tendon with the collagen fibers. H&E 
staining Bars - 100 µm. 
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Figure 34. Tendon tissue near Achilles-bone insertion site shows cell morphology change after 12-week 
intensive treadmill running. (A, B, C)  Control tendons near insertion site show regular tendon matrix structure 
and spindle cell morphology. Tenocyte is tightly packed amongst collagen fibers with little space between the cell 
body, and the matrix (D, E, F) show chondrocyte-like “round” cells with cavities called cartilage lacunae in ITR 
tendon (F, black arrow), with obvious “blank” area between cells and extracellular matrix. (G) The anatomy region 
near the insertional site of the tendon-bone junction where the tendon tissue is presenting. (H) fibrocartilage 
histology image shows the chondrocytes and the cartilage lacunae (Fig. 34 H source: Mescher AL: Junqueira's Basic 
Histology: Text and Atlas 12th edition) (I) semi-quantification of the percentage of round cells with cavities in a 20x 
field on the end site of Achilles tendon shows around 30% round cells with cartilage lacunae.  Bars - 100 µm. 
A total of 6 mice were divided into two groups, the control group and the treadmill 
running group. The control group was allowed cage activity, and the treadmill running group was 
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subjected to 12 weeks treadmill running similar to our intensive treadmill running protocol in 
previous chapters (3hrs a day, 5 days a week at 13m/min). After 12 weeks of intensive treadmill 
running, no obvious structural changes were found in the mid 1/3 section in Achilles tendon of 
TR (Fig. 33). But the histological analysis at the tendon tissue near the bone insertion site of the 
Achilles tendon showed significant cell shape changes in the TR group mice (Fig. 34 D, E, F) 
compared to the control group (Fig. 34 A, B, C). Part of the cells in TR group showed round 
shape with cavities around the cells which are a very typical chondrocyte appearance (Fig. 34F, 
arrows). Typical chondrocyte morphology in cartilage tissue can be seen in Fig. 34 H which is 
very similar to the arrow pointed cells in TR tendon (Fig. 34 F), which is largely different from   
 
 
 
Figure 35. GAGs deposition in Achilles tendon from 12-week ITR mice shows early degenerative changes of 
the overuse tendon in vivo. Achilles tendon stained with Alcian blue near the insertion site. (A) Control group 
shows minimal GAGs deposition near the insertion site. (B) Enlarge figure of (A). (C) Achilles tendon from ITR 
group shows a high amount of GAGs deposited in cells and the only slight amount in tendon matrix near the 
insertion site. (D) Enlarged (C), shows Alcian blue is positive in cells, but with weak matrix staining signal. The 
arrow in D points to the cells with cartilage lacunae in the ITR group. Bars - 100 µm. 
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normal tendon cells in control group that are tightly packed in the collagen tissue without lacuna 
and with spindle shape (Fig. 33B).  
Alcian blue staining was used to identify possible GAGs deposition in the TR mice 
Achilles tendon. While the control group showed minimal staining signal which indicated GAGs 
are not largely present in tendon cells or matrix (Fig. 35A, B), GAG was produced by the cells 
that were in round shape near the insertion site and only a minor amount was deposited to the 
tendon matrix in the treadmill running group (Fig. 35C, D). Some of those round shaped cells in 
TR tendon were also positive for SOX-9 (Fig. 36C, D), while most of the cells in normal tendon 
were negative for SOX-9 (Fig. 36 A, B).  
 
 
 
Figure 36. Cartilage lineage marker SOX-9 is expressed in ITR tendon near insertion site but not in control 
tendon in vivo. (A, B)  Achilles tendons from control group show minimal staining for SOX-9. (C, D) Achilles 
tendons from ITR group show Sox-9 staining in tendon area near insertion site (white arrow). (E) Semi-
quantification shows about 20% cells are SOX-9 positive near the insertion site while nearly no cells in control 
group express SOX-9. Data represent mean ± SD. n = 4. * P < 0.05. Bars - 50 µm 
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Semi-quantification revealed that about 20% cells in 12 weeks TR group tendons near 
insertion site were positive for SOX-9 (Fig. 36E). The structure of the tendon fiber was still 
well-organized. All these evidence implied that the mice on 12 weeks of TR could develop early 
symptoms that could represent the insertional tendinopathy similar to that in human patient 
settings. This will be a valuable model to evaluate possible treatment or prevention method for 
insertional tendinopathy. Unlike the chemically-induced tendinopathy model such as the 
collagenase model, or physical injury-induced tendinopathy, the injury was induced purely by 
overuse of the tendon itself in this model. Therefore, it may better represent the pathological 
development of the disease and thus may provide insights into the etiology and treatment of 
tendinopathy. 
These results prompted to re-evaluate the model and focus the analysis on the insertion 
site of Achilles where the insertional tendinopathy in humans likely occur. 
The insertional site of Achilles tendon is located at the tendon-bone junction, and it is 
divided into four continuous zones, 1) tendon zone, 2) fibrocartilage,3) mineralized fibrocartilage 
and 4) bone [72]. The degeneration often takes place in the tendon zone, and in human patients, a 
histological study showed typical degenerative tendinopathy appearance, increased number of 
cells, and more GAG in the matrix as well as disorganized collagen fiber in insertional Achilles 
tendinopathy [73]. It is of great value to use this model to evaluate the effect of GL in preventing 
the degenerative change in tendon due to mechanical overloading in this model. 
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4.4 GL PREVENTS DEGENERATIVE CHANGES NEAR INSERTION SITE IN 
ACHILLES TENDON SUBJECTED TO LONG TERM INTENSIVE TREADMILL 
RUNNING  
As we established an early tendinopathy model with 12-week intensive mice treadmill running, 
next aim was to prolong treadmill running period to 24 weeks to maximize the effect while 
testing the inhibitory effect of GL on HMGB1 in preventing the degenerative changes. 
The groupings for the mice were same as in the 3 weeks running groups. A total of 28 
mice were used in this study with 24 being analyzed. 4 mice were excluded from the experiment 
either because of accidental death during treadmill running (2 mice) or due to failure to carry out 
the treadmill running treatment (2 mice) for the entire duration. The mice were divided into 4 
groups: Cage control, GL, TR, and TR+GL as previously described. The treadmill running speed 
was 13 m/min but total running time remained the same, 3hrs per day, 5 days a week. The lower 
speed compared to 3 weeks treadmill running (15 m/min) was set to avoid possible acute injury, 
and sudden death during the long-term treadmill running that may significantly decrease the 
available mice at the end of the experiment.  
 
 
 
Table 3 Body weight of mice after 24 weeks TR study 
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In the first 12 weeks, the treadmill was set flat for the running, but for the next 12weeks 
of treadmill running, the 5° uphill was set up to increase the load on Achilles tendon. The body 
weight and activity level, as well as the gross appearance of all the GL,  injected mice were 
monitored. It was found that 24 weeks GL injection did not result in an obvious change in body 
weight (Table 3, Fig. 37A) or gross appearance and the body composition (percentage of fat, 
fat/lean ratio, measured by Echo MRI whole body composition analyzer echo medical systems 
Houston ,Texas)(Fig. 37B, C) was also very similar to control group. The treadmill running mice 
were thinner with lower body weight, fat percentage, and low fat: lean ratio compared to the 
control mice (Fig. 37 A, B, C). This finding indicates that long-term treadmill running reduces 
weight and body fat. 
 
 
 
Figure 37. Body composition of mice changes after 24 weeks treadmill running regimen.  All group of mice 
started with similar average body weight. (A) After 24 weeks treadmill running, both the TR and TR +GL injection 
group’s body weight is significantly less than control, and GL only injected groups. No significant difference in 
body weight was found between control and GL only injected group. (B) Percentage of fat and (C) fat to lean ratio 
are significantly lower in TR and TR+GL group. Data represent mean ± SD. n = 6. * P < 0.05. 
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Figure 38. HMGB1 (in the matrix) and CD68 expression are positive in 24-week treadmill running mice 
Achilles tendon near the insertional site. (A, B) The HMGB1 signal is minimal in the tendon matrix near the 
insertion site of the mice Achilles tendon. (C) HMGB1 is expressed in tendon matrix in the treadmill running group 
(arrows). (D) HMGB1 can also be detected in the matrix of GL+TR group. (E, F) CD68 is negative in cage control 
and GL injection only group. (G) CD68 is positive in TR sample (arrows) and gathered in a clustered form. (H) No 
positive CD68 signal in the GL-treated TR tendon tissue. Bars - 50 µm 
 
 
 
At the end of the 24 weeks, the Achilles tendons were harvested for tissue section and 
staining. We first checked the HMGB1 in the tendon matrix near the insertional site in all 
groups. HMGB1 was not present in the control or GL group as expected (Fig. 38A, B). HMGB1 
was still expressed in the matrix of the TR group mice after 24 weeks running (Fig. 38C). In the 
TR+GL group mice tendon (Fig. 38D), HMGB1 was positive in the matrix but was relatively 
weak compared to the TR group. For CD68 staining, we can clearly see that CD68 was only 
positive in the TR group (Fig. 38G) but not in control, GL or TR+GL group (Fig. 38E, F, H). 
This indicates that GL treatment did block the migration of CD68 positive cells into tendon 
matrix after treadmill running for 24 weeks. The weaker HMGB1 expression in GL+TR group 
also indicated that cells may still be stressed and may have released HMGB1. 
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Figure 39. GL attenuates cell shape change in 24-week intensive treadmill running mice Achilles tendon near 
the insertional site.  Achilles tendon near the insertion site in (A) Cage control. (B) GL injected only. (C) Treadmill 
running. (D) Treadmill running +GL injection groups. To better evaluate the TR’s effect and GL treatment effect, 
we roughly divided tendon tissue near insertion site to proximal region (to insertion), which is the tissue relative 
close to the tendon-bone junction, and the distal region (to insertion) which is relatively away from the junction. (E) 
The proximal region of cage control tendon. Because this site is very close to the junction, it may contain some 
round shaped cells with cavities (with space between cell and matrix, these cells are likely chondrocytes). (F) The 
proximal region of GL injection only tendon shows a few round shaped cells. (G) The proximal region of TR 
Achilles tendon shows lots of cells with cavities (arrows). (H) The TR+GL group tendon shows some round shaped 
cells without cavities. (I, J) Cage control and GL only group do not show round cells with cavities, meaning no 
cartilage cells exist in this area at the distal region. (K) Compared to the distal region of GL only tendon, TR tendon 
shows a high amount of chondrocyte-like cells with cavities. (L) GL treatment along with TR shows minimal 
chondrocyte-like cells in the distal region, indicating that GL treatment attenuates the cell type change near insertion 
site induced by TR. Pictures are representatives from 6 mice. Bars - 25 µm. 
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Then we closely examined the cellular and structural changes in the tendon tissue near 
the insertion site. In order to better evaluate the treadmill running effect and GL inhibitory effect, 
we divided the Achilles tendon near the insertion site into two parts, the proximal region of the 
tendon-bone insertion, which is very near the end of the tendon tissue that could be considered as 
the transitional zone between tendon and bone, and the distal region to the tendon-bone insertion, 
which is considered normal tendon tissue. We found that a small number of chondrocyte- like 
cells might exist in the proximal region in control group (Fig. 39E). So we focused on the distal 
region since it better represents tendon tissue degenerative change site rather than the region of 
possible pre-existing cells. 
H&E staining showed that the change in the morphology of tenocytes to round shaped 
cells with lacuna predominated at both the proximal and distal regions of TR tendon (Fig. 39 G, 
K), but not in the distal region of control, GL injected or TR+GL injected Achilles tendon (Fig. 
39I, J, L).  
Alcian blue staining for GAG deposition showed that the TR group had very strong blue 
staining in the tendon matrix at the proximal and distal regions (Fig. 40G, K). while control GL 
only and GL+TR group showed weak staining signal only at the proximal region (Fig. 40E, F) 
but not the distal region (Fig. 40 I, J). In the GL+ TR tendon, GAGs deposition could be 
identified weakly in the proximal part (Fig. 40H) and negative in the distal region (Fig. 40L). 
The round-shaped cells with lacuna were visible near the strong staining site with chondrocyte-
like morphology (Fig. 40K).  
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Figure 40. GL treatment prevents the GAGs deposition induced by 24-week treadmill running near the 
insertional site of mice Achilles tendon.  
Alcian Blue staining shows the overall GAGs deposition in (A) Control. (B) GL injected only. (C) Treadmill 
running. (D) Treadmill running +GL injection groups near the insertional site. (E, F) Cage control and GL only 
groups show slight staining in the proximal region (closer to the junction). (G) 24-week treadmill running group 
shows very strong staining of GAGs with cartilage-like cells (arrows). (H) GL-treated group shows weak staining in 
the proximal region. (I, J) Minimal staining of GAGS is present in the distal region (relatively away from the 
insertion) of the tendon tissue. (K) The distal region of TR group still shows strong staining of GAGs in the matrix 
with chondrocytes like cells (with very clear cavities around the cells called cartilage lacunae). (L) Minimal staining 
of GAGs at the distal region of the GL-treated TR tendon tissue. Bars - 25 µm. 
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Figure 41. GL treatment reduces the expression of SOX-9 induced by 24-week treadmill running near the 
insertional site of mice Achilles tendon Overview of SOX-9 staining. (A) Control. (B) GL injected only. (C) 
Treadmill running. (D) Treadmill running +GL injection groups near the insertional site. (E, I) Proximal and distal 
regions of the control group with round cells but without SOX-9 signal. (F, J) No signal of SOX-9 in GL only group 
at the proximal or distal region. (G, K) Strong SOX-9 staining at the proximal and distal region of 24-week TR 
tendon along with the round shaped cells. (H) SOX-9 is positive for some cells in the proximal region of the TR+GL 
group Achilles tendon, (L) but SOX-9 signal in the distal region was minimal in the TR+GL group, indicating that 
GL treatment can decrease but may not completely suppress the expression of SOX-9 induced by treadmill running. 
Bars - 25 µm. 
 
 
 
The SOX-9 staining is used as a marker for the chondrogenic cells. The results showed 
that in the control group, even some round-shaped cells exist in the proximal region that is not 
positive for SOX-9 (Fig. 41E), that hold true for the distal part (Fig. 41I). The GL injection only 
group also stained negative for SOX-9 at both sites (Fig. 41F, J). TR group showed very strong 
staining of SOX-9 in and around the nucleus of the round-shaped cells at both site (Fig. 41G, K), 
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further confirming that those cells are chondrogenic cells which are induced by long-term 
treadmill running.  
For the collagen II staining, in control tendon and GL only tendon, collagen II can be 
lightly detected at the proximal region (Fig. 42E, F) but not at the distal region (Fig. 42I, J), but 
collagen II was expressed strongly in the TR group at both sites (Fig. 42 G, K), which confirmed 
the structural chondrogenic change in tendon tissue induced by treadmill running. However, in 
the TR+GL group this effect was suppressed with much less collagen II staining at the proximal 
region (Fig. 42H) and minimal at distal region (Fig. 42L) 
These results indicated that the 24-week long-term TR induced a very strong 
chondrogenic degenerative change in the Achilles tendon tissue near the insertion site shown by 
increased chondrocytes cells, elevated GAGs deposition, SOX-9 expression in cells in the 
tendon, and collagen II deposition. That effect could be contributed to the chronic inflammation 
induced by inflammatory cells migrated to tendon tissue that was attracted by HMGB1. The GL 
injection along with the treadmill could very effectively reduce the CD68 cells and attenuate that 
degenerative effect, and as a direct inhibitor of HMGB1, the inhibitory effect from GL is very 
likely though inhibition of HMGB1 effect. Therefore, HMGB1 could be a therapeutic target for 
over-use induced insertional tendinopathy in Achilles tendon. 
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Figure 42. GL treatment reduces the deposition of Collagen II induced by 24-week treadmill running near the 
insertional site of mice Achilles tendon.  Overview of collagen II staining in (A) Control. (B) GL injected only. 
(C) Treadmill running. (D) Treadmill running +GL injection groups near the insertional site. (E) Collagen II 
presence in the proximal region of the cage control tendon. (F) Collagen II staining very weak in the GL injection 
only group. (G) Collagen II is strongly expressed in the matrix of the TR group in the proximal region. (H) Light 
staining of Collagen II in the matrix of the proximal region tendon tissue in the TR+ GL group. (I, J, L) Collagen II 
is mostly negative for the control, GL, and TR+GL group at the distal region, but the expression of collagen II is still 
very strong at the distal region of the TR group tendon tissue, which implies that 24-week running induced collagen 
II deposition in matrix can be attenuated by GL treatment at the distal region. Bars - 25µm. 
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4.5 METHODS USED IN THIS CHAPTER 
4.5.1 GL toxicity on tendon cells 
2000 rat Achilles tendon cells (P4) were plated in 10% FBS +DMEM into each well of 96 well 
plate and allowed to attach overnight. The medium was changed to 10% FBS+DMEM with 
different concentrations of GL (0, 1, 10, 100, 200, 1000, 5000, and 10000 µM) with condition 
repeated 6 times. The cells are then cultured for 72hrs and 10 µL CCK-8 solution was added to 
each 96 well. 6 wells with no CCK-8 addition and no GL treatment were served as a blank 
group. The whole plate was then cultured for 2hrs and then OD value under 450nm was 
measured as an indicator of the cell viability. 
4.5.2 Safranin O and Fast Green staining 
Safranin O staining was conducted by first putting slides with tissue section on into iron 
Hematoxylin for 5 min then rinsed with double distilled water. The slides were dipped in 1% 
acidic alcohol for 10s followed by rinsing with double distilled water. The slides were then 
dipped into 0.02% Fast Green for 1min, and then in 1% acetic acid for the 30s followed by 
staining with 1% Safranin O for 30min. The slides were finally rinsed in 95% EtOH and then 
dehydrated with 2 changes of 95% EtOH and 2 changes of 100% EtOH each for 1min. Finally, 
slides were washed 3 times with Xylene and covered with coverslips. Pictures were taken under 
histology microscope.  
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4.5.3 Alcian blue staining 
Alcian blue staining kit was purchased from Abcam, (Cambridge, UK, ab15066) and followed 
the manufacturer’s protocol. Briefly, glass slides with tissue on it were hydrated first and 
incubated in acetic acid for 3 min. The slides were incubated in Alcian blue (pH 1.0) solution for 
30min at room temperature and then rinsed with acetic acid. They were then rinsed with running 
tap water for 2 min, followed by washing with two changes of distilled water. The slides were 
stained with Alcian blue solution for 5min, followed by rinsing with running tap water and two 
changes of distilled water. The slides were dehydrated with graded alcohols, washed in with 
Xylene and covered with coverslips. The pictures were taken with histology microscope.  
4.5.4 ELISA and Immunostaining of tendon tissue  
For PGE2 and MMP-3 ELISA, the samples were placed in 200 µl T-PER tissue protein 
extraction reagent (ThermoFisher, Pittsburgh, PA, 78510) instead of PBS. The samples were 
vigorously homogenized with BioMasher Standard (Takara, Shiga, Japan, 9790A), centrifuged at 
2,000 g for 30 min at 4°C, and the supernatants were collected for ELISA.  
For immunostaining, Achilles tendons samples were dissected from the mice 
immediately at the end of treadmill running and fixed with 4% paraformaldehyde for 2hrs then 
embedded in paraffin, and sectioning was performed to obtain about 5 µm thick tissue sections. 
The sections were deparaffined with Xylene and were treated with EtOH, with concentrations 
decreased for each treatment (100%, 80%, 50%, and 30%). For CD68, Sox-9 and Collagen II 
staining, the tissue sections were treated with 0.2% Triton X-100 in PBS for 1hr at RT to 
penetrate cell membrane before the blocking with universal blocking solution at RT for 1hr 
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(ThermoFisher Scientific, Pittsburgh, PA, 37515). The tendon tissue samples were stained with 
rabbit anti CD68 (2 µg/ml, Abcam, Cambridge, UK, ab125212), goat anti SOX-9 (1 µg/ml, 
Santa Cruz, Dallas,TX, Sc-17340) or rabbit anti collagen-2(1 µg/ml, Abcam, Cambridge, UK, 
ab116242) at 4˚C overnight followed by corresponding secondary antibody conjugated with Cy3 
for 1hr at room temperature (0.5 µg/ml, Millipore, Billerica, MA, AP132C, AP305P). All 
antibodies were prepared in the blocking solution. Then they were counterstained for the nucleus 
with 10 µg/ml Hoechst 33342 for 5min. Pictures were taken with fluorescence camera same as 
mentioned in chapter 2. The HMGB1 was stained similarly with rabbit anti HMGB1 (2 µg/ml, 
Abcam, Cambridge, UK, ab18256), and goat anti-rabbit secondary antibody conjugated with 
Cy3 (0.5 µg/ml, Millipore, Billerica, MA, AP132C), but without Triton X-100 treatment.  
4.5.5 Determining the presence of GL in mice tendons after GL injection  
Tendon tissues from the control and treadmill running mice (see above) were weighed, minced 
and homogenized in PBS (1 mg tissue/0.5 ml PBS) at 4˚C. Then, the samples were centrifuged at 
10,000g for 30 min at 4˚C to collect the supernatant. Simultaneously, a 1 mg/ml GL stock 
solution in methanol was prepared and diluted in double distilled water to prepare various 
concentrations of GL solution (0-1000 µg/ml) to get a standard curve for GL quantification. 
Then, 0.1 ml of a GL standard (0-1000 µg/ml) was mixed with 0.1 ml of the supernatant from the 
GL injected (GL group) mice tendons (see above for details). The control received 0.1 ml PBS 
(0.1 ml). Nucleic acids and proteins in all samples were removed by passing 0.2 ml of each 
sample through individual spin columns (Qiagen, Valenia, CA) followed by centrifugation at 
8000 rpm for 2 min. The GL concentrations in the resulting supernatants were determined at 252 
nm using a spectrophotometer (Molecular Device, Sunnyvale, CA) according to a previous 
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publication [269] and calculated based on the equation OD=0.0015X + 0.2041 (R2=0.9931) 
obtained by the standard curve.  
4.5.6 GL inhibition of HMGB1 effect in vitro 
To test whether GL can inhibit HMGB1’s inflammatory effect on tendon cells in vitro, the 
following experiment was performed. Tendon cells isolated from rat patellar tendons in passage 
3 (~2 x 10^5 cells) were seeded in 6 well plates and allowed to attach overnight in 10% 
FBS+DMEM. Next day, the culture medium was replaced with 2% FBS DMEM. Then, the 
control group received PBS while the treated group was supplied with HMGB1 such that the 
final concentration was 10 µg/ml. HMGB1+GL group received a mixture of GL (200 µM, 
Sigma, St. Louis, MO, 50531) + HMGB1(10 µg/ml). The culture medium was collected at 0.5, 2 
and 4hrs to quantify PGE2 production by ELISA. 
4.5.7 3-weeks Treadmill running and GL inhibition of HMGB1 effect in vivo 
In these experiments, a total of 24 female C57B6/L mice (3 months old) were used with 6 mice 
in each of the 4 groups; i) Cage control group (C) where mice received intraperitoneal(IP) 
injection of 400 µL PBS 5 days a week and allowed cage activity served as control group, ii) 
Intensive treadmill running (TR) group where mice ran on the ITR regimen (see in vivo mouse 
treadmill running model in chapter 2 for details) with daily injection of PBS, iii) Glycyrrhizin 
injection only (GL) where mice received daily (IP) injection of GL (50 mg/kg body weight), and 
iv) Intensive treadmill running with Glycyrrhizin injection (TR+GL) group where mice received 
daily IP injection of GL (50 mg/kg body weight) and ran on the ITR regimen. After treadmill 
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running, patellar and Achilles tendons were dissected out, and the right and left side of each 
tendon from a single mouse were homogenized in T-PER buffer (Themofisher, Pittsburgh, PA) 
and the supernatants were used for ELISA to measure PGE2 and MMP-3. 
4.5.8 24 weeks treadmill running and GL inhibition  
The treadmill running protocol was the very similar to the 3-week running protocol, totally 24 
mice were divided into 4 groups, the only difference was that the TR mice and GL+TR mice ran 
a horizontal treadmill in the first 12 weeks, and then ran a 5° uphill treadmill to increase the load 
on Achilles tendon to maximize the treadmill running effect. At the end of week 24, all mice 
were sacrificed, and the Achilles tendons were dissected and used for histology and IHC 
analysis.  
4.5.9 Statistical Analysis 
Student’s t-test and One-way ANOVA was used, followed by Fisher's least significant difference 
(LSD) test for multiple comparisons. When P-values were less than 0.05, the two groups 
compared were considered to be significantly different.  
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5.0  DISCUSSION 
This study demonstrated that mechanical overloading-induced HMGB1 release from the nucleus 
into the extracellular milieu both in tendon cells and in tendons. Also, we showed that addition of 
HMGB1 promoted tendon cell migration and inflammatory reactions by enhancing the levels of 
COX-2 and PGE2 in vitro. Furthermore, high dose HMGB1 implantation into rat patellar tendon 
resulted in hypercellularity, angiogenesis, and inflammatory cell infiltration, characteristics of 
the early inflammatory stage of tendinopathy in tendon tissue in vivo. Interestingly, GL reversed 
the HMGB1-induced PGE2 and MMP-3 release in vitro, and mechanical overload-induced PGE2 
and MMP-3 in an in vivo model. We also established an insertional tendinopathy model induced 
by long-term treadmill running(up to 24 weeks). The exercised tendon showed cell shape 
change, Sox-9 expression, GAGs and collagen II depositions near the insertion site of Achilles 
tendon. Additionally, we showed that daily GL injection effectively reversed the overloading- 
induced degenerative changes in Achilles tendon. 
These results provide the first evidence for the role of HMGB1 in the onset of the 
inflammatory cascade in tendon pathology which leads to the development of degenerative 
tendinopathy. Therefore, HMGB1 could serve as a potential therapeutic target to curb chronic 
inflammation associated with the pathology of tendinopathy. The reversal of inflammatory 
reactions in tendons by GL also suggests the putative therapeutic potential of this natural 
triterpine. 
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GL treatment could be suitable for the athletes who have to participate in overload 
training, and provides a protective effect against the HMGB1 generated during these overloading 
on the tendon, thus block the sustained inflammation in tendon and allow the tendon to heal 
without being stuck in the inflammation phase due to the constant HMGB1 release. The 
treatment could also be helpful to the athletes who have to participate in the overexercise for a 
while, as we found in our study that administration of HMGB1 could induce hypercellularity and 
vessel ingrowth in 2 weeks. But by the end of 4 weeks, there is a great reduction of all these 
effects which may be due to the depletion of HMGB1, suggesting that HMGB1 induced change 
could be reversible in the early stage.  
GL treatment may not be able to treat established degenerative tendinopathy directly, but 
it might be helpful to act as a post-surgical treatment. Surgical removal of the degenerative tissue 
is sometimes conducted in late stage tendinopathy to attenuate the inflammation induced by 
HMGB1 released from the damaged and necrotic cells during the trauma of the surgical process. 
One important issue is about the safety and cost of GL administration. GL is the major 
bioactive component in licorice and can be extracted and purified without relatively low cost. 
Licorice is a widely used Chinese medicine [270], and it is also a popular sweetener found in 
many soft drinks, food products, snacks and herbal medicines [271]. It is approved by Food and 
Drug Administration. Health products like licorice-flavored cough mixtures, throat pearls, 
licorice tea, licorice-flavored diet gum, laxatives are known to contain licorice [271]. There are 
known side effects of overdose licorice. The side effect of GL is mainly from its metabolic 
product glycyrrhetic acid after oral ingestion. Glycyrrhizin or glycyrrhizic acid(Fig. 43A), can be 
hydrolyzed to glycyrrhetic acid(Fig. 43B) by intestinal bacteria through a specialized β-
glucuronidase [272], both glycyrrhizic acid and glycyrrhetic acid can inhibit 11-β-hydroxysteroid 
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dehydrogenase(11- β-HSD), which will result in increased sodium reabsorption, causing pseudo-
hyperaldosteronism[273], usually characterized by hypertension, kaliuresis and reduced plasma 
renin [274]. However, the metabolic product glycyrrhetic acid is 200-1000 times more potent 
inhibitor of 11- β-HSD, so the side effect is more relevant after oral ingestion of licorice [271]. A 
dosage of 380 and 814 mg/day but not 108 or 217 mg/day GL ingestion was able to induce side 
effect in healthy volunteers in 4 weeks [275]. A case study reported a 78-year old male patient 
who ingested GL (280 mg/day) for 7 years was hospitalized for damaged skeletal and cardiac 
muscles and acute kidney failure with other symptoms like hyporeninemic hypoaldosteronism 
which are closely related to GL side effects [276]. Those studies suggested that the side effect of 
GL is largely dosage and time dependent. 
 
 
 
Figure 43. The structure of Glycyrrhizin and glycyrrhetinic acid.  (A) Chemical structure of Glycyrrhizin (B) 
Structure of hydrolyzed product of glycyrrhizin: Glycyrrhetinic acid. (Source: [277]) 
 
 
 
Intravenous GL has already been in clinical use to treat chronic hepatitis patients [278], 
but overall, the non-oral administration of GL was not extensively studied in human patients. 
However, according to our animal study, 50 mg/kg IP administration of GL for up to 24 weeks 
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(5 days a week) did not induce significant body weight or body composition change in young 
mice, and the mice received GL injection ran treadmill as good as the control group without GL. 
This finding is also in agreement with several other GL studies which used similar dosage 
injection [263, 264].Overall, non-oral GL administration seems to be a safe way, but still, needs 
to be extensively tested clinically. 
Another concern about GL is its off-target effect. It was reported that GL administration 
has anti-inflammatory effects. One study found that GL treatment can attenuate sepsis-induced 
kidney injury through inhibition of NF-κb pathway [279]. This attenuation effect in this study 
could be highly related to the inhibition effect of GL on HMGB1 since, in the mice model, the 
HMGB1 antibody is sufficient to attenuate sepsis-related mortality [151]. It is known HMGB1 
binding to its receptor can subsequently activate NF- κb pathway [280, 281]. Another study 
found that GL treatment could decrease COX-2 expression in macrophage from parasites-
infected mice in vitro [282]. COX-2 is also regulated by NF-κb pathway [283-285].None of these 
studies mentioned or excluded the possibility of GL’s inhibition of HMGB1 effect. It is highly 
possible that that “off-target” effect of GL is still through the inhibition of HMGB1 directly. 
However, clinically speaking, even if the GL off-target effect on NF-κb and COX-2 is 
independent of HMGB1 inhibition effect. It can still work synergistically with its principal effect 
on blocking HMGB1 on the attenuation of the inflammatory reactions during the development of 
tendinopathy, those off target effects are not considered detrimental.  
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5.1 HMGB1 RELEASE TO EXTRACELLULAR MILIEU INDUCED BY 
REPETITIVE OVERLOADING 
5.1.1 HMGB1 is new to tendon biology 
Our study identified the presence of HMGB1 for the first time in patellar and Achilles tendon 
cells and tissues of rodents. The identification of the presence of HMGB1 in patellar and 
Achilles tendon in this study is the first confirmatory study of HMGB1 in the tendon. This 
finding is of importance as the role of inflammation in the development of tendinopathy is 
gaining attention, based on the premise that alarmins including HMGB1, HSPs, S100 may 
participate in the development of tendinopathy [174, 286]. The putative role of HSP-70 and HIF-
1 in inflammatory tendinopathy has been reported, but the role of HMGB1 is not investigated 
yet. These findings will reinforce the notion that as an alarmin, HMGB1 functions as an 
inflammatory mediator in tendon biology and pathology. 
To date, there are no in-depth studies on the role of HMGB1 in tendon physiology and 
pathology. However, as researchers are focusing on the relationship between tendon 
inflammation and development of tendinopathy, there is a strong trend now to explore the effect 
of HMGB1 and other DAMPs in tendon biology and tendinopathy [174]. A recent study has 
identified significantly elevated levels of HMGB1 in the tenocyte of the rotator cuff in arthritis 
patients. However, it lacked additional research about the role of HMGB1 in such disease 
settings [220].  
 It was found that extracellular HMGB1 play important role to promote inflammation 
when cells were subjected to accidental damage[158].The role of HMGB1 as an inflammatory 
mediator was not investigated in muscular-skeletal disorders until its presence was identified in 
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synovial tissues and fluids of rheumatoid arthritis patients [287]. Moreover, inhibition of 
HMGB1 release and activity could prevent the development of arthritis in experimental animals 
[288, 289]. It is very worthwhile to explore the potential function and pathological significance 
of HMGB1 in tendon research field. 
5.1.2 The different expression pattern of HMGB1 in tendon cells in vitro and in vivo  
 HMGB1 is widely-expressed in various tissues [290]. Its expression and localization may 
change depend on cell and tissue types [130]. It is very interesting that in our study we found that 
in vitro cultured tendon cells are almost 100% positive for HMGB1 and most of the signal is 
concentrated in the nucleus (Fig. 9E), while the in vivo staining of HMGB1 in tendon tissue 
suggested that HMGB1 expression pattern is different from that of in vitro. HMGB1 is expressed 
in nucleus and cytoplasm in tenocytes in vivo, and some cells are even negative for HMGB1. 
One possible explaining is that the HMGB1 negative cells are aged or inactive cells, and 
HMGB1 positive cells (especially cells with HMGB1 in the nucleus) are young and active cells. 
When the cells are extracted and cultured in vitro, those “young” and active cells will overgrow 
those inactive cells and dominate in the culture.  
HMGB1 is considered involved in the aging process. HMGB1 is down-regulated in aged 
neurons in the brain [291] and also down-regulated in the liver in old rat [290]. Our preliminary 
data also suggested that the location of HMGB1 in high passage cells (>passage 15, considered 
“aged” cells) was different from the low passage cell (passage<4, considered “young” cells) in 
the tendon. HMGB1 in “aged” tenocytes are translocated to the cytoplasm or even lost in cells 
(Fig.44B) while most HMGB1 in normal “young” Fig.44A tenocytes from mice reside in the 
nuclei(Fig. 44A). Please note that there is an enlarged cell (Fig.44A, arrow) in the “young” 
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group morphologically as a senescent cell, lost HMGB1 staining in the nucleus and cytoplasm. 
The HMGB1 expression maybe largely depends on the physical status of the cell. 
 
 
 
Figure 44. HMGB1 location in low and high passage cultured rat Achilles tendon cells.  (A) HMGB1 is located 
in the nucleus of most cells in low passage “young” cells (P3). (B) HMGB1 is located in the cytoplasm or lost in the 
majority of high passage “old” cells (P15), please note in (A) there is a giant cell (arrow) with minimal HMGB1 
staining, it is possibly a senescent cell. Bars - 50 µm 
 
 
 
 Another possible explanation for the lack of HMGB1 staining in some cells is from the 
technique side; tenocytes are highly packed in collagen fibers, it is possible that the antibody was 
not easily accessed to all cells in a tissue section slides. Thus result in the different staining 
pattern of in vivo tenocytes.  
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5.1.3 HMGB1 is released to extracellular milieu in tendon cells and tendons in response to 
excessive mechanical loading 
Our result showed that uniaxial repetitive stretching of the tendon cells in vitro at 8% but not 4% 
strain for three days caused translocation of HMGB1 from the nucleus, and there was also a 
remarkable increase in HMGB1 in the cell culture supernatants, suggesting HMGB1 is released 
to extracellular space due to mechanical overloading. When in vitro findings were transferred to 
in vivo treadmill running model in mice to examine the physiological relevance, the results were 
in agreement with the in vitro findings for the intense treadmill running regimen. We found that 
that intensive treadmill running but not moderate treadmill running for three weeks resulted in 
increased expression of HMGB1 in tendon matrix, confirmed by ELISA and immunostaining. 
The finding of our study is consistent with those in previous studies. Mechanical loading 
also has a similar stimulatory effect that is demonstrated in periodontal ligament (PDL) cells and 
tissues previously [182]. In this study, PDL under mechanical load showed that the compression 
and tension force induced translocation of HMGB1 from the nucleus to the cytoplasm in vivo, 
and increased the amounts of HMGB1 protein expression in response to the induction of 
mechanical loading following orthodontic tooth movement as early as at day 3 and day 6 in rat 
model. As tooth movement continued over 9 and 12 days, HMGB1 immunoreactivity decreased 
suggesting a role of HMGB1 acting as an alarmin indicating tissue damage and functioning as an 
early mediator in the periodontal remodeling process [182]. 
The finding that only mechanical overloading and intensive running induced HMGB1 
release suggested that tendon disorder might be loading-magnitude dependent that is, 
overexercised but not moderately exercised tendons results in inflammation. This finding is in 
agreement with the previous finding in our lab that only excessive loading in vivo induces 
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significantly higher production of PGE2 in the mouse treadmill running model[66], also in 
another study, moderate exercise could enhance the tendon stem cell pool and increase collagen 
production[116]. Together these findings provide practical suggestions to the athletes and the 
recreational population that proper exercise is beneficial for tendon, but over-exercise can be 
detrimental, especially in long term practice. Interestingly several studies found that in humans , 
both the collagen synthesis and degradation are increased in tendon tissue after acute exercise, 
but the first 24-36hrs the response in total is a net loss of collagen, and it is followed by a net 
synthesis 36-72hrs after exercise[292-294](Fig. 45). These results suggested that repeated 
training with short rest period may lead to net loss of collagen resulting in overuse tendon injury 
[295]. As our finding indicate that HMGB1 is already present in tendon matrix after one-bout 
treadmill running, its inflammatory invoking potential is considerable. It is highly possible that 
tendon tissue turned into a pro-inflammatory phenotype and lasted for 24-36hrs, the 
inflammatory response may gradually get resolved after the first day or two. But if the exercise is 
repeated with short rest time (i.e. daily treadmill running in our experiment), the inflammation 
may sustain to cause more collagen degeneration, which could lead to tendinopathy in the long-
term running. 
.Another interesting finding is that, while both ITR and OTR groups were positive for 
HMGB1 in tendon matrix(Fig. 16). ITR Achilles tendon tissue was positive for CD68 while 
OTR was negative, macrophages are known to actively secrete HMGB1 under inflammatory 
status, it is hard to tell if the HMGB1 in the ITR groups is from the release of the tenocyte due to 
overloading or from the recruited macrophage possibly through other pathways. The negative 
result of CD68 indicated that there is minimal macrophage infiltration in tendon matrix during 
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the one time 5hrs running, which implied the HMGB1 released during OTR is mainly released 
from resident tenocyte induced by overloading 
We also found that HMGB1 and CD68 are both positive in the mid-portion and near the 
insertional site of the Achilles tendon, as we found later that long-term treadmill running induced 
degenerative change was only occurring in the near the insertional site of the Achilles tendon 
indicate there might be other risk factors involved in the development of degenerative 
tendinopathy, HMGB1 might be necessary but not sufficient for the development of 
tendinopathy in vivo.  
 
 
 
Figure 45. Schematic graph show collagen synthesis and degradation followed by an acute exercise in 
humans. In the first 24-36hrs, both synthesis and degradation are increased but result in a net loss of collagen; then 
both effects decreased gradually during the 36-72hrs time after exercise. So repeated the intensive exercise with 
short rest time can result in a net degradation of tendon matrix and lead to overuse injury. (Source: [295]) 
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5.1.4 In vitro mechanical loading model 
This study focused on load-bearing tendons like Achilles and patellar tendon. This type of 
tendon only bears uni-axial tension but not compression in vivo. The translocation of HMGB1 
was tested in tenocytes with a customized uniaxial stretching device which was designed to 
mimic the physiological condition where tenocytes are subjected to mechanical loading in vivo.  
There is a commercially available in vitro cell stretching system from flexcell 
International Corporation including early BioFlex model and new UniFlex system, and this 
system utilizes vacuum to create mechanical loading to stretch the soft substrate where cells 
reside. However, the commercialized in vitro cell stretching systems apply stretch in arbitrary 
directions, which is not suitable for our study. 
The customized uni-axial stretching device developed earlier in our laboratory had been 
successfully used in several studies [35, 111, 296, 297]. With a different configuration, it could 
apply 3 different magnitudes of tension regarding percentage stretch or strain-4%, 8% and 12%. 
Both 4% and 8% are the most applicable magnitudes, 12% stretch is far beyond the physiological 
deformation of the tendon. A biomechanical study on tendon suggested that a 4% stretch 
represents the physiological limit of tendon deformation, and 8% stretch in tendon tissue results 
in micro-level damage that is considered detrimental. When the stretch exceeds 8%, macroscopic 
rupture of the tendon occurs [30]. Any magnitude over 8% does not reflect the actual in vivo 
tendon stretching condition, and therefore, it was not considered for this study.  
 The previous study showed increased inflammatory mediator PGE2 production in human 
tenocytes with 8% cyclic stretch but not with 4%, compared to non-stretched control [35]. The 
human tenocytes were stretched in micro-grooved silicone dish for 24hrs at 4% and 8% 
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stretching magnitudes, and only 8% stretch resulted in a 1.7-fold increase of PGE2. These results 
indicated that 4% stretch was relatively mild and did not invoke a strong inflammatory response. 
Based on these results, non-stretch, 4% stretch, and 8% stretch groups were selected to 
explore the effect of cyclic stretching on HMGB1 release from rat Achilles tendon cells in this 
study. Besides the stretching device, the stretch container is also specifically designed. An earlier 
study in our laboratory found that if cells were stretched on a smooth surface such as silicone, 
initially, the orientation of cells will be arbitrary after seeding, but during the cyclic stretching, 
the cells will change their orientation to minimize the stress they are subjected to [298]. 
Therefore, the magnitude of stretch applied on the cells will be reduced from the initial design; 
cells also will not be stimulated in a uniform manner which may potentially result in inconsistent 
results. A micro-grooved dish was then designed to resolve the problem. The surface of the 
silicon dish where cells were seeded was micro-patterned with horizontal grooves (10 µm wide 
and 3 µm deep, optimized for cell attachment) parallel to the stretching axis. The description of 
the microgrooves silicone dish fabrication is detailed previously [299]. This design ensures that 
the cells only align along the stretch axis without any change in orientation during the stretch, 
which very closely mimics the circumstances the tendon cells are subjected to in vivo tendon 
stretching situation(Fig. 10B).  
 For the stretching experiment, the cyclic frequency should be set at a reasonable value, 
favorably mimicking the frequency of human activity. The previous studies in our laboratory 
used 0.5Hz[37] so as to mimic the frequency during normal walking activity. In this study, the 
frequency was set at 1Hz with increased intensity to increase the odds of detecting changes of 
HMGB1 in tendon cells. A frequency of 1Hz is still physiologically valid since it is similar to the 
stretching frequency during running. 
 133 
 The in vitro stretching model has certain limitations. With this setup, the stretching 
machine is customized and only available in our laboratory, and even with the commercially 
available system, it might be difficult to directly use the parameter in this study and trying to 
replicate the well-established model. 
5.1.5 In vivo tendon mechanical loading model 
The in vivo experiment model utilized in this study for assessment of HMGB1 release in tendon 
matrix is mouse treadmill running.  
Study of the pathogenesis of tendinopathy in human is difficult since tissue biopsy could 
only be obtained from individuals with advanced tendinopathy. Comparative normal tendon 
samples are rare [300]. Furthermore, the samples from early stage tendinopathy are almost 
impossible to obtain since there are no symptoms for early diagnosis. By using the animal model, 
the development of tendinopathy can be studied more thoroughly especially the early stage, 
which may lead to novel treatment and prevention options for patients.  
Several different overuse models are employed in tendon biology and pathology studies. 
One method was developed in rabbits by stimulating the muscle to produce contractions with a 
certain frequency that results in cyclic passive loading of the tendon[118, 301]. By stimulating 
the flexor Digitorum muscle, with 10 reps/min and 60 reps/min stimulation increased micro-tears 
in the tendon [301], and, stimulated triceps surae muscle of rabbit resulted in increased 
capillaries and inflammatory cells[118]. However, even the unexercised leg also had 
tendinopathic changes [302], so there might be other mechanisms involved. The use of relatively 
high-frequency electronic stimulation would potentially affect the direct assessment between 
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HMGB1 release and mechanical loading. Therefore, treadmill running method was considered 
for the in vivo mechanical loading model in this study. 
The most developed and used in vivo tendinopathy model is rat downhill treadmill 
running. The rats ran on a 17m/min, a 10-degree decline treadmill for 1hr a day, 5 days a week 
for 4,12, and 16 weeks. Increased cell number and change of cell shape were detected as early as 
4 weeks in supraspinatus tendon, and mechanical property including maximum stress and tissue 
modulus were decreased in 12 and 16 weeks [114]. The reason for using rat model over a mouse 
one is that the supraspinatus tendon of rat is anatomically very similar to its counterpart in 
human. Several studies that used this model found increased growth factors, inflammatory 
mediators, GAG accumulation, etc.[300]. However, despite all the changes found in 
supraspinatus tendon, the similar downhill running protocol had no effect regarding mechanical 
properties of Achilles tendon up to 16 weeks[303]. These results indicate that tendons respond to 
mechanical loading in a variety of ways. But while the downhill running increases the loading 
intensity on supraspinatus tendon, Achilles tendon may experience relatively decreased loading; 
this might explain the difference in effects between two types of the tendon. 
 A 10° uphill treadmill running effect on rat Achilles tendon found disorganized collagen 
fibers, hypercellularity, and neovascularization [34]. In contrast, no pathological changes were 
identified with same treadmill running protocol up to 12 weeks with even increased running 
speed (20m/min compared to 17m/min), and it even improved the mechanical properties of 
Achilles tendon[304]. While using a similar running protocol, no significant changes was found 
in Achilles tendon up to 9 weeks [305]. The effect of uphill treadmill running is still in 
controversy. One possible explanation is the variability in the running duration that is relatively 
short during each day. All the uphill rat treadmill running were done with 1hr running per day, 
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the age of the rats was between 2-6 months, generally considered young, all but one study[305] 
used male SD-rat. For this study, a strain of HCR rat was used, HCR rat was selectively bred 
with high running capacity[305], which may help explain the reason for not developing 
tendinopathic changes. Other studies are also not in agreement with each other. Short term 
running was found beneficial in our previous studies[116]. In the mouse treadmill running 
conducted earlier in our lab found that only 3 hrs but not 50 min treadmill running resulted in 
increased PGE2 production in mouse patellar and Achilles tendon after 3 weeks running[66]. 
This study also found that HMGB1 was released in the 3 hrs running group but not the 50min 
group. These findings indicated the running duration is a critical factor in generating the positive 
or adverse effect on the tendon. 
Another reason for the controversial results is about the total running duration.; It was 
found that rat supraspinatus tendon change cell shape as early as 4-weeks and tendinopathy 
change after 12 weeks treadmill running. But it is not necessary that Achilles tendon respond in 
the same way. In fact, Achilles tendon is subjected to ~1400 N(2 times body weight) during slow 
running[306] and >2000 N(3 times body weight) during jumping[307]. It is reasonable to assume 
that Achilles tendon could better resist the stress during running and need longer time to develop 
a stable degenerative change. 
Mouse treadmill running was studied to explore its effect on cardiac and skeletal muscle 
[308] and later introduced in tendon as a counterpart of rat treadmill running. Mouse treadmill 
running now is focused on the weight bearing tendon on the hinder leg. For example, for patellar 
tendon and Achilles tendon, the running protocol of mice and rats are similar but different in 
running speed (12-15 m/min v.s. 17-20 m/min in rat), and with longer running duration each day 
(3-5h v.s. 1hr in rat). As mentioned above, the running duration is critical in mice treadmill 
 136 
running. 3-5h running was referred as intensive running(ITR) and known to render detrimental 
effect on mice Achilles tendon as a result of inflammatory mediator PGE2 accumulation[66]. In 
this study, we found that HMGB1 increased PGE2 production in tendon cells which may at least 
partially account for the elevated levels of PGE2 generated during intensive running. Moreover, 
PGE2 induced a degenerative change in tendon tissue[309] potentially through the induction of 
non-tenogenic differentiation of resident Tendon Derived Stem/progenitor cells(TSCs)[66]. 
Short term (50min) referred as moderate treadmill running (MTR) was beneficial to tendon 
quality by expanding stem cell pool in tendon [116]. Mouse treadmill running model is suitable 
for HMGB1 study as the distinct effects of intensive and moderate running protocols may induce 
different cellular responses and that we could expect to see a differential response of HMGB1 
under different loading regimens.  
The setup of the One-time fatigue Treadmill running (OTR) group was to validate the 
model and explore the presence of HMGB1 in tendon matrix (Fig.16). As HMGB1 exists in 
tendon cells, it is possible that the increased HMGB1 seen in ITR groups may be due to the cell 
proliferative effect since exercise could activate tendon stem cells with higher proliferative 
potential[116]. To exclude that HMGB1 content from proliferative cells in 3-week time point, 
OTR group was set up where the mice run 4-7 hrs until final fatigue(average 5hrs). While testing 
to see if HMGB1 can be released with one-bolt running without inference of proliferative effect, 
we found that OTR group had increased HMGB1 release but significantly lower than that in ITR 
group afterr 3 weeks running. This result also confirmed the cumulative effect of HMGB1 on the 
repetitive loading condition, if tendon was repeatedly exposed to overloading condition, the 
HMGB1 level might be elevated and sustained which may result in chronic inflammation. Since 
macrophage could actively secrete HMGB1 in the presence of other inflammatory mediators like 
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IL-1β, INF-γ and TNF-α[310, 311], it is very hard to distinguish whether HMGB1 in the matrix 
is derived from tendon cells or infiltrated inflammatory cells at the 3-week time point as we 
identified inflammatory cells in tendon tissue. It is more likely that both cells are contributing to 
the accumulation of HMGB1 in longer duration runs. However, in the OTR group, minimal 
inflammatory cells were identified in the matrix after 5hrs running while with an increase of 
HMGB1 release in tendon matrix, this finding suggested that the tendon cells are mainly 
responsible for the initial release of HMGB1 due to mechanical loading. 
It is widely accepted that only extracellular HMGB1 acts as damage signal and invokes 
inflammatory reactions [312]. Since most cells possess intracellular HMGB1, it is possible the 
intracellular HMGB1is released during the tissue processing. It will create a general concern 
when interpreting the results, especially in this study. To avoid the interference from the 
intracellular HMGB1, the tendon samples are not processed in a total lysis buffer but chopped up 
and soaked in PBS. Also, HMGB1 in the matrix to diffuse into the solution, the DNA content in 
the solution as an indicator of cell destruction was measured and found consistently low in all 
samples compare to the total lysis sample. The leakage of DNA is not avoidable and may 
contribute to the background measurement value. That explains the reason why we still found 
HMGB1 in the control sample during the ELISA measurement. 
It is well known that mechanical loading well within the physiological range does not 
harm the tendon but reinforces it. This biochemical adaptation of loading is characterized by the 
release of inflammatory mediators and growth factors both in the circulation and locally in 
tendons, well known among them is IL-1β that can upregulate COX-2 and MMPs. [37, 208, 
313]. HMGB1 also seems to have a similar function in pathological progress in tendon as 
evidenced by our studies in which we applied moderate level stretching or moderate treadmill 
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running regimen. Appropriate loading range may keep HMGB1 levels appropriate for the tendon 
cellular regulation, function and remodeling; however, under excessive mechanical loading, 
abnormal release from the nucleus and subsequent extracellular placement will render HMGB1 
as a danger signal that initiates inflammatory reactions which may finally lead to chronic 
tendinopathy. 
There are limitations of the mouse treadmill running model. Most mouse TR models 
focused on the load-bearing tendons like patellar and Achilles tendons instead of other types of 
mostly motion-transmitting tendons such as flexor tendons. Therefore, the findings of HMGB1 
in this model may not be directly translated to those tendon tissues and related diseases like 
flexor tendinopathy, but still, provide possible research target in future studies of the different 
type of tendon. 
5.1.6 The mechanism of HMGB1 release induced by mechanical loading in tenocytes 
The intracellular HMGB1 could go through active or passive release. Active release is usually 
induced by exogenous microbial products like endotoxin, or endogenous stimuli inflammatory 
cells like macrophages and monocytes [151]. The passive release was first described in necrotic 
cells[158], then in apoptosis, and in autophagic cell death[130]. The HMGB1 release also 
happens during cellular injury following chemical or physical stimulations such as 
chemotherapy, irradiation, hypoxia, hyperpressure[224]. As in passive release, cell structure 
integrity is often lost, which happens both in immune cells and stromal cells like fibroblasts. 
HMGB1 can be secreted from human fibroblast upon the stimulation of microbial products 
without necrosis[314]. When human gingival fibroblast was exposed to lipopolysaccharides 
(LPS) and other microbe products, HMGB1 was translocated from the nucleus to cytoplasm as 
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early as 6hrs and was also detected in the cell culture supernatant after 48hrs stimulation. 
HMGB1 was also released from epithelial cells with stimulation of 100 µg/ml LPS at 48 or 72hrs 
time point but not as early as 24hrs [315]. Tenocytes are regarded as fibroblast cells implying 
that there could be the underlying mechanism for HMGB1 release in stromal cells. In our in vitro 
mechanical loading experiment, HMGB1 was translocated to the cytoplasm and discharged into 
the supernatant (confirmed by ELISA) after intensive (8%) stretching. Cell density was not 
significantly decreased, indicating that no major cell death occurred during mechanical loading 
at this magnitude. DNA damage, which is often associated cell necrosis, was minimal in tenocyte 
subjected to intensive mechanical loading in vitro and the coincidence of HMGB1 translocation 
and DNA damage was also minimal. These results indicated that HMGB1 translocation and 
release in tenocytes subjected to mechanical stress was not regulated by necrosis or cell death.  
Acetylation regulates the cytoplasmic translocation and secretion of HMGB1 in mouse 
monocytes and fibroblast[135]. Deacetylase inhibitors(TSA) and mutation of six lysines to 
glutamine to mimic the acetylated lysine in the nuclear location signal(NLS) sequence resulted in 
relocalization of HMGB1 to the cytoplasm [135]. Also, LPS induced HMGB1 translocation was 
inhibited by acetylase inhibitor anacardic acid[226]. In this study, since TSA treatment resulted 
in HMGB1 translocation in tenocyte from the nucleus to the cytoplasm, and in vitro stretching 
model also induced HMGB1 translocation, it is possible that mechanical loading mediated 
HMGB1 translocation is through the regulation of acetylation process. Mechanical stimulation 
and acetylase inhibitor showed that treatment with AA blocked the majority of HMGB1 
translocation induced by 8% mechanical stretch.  
 Mechanical stress could result in temporarily and reversible plasma membrane damage 
[228], and mechanically active tissue cells like skeletal muscle cells, cardiac myocyte, 
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endothelial cells frequently and normally experience plasma membrane disruption[316], with 
outflux of cytosolic constituents and influx extracellular contents. bFGF was released from a 
cytosolic storage site through the plasma membrane disruption in endothelial cells[317]. Similar 
to skeletal muscle, load-bearing tendons like Achilles and patellar tendons are constantly under 
cyclic mechanical stress. In tendon tissue, tenocytes could also suffer from plasma membrane 
disruption under intensive and long term stretching. In this study, the live/dead cell assay was 
utilized with propidium Iodide (PI) and Fluorescein Diacetate (FDA). FDA marks the live cells 
with green fluorescence, and PI is a membrane impermeable DNA binding reagent that stains the 
necrotic cells by binding to its DNA through the compromised membrane. A special feature of PI 
is that it would go through the plasma membrane when the membrane is temporarily disrupted. 
Tenocytes subjected to mechanical stress at the magnitude of the possible release of HMGB1, 
double staining with PI and FDA was regarded as cells with temporary membrane disruption. 
FDA processed intracellularly will generate green fluorescence signal but not in dead cells, Over 
95% cells were positive for green fluorescence (means cells are alive), indicating no major cell 
death which was in agreement with our finding during the in vitro stretching (Fig. 16). 
Furthermore, we found that around 50% of the cells were PI positive and green fluorescence 
positive, which was a strong indication of the occurrence of reversible plasma membrane 
damage. These findings explain the possible HMGB1 release to extracellular milieu once it was 
translocated to cytoplasm due to repetitive and intensive mechanical stress. 
Based on these findings, we propose a plausible theory to explain the HMGB1 release in 
tenocytes under mechanical stress. First, the magnitude of mechanical stress should be sufficient 
to induce HMGB1 translocation through the regulation of acetylation of HMGB1, the acetylated 
HMGB1 lost nuclear localization signal (NLS) and was fast trafficked to the cytoplasm. At the 
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same time, the mechanical stress results in temporary plasma membrane damage, that results in 
an outflux of HMGB1 from the cytoplasm. The plasma membrane disruption is repairable, and 
may not lead to major cell death or necrosis during the mechanical stretching. 
5.2 HMGB1 EXERTS INFLAMMATION EFFECT ON TENDON  
5.2.1  Physiological and pathological effects of HMGB1 in tendon  
We demonstrated that addition of HMGB1 promoted tendon cell migration and inflammatory 
reactions by enhancing the levels of COX-2 and PGE2 in vitro. HMGB1 did not induce tendon 
cell proliferation but induced MMP3 production in vitro. Furthermore, high dose HMGB1 
implantation resulted in hypercellularity, angiogenesis, and inflammatory cell infiltration 
characteristics of the early inflammatory stage of tendinopathy in tendon tissue in vivo. In 
agreement with in vitro finding, COX-2 and MMP-3 were also increased at the HMGB1 
implanted site in the tendon. 
Tendinopathy may not progress through a classic pathogen-induced inflammatory 
pathway, but may rather involve a local sterile inflammation initiated by damaged cells that 
could produce and release molecules functioning as danger signals like HMGB1. In tendons 
under mechanical loading, this release is initiated by resident cells. Previously we reported 
mechanical loading associated inflammatory reactions via upregulation of COX-2 and PGE2 both 
in vitro and in vivo [35]. The mechanism for the pathogenic role of HMGB1 could be through 
enhancement of inflammatory and destructive mechanisms induced by other inflammatory 
mediators. Also, in synovial fibroblasts of RA and OA patients when stimulated with HMGB1 
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alone or in combination with IL-1β, it was shown that HMGB1 in complex with IL-1β increased 
MMP production and PGE2 compared to treatment with HMGB1 or IL-1β alone [178, 318]. 
HMGB1 also acts as a chemoattractant in various cell types [152]. Our study also demonstrates 
this well-known property of HMGB1 in tendons. 
The concept of inflammation in tendinopathy is a hotly debated issue and controversial 
with conflicting results. Some previous studies have reported the absence of clinical signs of 
inflammation and invasion of inflammatory cells [189, 319, 320]. However, this may not be true 
since previous studies did not closely check the presence of inflammatory cells in injured 
tendons. The availability of tissues for analysis at different times after injury, small sample size, 
and late presentation of human patients when the inflammation may have resolved may be some 
of the contributing factors for such findings.  
In the implantation experiment, we found hypercellularity at the implantation site. It is 
highly possible that after the first few tendon micro-injuries, stressed or injured tendon cells 
release the initial wave of HMGB1 which triggers the sterile inflammation process. HMGB1 by 
its chemoattractant property may recruit neutrophils, monocytes, and macrophages to sites of 
injury. While exploring the HMGB1 effect in vitro, we found that this mediator did promote cell 
migration and inflammatory reactions, but did not induce cell proliferation. Interestingly, in the 
HMGB1 implantation experiment, HMGB1 induced hypercellularity in tendon tissues and 
among those cells, only a partial population of the cells was stained with CD68 indicating 
themselves as inflammatory cells. Other cells displayed elongated shape that appeared at the 
outer skirt around the CD68 positive cells. It is highly possible that they are tenogenic cells. It is 
most likely that HMGB1 exerts its function by recruiting inflammatory cells to the “injury site,” 
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and then initiates the release of cytokines and growth factors that result in the proliferation of the 
recruited tendon cells in vivo.  
As reported in previous studies, HMGB1 was found to activate and migrate endothelial 
cells[216], attract other pro-angiogenic cells like mesoangioblasts in vivo[238], and macrophages 
attracted by HMGB1 may secrete pro-angiogenic cytokines and growth factors[246, 321] thus 
promote angiogenesis process. In our study, we found HMGB1 did not induce HUVECs tube 
formation in vitro (Fig. 21), but induced blood vessel formation in the skin implantation and 
tendon implantation experiment, this finding indicate that HMGB1 angiogenesis effect is 
potentially through the cytokines and growth factors recruited inflammatory cells. At the same 
time, as we found in our in vitro study that HMGB1 treatment induced tenocyte migration in a 
dosage-dependent manner (Fig. 19) it is also possible that HMGB1 released in tendon matrix 
makes resident tendon cells to switch to pro-inflammatory phenotype by secretion of the 
inflammatory mediator such as PGE2 as well as a matrix-degenerative enzyme like MMP-3. 
Indeed our in vitro study showed that HMGB1 could induce PGE2 and MMP-3 production.  
Our implantation experiment showed that a high dose HMGB1 implantation evokes 
inflammatory reactions such as inflammatory cell infiltration, angiogenesis, and hypercellularity 
that took place at the 2-week time point, but not at the 4-week time point. This observation 
indicates that there might be a pathway in vivo to counteract HMGB1 effect and can resolve 
inflammation-related tendon tissue damages if HMGB1 is not continuously present in tendon 
matrix. This result might explain why tendinopathy is more often found in athletes who are 
subjected to long term, repetitive joint loading. After tendon gets overloaded and micro-injured 
for a short period, only a small amount HMGB1 may be released causing relatively low and 
repairable change in tendon structure; then tendon tissue could be able to recover from the injury 
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and restore normal structure by itself without any intervention. However, in persistent 
overloading, continuous release of HMGB1 into tendon matrix may result in chronic sterile 
inflammation. HMGB1 can form a complex with another molecule like IL-1β to exert stronger 
inflammation effect in synovial fibroblast [318], and cytokines produced during inflammation 
may also contribute to the persistence of inflammation, which is harder to resolve. Chronic 
sterile inflammation is potentially detrimental to tendon tissue since it may disturb the well-
organized tendon structure by introducing inflammatory cells into the tendon while causing 
hypercellularity, angiogenesis, and catabolic phenotype of the tendon tissue with increased 
production of MMPs. Replacing the well-organized collagen fibers with cells, vessels or 
disrupted fibers will substantially impair the mechanical properties of the tendon which makes 
them vulnerable to rupture or macro-scale injury when subjected to even regular mechanical 
loading. 
 
 
 
Figure 46. HMGB+GL implantation attenuates the structural and cellular change induced by HMGB1 in rat 
patellar tendon in 2 weeks. (A) Implantation site of control tendon with empty bead, show normal tendon structure 
after 2 weeks implantation. (B) HMGB1-encapsulated bead (2.5 µg in 5 µl) induce hypercellularity and vessel 
formation (arrow) 2 weeks after implantation. (C) HMGB1+GL encapsulated bead (2.5 µg in 5 µl HMGB1+ 1mM 
GL) showed little change at the implantation site. Bars - 100 µm 
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To further confirm that the inflammation effect is from HMGB1 itself rather than just 
response to large amout of foreign protein, we did an additional experiment on the implantation, 
we prepared the alginate beads with 1mM GL and 2.5 µg HMGB1 and implanted them into the 
SD-rat’s patellar tendon as described in chapter 2 for 2 weeks. And found the very little 
structural change in the implanted tendon tissue without any vessel found near the implantation 
site (Fig. 46C) similar to the control tendon implanted with empty beads(Fig. 46A), the HMGB1 
bead implanted tendon show vessel formation and hypocellularity(Fig. 46B).  
The result indicated that HMGB1 is responsible for the structural change in the 
implantation experiment. Also,this finding indicated that inhibition of HMGB1 with GL could 
attenuate the structural changes induced by HMGB1.  
5.2.2 In vivo implantation model with alginate beads 
In our in vivo experiment, to explore potential effect HMGB1 on tendon tissue, we used one-time 
alginate bead implantation of high concentration of HMGB1 instead of direct injection for the 
following reasons. 
Firstly, development of tendinopathy or visible tendon structure change by the natural 
cumulative effect of long-term micro-injury is likely with lower but sustained HMGB1 presence. 
The gradual degradation of alginate beads provided a relatively slower and localized release 
pattern of HMGB1 in tendon tissue to maximize its in vivo effect. Also, we have previous 
experience using alginate beads with KGN implantation into patellar tendon to create a 
tendinopathy model successfully [112].  
Secondly, as considering the alternative method with the one-time injection of HMGB1, 
patellar tendon is relatively flat, and tendon tissue is usually very densely packed, thus not 
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capable of “holding” liquid. Moreover, the majority of the injection may diffuse to adjacent 
tissue quickly may not be able to retain in tendon long enough to cause any substantial structural 
change. However, if multiple injections were to be applied, it may be very hard to ensure that the 
injection was directed to the same location every time. Also, multiple injections may create 
trauma in the tendon, and also the surrounding tissue may mask the effect from HMGB1 as the 
trauma is enough to invoke inflammatory reactions free from HMGB1. 
Moreover, Alginate is a natural polysaccharide with excellent biocompatibility and 
biodegradability [247], and it is non-toxic, with minimal pro-inflammatory effect [322]. It has 
been widely used in wound healing, cartilage repair, bone regeneration and drug delivery[248, 
249]. Although many other synthetic biomaterials could serve as a delivery system, the 
denaturing and loss of bioactivity of the carried drug is a big concern as preparation of these 
materials often involves using organic solvents[250]. Alginate could be easily cross-linked and 
shaped with metal ions (usually Ca2+) under room temperature and does not require other harsh 
chemical processing to retain protein activity. The preliminary result showed that 2% alginate 
beads remained in vivo in tendon without much degradation for at least 2 weeks.  
In our early trials, we also tried to implant the beads into Achilles tendon but found as 
Achilles tendon is macroscopically cylindrically shaped; it is extremely hard to keep the beads in 
a fixed position for 2 weeks. Although it is easy to implant and keep beads in position in patellar 
tendon, after the beads implantation; some beads may migrate out of tendon and move away 
from its original position. This phenomenon may be due to the movement of rat joint that 
“squeezed” the beads out and resulted in certain failure rate in inducing a structural change in the 
tendon. The problem was solved by suturing the connective membrane above tendon tissue, and 
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beneath skin tissue, which acts as a barrier to keep the beads in the tendon area, thus we can 
obtain a more stable result from this animal model. 
Before we implanted HMGB1 alginate beads into the tendon, we first tested its effect 
within the skin, skin is a more vascularized area compared to the tendon. The beads were 
implanted subcutaneously for one week and found inflammatory change near the beads (beads 
not yet degraded) including significant vessel formation (Fig. 23). By 2 weeks HMGB1 could 
invoke major structural changes in tendon and another 2 weeks allowed the changes to 
resolve(Fig. 25). It is possible that tendon inflammation takes longer to induce structural change 
and takes long to resolve which makes tendon more vulnerable to repetitive loading for an 
extended period without enough rest, the repetitive loading constantly induce the release of 
HMGB1 thus maintain a chronic inflammatory environment which continuously damages the 
tendon tissue. 
5.3 INHIBITION OF HMGB1 EFFECT WITH GL 
5.3.1 The logical reasons for the selecting GL as HMGB1 inhibitor in vivo 
Several HMGB1 inhibitors are available, and major inhibitors widely used in HMGB1 related 
studies are an HMGB1 neutralizing antibody, recombinant Box A, and Glycyrrhizin. A few other 
chemically synthesized compounds (sivelestat, atorvastatin, simvastatin, gabexate mesilate) were 
also explored in HMGB1 inhibition studies [100, 323-326].  
The HMGB1 neutralizing antibody is designed to target the functional area of HMGB1 
sequences to prevent HMGB1 from binding to its receptors; the HMGB1 antibody was mainly 
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utilized to demonstrate the HMGB1 involvement in disease conditions due to its high specificity. 
Administration of HMGB1 antibody attenuated endotoxin lethality in mice [151], and polyclonal 
HMGB1 antibody applied systemically successfully suppressed inflammation and tissue damage 
in collage-induced arthritis in mice and rat model [180]. The HMGB1 antibody was also used in 
hemorrhagic shock and resuscitation (HS/R)-induced gut barrier dysfunction, with an improved 
survival rate in mice model [327]. In these experimental models, the administration of HMGB1 
antibody was relatively short, but as we are developing a long-term exercise model, the usage of 
HMGB1 antibody will be huge and extremely costly. Moreover, since tendon is relatively 
avascular; one may need even higher amount to ensure effectiveness. Host immune reaction is 
another concern when antibody as a foreign protein, may invoke adaptive and innate immune 
response. 
Box A is the functional domain of HMGB1 peptide; it is the 9-79 amino acid of HMGB1. 
Box A could act as an antagonist for HMGB1 by binding to its receptor RAGE but not activate it 
since it lacks the inflammatory signal from Box B [281]. Recombinant Box A was found to 
protect endotoxin and sepsis lethality [328], as well as protect joint tissue and inhibit 
inflammation in collagen-induced arthritis model [180]. Its behavior has been shown very similar 
to HMGB1 antibody, but Box A directly binds to RAGE by competing with HMGB1. One 
concern about using Box A is that HMGB1 may signal through other receptors like TLR2, 
TLR4. However, Box A, in some scenarios may only partially block HMGB1 functions.  
Glycyrrhizin (GL), a glycoconjugate triterpene produced by the licorice plant, 
Glycyrrhiza glabra, has anti-inflammatory and antiviral properties. GL binds to both Box A and 
Box B of HMGB1 (KD≈150 µM), and it inhibits the chemoattractant and mitogenic activity of 
HMGB1 in vitro[253]. GL has been administered to patients with hepatitis B and C and 
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considered safe to use[253]. It is the most studied small-molecule inhibitor of HMGB1 and has 
been demonstrated numerous times that GL successfully inhibits extracellular HMGB1 cytokine 
activity and shows a protective effect on spinal cord, liver, brain, renal tissue against HMGB1 
mediated ischemia-reperfusion injury in animal models[323]. Especially in collagen-induced 
arthritis model, GL was equally effective as HMGB1 antibody and Box A[253]. It is also used in 
other preclinical investigation to treat other diseases by inhibiting HMGB1 signaling [256].  
Gabexate mesilate (GM) and sivelestat sodium hydrate(sivelestat) are synthetic 
molecules found to at least partially inhibit HMGB1 effect through indirect ways. GM was found 
to inhibit HMGB1 through blockage of HMGB1 release after LPS treatment [324]. Sivelestat,an 
inhibitor of neutrophil elastase, which is important in acute lung injury, inhibited NF-kB activity 
then reduced the release of HMGB1 from neutrophils[326]. The two statin molecules, 
atorvastatin, and simvastatin were found to downregulate HMGB1-RAGE axis. Atorvastatin was 
found to protect rat brain from ischemic injury through attenuation of over-expressed 
HMGB1[325], and simvastatin administration to ApoE-/- mice was found to attenuate vascular 
inflammation and atherosclerotic lesion and decreased HMGB1 expression in aortic tissue[94] 
In this study, GL was selected as the inhibitor for the in vivo model for the following 
reasons. 
Firstly, it is undoubted that the neutralizing antibody has the most precise and direct 
inhibition of HMGB1, but it may not be suitable for our long term in vivo study. It is extremely 
expensive if it has to be injected into mice every day for 3 weeks or even longer since it is still an 
extraneous protein that might invoke immune- reaction in the long run, which may also interfere 
with the effect directly come from the treadmill running. 
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Secondly, the inhibition potential of GL is similar to neutralizing antibody and Box A. 
GL has a similar inhibitory effect on HMGB1 as recombinant box A peptide in a mouse liver 
disease model by reducing the inflammatory cells recruitment to the liver[329], which indicates 
the GL is not an inferior choice as HMGB1’s inhibitor in vivo. The small synthetic molecules 
mentioned above are usually targeting the inflammatory cells’ release of HMGB1 or other 
indirect ways; most of them are only tested in one certain model. GL is the only small molecule 
that is known for sure to directly bind to HMGB1 and inhibit its chemoattractant and cytokine 
activity. GL has been used in multiple disease models and shows significant attenuation of 
HMGB1 effect[180, 253, 258, 330]. So GL is a better choice over the small synthetic molecules. 
Thirdly, GL could be prepared in relatively high dosage and could be administrated 
through IP injection instead of local injection into the tendon. Local injection into tendon tissue, 
in the long run, creates trauma that may very much interfere with the experimental outcomes 
since the inflammation effect from the procedure could very possibly mask that from the 
treadmill running. Moreover, if we would use antibody or Box A to inhibit HMGB1, the likely 
choice will be the local injection method due to the relatively small amount of the preparation. 
Fourthly, GL administration in an animal model has been proven safe; previous studies 
show that 50 mg/kg body weight GL injection daily for up to 6 weeks without adverse effect in a 
lung disease rat model[264]. Overall, there was no negative response up to 80 mg/kg body 
weight GL administration in mice for consecutive 20 days[263]. GL’s safety is also proven by 
our finding that GL-injected mice for up to 24 weeks had similar average body weight and body 
composition compared to the cage control group. Before conducting the in vivo experiment, we 
also showed in vitro that GL is safe by demonstrating that GL does not decrease tendon cell 
 151 
proliferation at the concentration of 100uM. But it does decrease cell number at 1mM, which 
may be due to the change in pH of the culture medium instead of GL toxicity itself. 
There is also some concern about using GL in vivo. As a naturally existing small 
molecule, there are some potential off-target effects of GL including inhibition of NF-kB 
activity[331]. It is possible that some conjunction effect in the study exerted by GL could not be 
attributed to HMGB1 inhibition.  
Another concern is that whether GL would affect the normal function of the intracellular 
HMGB1. The binding site of GL has been identified on HMGB1 with NMR chemical shift 
difference mapping. Moreover, surprisingly, even the binding site of GL on HMGB1 partially 
overlap with HMGB1's DNA binding site intracellularly, and GL only mildly interferes with 
HMGB1 binding to DNA in living cells with slightly decreased affinity to DNA[253]. This 
finding implied that administration of GL would not greatly interfere with HMGB1’s normal 
function as DNA chaperone. By considering all the pros and cons, GL is still the most suitable 
inhibitor in our study. 
5.3.2 GL reverses the inflammatory effect of HMGB1  
Our studies using this inhibitor demonstrated that GL is very effective in reversing the 
inflammatory effects caused by HMGB1 in vitro and in vivo. HMGB1 could upregulate COX-2, 
PGE2, and MMP3 in vitro and in vivo, and GL could inhibit these effects. We found in our 
implantation experiment that HMGB1 can cause hypercellularity, vessel ingrowth, and 
inflammatory cell infiltration when administrated to rat patellar tendon in alginate beads, and if 
GL is mixed with HMGB1 in the alginate beads, it can effectively attenuate the effect mentioned 
above. Therefore, it is conceivable that HMGB1may act as an upstream mediator in tendinopathy 
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associated inflammatory cascade. Currently, NSAIDs administration and corticosteroid 
injections to suppress PGE2 via COX inhibition dominate the treatment strategies to manage 
tendinopathic pain and inflammation [92, 332]. However, they have limited success in offering 
long-term relief without unwanted detrimental side effects [85]. Unfortunately, conservative 
treatments like rest, drugs (NSAIDS, corticosteroids), stretching and strength training can lead to 
surgical intervention in up to 45% of cases [333, 334]. Moreover, non-steroidal anti-
inflammatory drugs and steroids may be beneficial for pain and function in the early phases of 
the disease but are usually ineffective later [335-337]. Furthermore, COX activity is a relatively 
downstream player in the inflammatory cascade of tendinopathy. Therefore, NSAIDs are useful 
only for the inhibition of late mediators not for the source itself. In clinical settings, current 
treatment with steroids on chronic tendon injury can suppress the overall immune response, but it 
is considered harmful with side effects. It is also possible that suppression of PGE2 may have 
reduced the extent of degenerative injuries, but the regular matrix remodeling would also be 
affected, which may contribute to the failed tendon healing. Therefore, HMGB1 as an upstream 
mediator in the inflammatory cascade may serve as a better therapeutic target than PGE2, 
especially for early intervention. 
MMPs have been studied in tendon pathology with human samples, and one human study 
compared the MMPs in ruptured and normal supraspinatus tendon and found increased MMP-1 
but decreased MMP-2 and MMP-3 activity[61]. Another study on chronic Achilles tendinosis 
with 5 female patients(mean age around 60) found that compared to clinically normal tissue, the 
biopsy from tendinosis sites showed higher mRNA level of MMP-2 but lower MMP-3 in the 
same patient[60]. Moreover, in various studies of cultured tendon fibroblasts, mechanical 
stretching increased MMP-1 and -3 expressions, with no change in MMP-2 or -9[313, 338]. 
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HMGB1 was found to increase MMP-3 expression in rheumatoid synovial fibroblasts 
with the presence of LPS, but in relatively low concentration (100ng/ml). Another study also 
indicated that HMGB1 could induce MMP-3 expression with IL-1β, at low concentration 
(40ng/ml). We found that MMP-3 was elevated with 10 µg/ml HMGB1 treatment both 
intracellularly and in cell culture medium; also found increased in the tendon of 3-week intensive 
treadmill running and was suppressed by GL intervention. This finding may suggest that MMP-3 
induced by HMGB1 in early stage could have a different function compared to that of the late 
stage of tendinosis without inflammation. It is possible that MMP-3 may contribute to the 
development of early stage tendinopathy. It is hard to conclude the role of MMP-3 in the context 
of our model since the degeneration of tendon collagen matrix is regulated together with other 
MMPs as well as TIMPs. Therefore their behavior should be extensively studied in overuse 
models in future. 
5.3.3 Establishment of novel experimental insertional Achilles tendinopathy model 
By conducting long-term (12-24weeks) treadmill running, we first successfully developed an 
overuse insertional tendinopathy model in mouse Achilles tendon with degenerative changes, 
like the appearance of round-shape chondrocyte-like cells, deposition of GAG in matrix and 
cells, expression of chondrogenic marker Sox-9 and collagen type II in tendon matrix. We found 
that the round-shaped cells with the Sox-9 expression as well as GAG deposition in cells appear 
as early as 12 weeks. Moreover, by the end of 24 weeks, GAGs deposition was found 
extensively in tendon matrix as well as collagen II began to appear near the insertion site. We 
also found that daily injection of GL to the treadmill running mice could effectively decrease the 
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GAG deposition with minimal collagen II in tendon matrix, also with less round shaped cells 
compared to the treadmill running the only group. 
Clinically, the insertional tendinopathy is more frequent in young (the average patient age 
in the 40s [75, 339]) and more active population, whereas non-insertional tendinopathy is found 
more in older, less active and overweight population [75]. These findings suggest that all types 
of tendinopathy do not develop in the same way while insertional tendinopathy may largely 
relate to recreational or athletic activities. Insertional tendinopathy shows a typical degenerative 
change in tendon matrix with increased number of cells and more GAG in the matrix and 
disorganized collagen fiber [73]. We found that the degenerative change is occurring near the 
insertion site of Achilles tendon towards the calcaneus bone. In our model, the mice started 
running when they were around 8-9 weeks old and ended up around 32 weeks. Since the average 
lifespan of the C57BL/6 mice is around 600-700 days[340], 32 weeks old mice can be 
considered young and equivalent to about 30-40 years old human. Our model is in agreement and 
recapitulates the major degenerative change found in real patients. This similarity emphasizes the 
significance of this model, and the model may be of great value in exploring the underlying 
mechanism of insertional tendinopathy development induced by overloading, and to help 
develop possible treatment or prevention method in the management of insertional tendinopathy. 
The findings from this model could be highly translational to clinical practice.  
 Several models of tendinopathy have been created with various chemicals like 
Carrageenan, corticosteroid, prostaglandins, as well as collagenase[105]. Although in these 
models, the degenerative change could be found as evidence of the successful development of 
the model, and they provided useful information in post-tendinopathy treatment, they could not 
provide much information on the risk factors that initially trigger the pathological change. A few 
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treadmill running models have also been developed, among them, the rat supraspinatus 
tendinopathy model induced by downhill treadmill running was widely accepted [114]. 
However, the development of Achilles tendinopathy through treadmill running results are 
controversial with some reports that did not find any effect of treadmill running in terms of 
inducing tendinopathic changes [34, 305]. One possible reason is that the running protocol was 
not intense enough to induce damage to Achilles tendon. Moreover, all the rat treadmill running 
protocols were derived from the initial supraspinatus tendon study with 1hr running per day and 
5 days a week, for up to 16 weeks. Based on this study and previous finding in our lab that 
50min running every day for 3 weeks result in an expansion of the stem cells pool in tendon 
[116] and also did not induce PGE2 production in tendon[66], we consider 1hr of running per day 
as beneficial and may not invoke an inflammatory reaction. We showed that 1hr treadmill 
running for 3-week did not significantly increase HMGB1 release in tendon matrix. Another 
reason is that the researchers may focus on the mid-section of the tendon instead of closely 
checking throughout the whole tendon piece. It is very hard to retain the appropriate structure on 
the end of tendon tissue during the dissection and tissue section, but it is relatively easy to do so 
in the mid-section. Our findings also suggest that future development of tendinopathy models 
should check the tendon tissue more closely for any potential structural and cellular changes.  
5.3.4 GL prevents degenerative changes in long-term treadmill running model 
We found that GL intervention could effectively block or delay the development of tendinopathy 
by decreasing GAGs deposition and prevent collagen II in tendon matrix in our 24-week long-
term treadmill running model. This finding indicates that GL blocked the pathway which is 
directly related to the degenerative changes. As we previously found in the 3-week running 
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model, GL was able to decrease the production of inflammatory mediator PGE2 induced by 
overloading in vivo. HMGB1 also attracted inflammatory cells and resulted in an increase of 
COX-2 and PGE2 production in tendon tissue which could lead to the non-tenocyte 
differentiation of  TSCs as our previous study indicated[16, 66]. GL is known as the direct 
inhibitor of HMGB1, and even with possible off-target effect, we think that the inhibitory effect 
of GL in the development of tendinopathy may be mainly through the inhibition of HMGB1 
released as a result from overloaded tendon cells.  
 
 
 
Figure 47. GL did not prevent Chondrogenic differentiation of Tendon stem cells (TSCs) in 3 weeks. TSCs are 
treated with chondrogenic differentiation medium with 0, 50, 200 µM GL for 3 weeks, the medium was changed 
every 3 days. (A) Control group without GL treatment show strong Safranin O staining indicate strong GAGs 
deposition (B, C) Chondrogenic differentiation of TSCs with 50 µM (B) and 200 µM (C) GL treatment show similar 
staining to control. (C) Chondrogenic differentiation of TSCs with GL treatment. Bars - 100 µm 
 
 
 
One may argue that GL may potentially block the differentiation process directly without 
interacting with HMGB1, As in the model, we found most degenerative change is related to 
chondrogenesis, we conducted an additional experiment that to test out the prevention effect of 
GL in the differentiation of tendon stem cell in vitro. Chondrogenesis induction medium was 
prepared according to our previous study [15]. We found that neither low (50 µM, Fig. 47B) or 
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high (200 µM, Fig. 47C) GL affected the differentiation of TSCs into chondrogenic lineage 
compare to the control group without GL treatment, all groups are stained mostly positive for 
GAG-rich matrix with Safranin O assay (Fig. 47A, B, C). This result indirectly supported that 
the GL prevention effect in tendinopathy is through the inhibition of HMGB1.  
5.3.5 Proposed pathological model for Achilles insertional tendinopathy 
The pathological model we proposed from all findings in this research could be summarized as 
below (Fig.48). Repetitive loading and overloading of tendon result in micro-tears and release of 
HMGB1 from stressed or injured tendon cells. The extracellularly released HMGB1 attracts 
inflammatory cells and resident tendon cells to the injury site, and in response to the damage 
signal from HMGB1, inflammatory cells release cytokines and growth factors. The resident 
tendon cells are also activated and shift to pro-inflammatory phenotype. The proliferation of 
tenocytes, ingrowth of blood vessels and destruction of well-organized collagen matrix result in 
compromised mechanical property of the tendon that is vulnerable to even normal mechanical 
loading. Like the persistence of the overloading, the inflammation status was not resolved but 
further enhanced, and result in chronic sterile inflammation in tendon tissue, which leads to 
degenerative changes that finally develop tendinopathy. The previous study on the PGE2 
treatment induced non-tenogenic differentiation of tendon stem cells into adipocyte, 
chondrocyte, and osteocytes both in vivo and in vitro[16, 66], and this study helped to explain 
how chronic inflammation may result in a chondrogenic phenotype change in our treadmill 
running model.  
There are a few limitations to our study. First, our research focuses on the load-bearing 
tendons like patellar and Achilles tendons instead of other types of mostly motion-transmitting 
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tendon such as flexor tendons. Therefore, the inflammatory reactions elicited by HMGB1 may 
not be directly translated to those tissues and their related diseases. Second, this model takes very 
long time to develop before inducing its effects, and may only suitable for exploring the 
insertional tendinopathy in Achilles. We are not sure about what will happen to the tendon if 
longer running time is permitted (i.e. 36 weeks), as the tendon structure has been compromised, 
its mechanical property may also decrease and may result in more damage and the degenerative 
change may spread to the middle portion of the tendon, or even result in tendon rupture. 
 Also, even when we detected inflammation in patellar tendon, patellar tendinopathy did 
not develop through this model even after 24 weeks running. Patellar tendon also has a unique 
structure and may have an even higher tolerance of inflammation than Achilles and 
supraspinatus tendons before developing into tendinopathy. Overloading patellar tendinopathy 
models have not been developed yet, which implies that the development of patellar 
tendinopathy may have other important risk factors involved such as nutrition and individual 
genetic variance.  
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Figure 48. The proposed model of tendinopathy development in bear-loading tendon caused by HMGB1 due 
to mechanical overloading.  (A) Shows the tenocyte a tendon stem cell resident in between collagen fibers in the 
tendon, red in nucleus indicate the HMGB1 location in normal tenocytes. (B) When under mechanical overloading, 
tenocyte passively release HMGB1 (red dots) in tendon matrix, inflammatory cells like macrophages were attracted 
to tendon tissue. (C) In responding to HMGB1 signaling, inflammatory cells begin to release cytokines, growth 
factors and inflammatory agents that trigger the sterile inflammation in tendon, prolonged inflammation may cause 
the hypercellularity, vessel ingrowth and breakdown of matrix, tendon stem cells under inflammatory condition tend 
to differentiate into non-tenogenic lineage cells like adipocyte, chondrocytes, and osteocytes. (D) If this pathological 
condition persists, the tendon will develop into chronic tendinopathy with degenerative changes like lipid 
deposition, chondrogenic change and even calcification which drastically compromise the mechanical properties of 
tendon tissue, and may possess a high risk of tendon injury and rupture. 
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5.4 CONCLUSION  
In conclusion, our study helps to understand better how excessive mechanical loading-induced 
inflammation is developed into degenerative tendinopathy within the tendon through the release 
of the pro-inflammatory factor HMGB1. This study will also contribute to identifying a novel 
therapeutic target – HMGB1 signaling – in the management of tendinopathy. Our finding of GL 
as a direct inhibitor of HMGB1-induced inflammation in tendons will serve as a potential lead to 
develop this compound as a novel therapeutic agent to protect the tendon from the long-term 
structural change which impairs the tendon and make it vulnerable to injury or rupture. These 
findings may have a great impact in clinical trials of tendinopathy and may encourage further 
studies on how to target early tendon injury symptoms rather than focusing on late treatments 
after the injury. Future studies may focus on detailed molecular mechanisms of tendon 
inflammation and involvement of the MMPs regarding their role in the early and late stage of 
tendinopathy. This finding might help develop better treatment plans for athletes who have to 
constantly undergo high training burden especially those involved in excessive repetitive motion. 
Also, this study may inspire the research of other non-bear loading tendon diseases to uncover 
potentially new mechanisms and development of new and improved treatment strategies. 
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APPENDIX A 
LIST OF ABBREVIATIONS 
Abbreviation Full term 
AA Anacardic Acid 
AT Achilles tendon 
CCK-8 Cell Counting Kit-8 
CCL18 Chemokine (C-C motif) ligand 18 
CD68 Cluster of Differentiation 68 
CITED2 Cbp/P300 Interacting Transactivator With Glu/Asp Rich 
   Col II Collagen type II 
COX-2 Cyclooxygenase-2 
CXCL Chemokine (C-X-C motif) ligand 
CXCR Chemokine (C-X-C motif) receptor 
CY3 Cyanine 3 
DAMPs Damage-associated molecular patterns 
DMEM Dulbecco's Modified Eagle Medium 
DNA Deoxyribonucleic acid 
ECM Extracellular Matrix 
ELISA Enzyme-linked immunosorbent assay 
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Abbreviation Full term 
ERK Extracellular signal-regulated kinases 
FBS Fetal Bovine Serum 
FDA Fluorescein Diacetate 
FITC Fluorescein isothiocyanate 
GAGs Glycosaminoglycans 
H&E Hematoxylin and eosin 
HAT Histone acetyltransferase 
HDAC Histone deacetylase 
HIF-1α hypoxia-inducible factor 1α 
HMGB1 High mobility group box 1 
HSP heat shock proteins 
IHC Immunohistochemistry 
IL-1b Interleukin 1 beta 
IP injection Intraperitoneal injection 
ITR Intensive treadmillrunning 
JNK c-Jun N-terminal kinases 
KGN Kartogenin 
LPS Lipopolysaccharides 
MCP-4 Monocyte chemotactic protein-4 
MMPs Matrix metalloproteinases 
MRI Magnetic resonance imaging 
MTR Moderate treadmill running 
NES Nuclear-emigration signals 
NLS Nuclear localization signals 
NMR Nuclear magnetic resonance 
NSAIDs Non-steroid anti-inflammatory drugs 
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Abbreviation Full term 
OTR One-time fatigue treadmill running 
PAMPs Pathogen-associated molecular patterns 
PBS Phosphate-buffered saline 
PFA Paraformaldehyde 
PGE2 Prostaglandin E2 
PI Propidium Iodide 
PT patellar tendon 
RA rheumatoid arthritis 
RAGE the receptor for advanced glycation endproducts 
RASFs rheumatoid arthritis synovial fibroblasts 
SDF-1 Stromal cell-derived factor 1 
SD-rat Sprague Dawley rat 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SOX-9 SRY-box 9 
TSCs Tendon-derived stem/progenitor cells 
TIMPs tissue inhibitors of metalloproteinases 
TLC with thin layer chromatography 
TLR Toll-like receptor 
TNF Tumor necrosis factor 
TSA Trichostatin A 
α-SMA Alpha-smooth muscle actin 
γ-H2AX 
 
Gamma-histone H2A member X 
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